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ABSTRACT OF DISSERTATION 
 
 
 
 
PHARMACEUTICALLY ENGINEERED NANOPARTICLES FOR ENHANCING 
IMMUNE RESPONSES TO HIV-1 TAT AND GAG p24 PROTEINS 
 
These studies were aimed at investigating the potential application of 
nanoparticles engineered from oil-in-water microemulsion precursors for enhancing 
immune responses to HIV-1 Tat and Gag p24 proteins.  Both of the HIV-1 proteins have 
been reported to be critical in the virus life cycle and are being evaluated in clinical trials 
as vaccine candidates.   
Anionic nanoparticles were prepared using emulsifying wax as the oil phase and 
Brij 78 and sodium dodecyl sulfate as the surfactants.  The resulting nanoparticles were 
coated with Tat and were demonstrated to produce superior immune responses after 
administration to BALB/c mice compared to Tat adjuvanted with Alum.  Similarly, 
cationic nanoparticles were prepared using emulsifying wax and Brij 78 and cetyl 
trimethyl ammonium bromide as the surfactants.  The cationic nanoparticles were 
investigated for delivery of immunostimulatory adjuvants, namely three Toll-like 
receptor ligands, for obtaining synergistic enhancements in immune responses to a model 
antigen, Ovalbumin (OVA).   
In vitro and in vivo studies were carried out to elucidate possible mechanisms by 
which nanoparticles may result in enhancements in immune responses.  In vitro studies 
were carried out to evaluate the uptake of nanoparticles into dendritic cells and to assess 
the release of pro-inflammatory cytokines from dendritic cells in the presence of 
nanoparicles.  In vivo studies were carried out using a MHC class I restricted transgenic 
mouse model to investigate the potential for nanoparticles coated with OVA to enhance 
presentation of the protein to CD8+ T cells compared to OVA alone. 
 Finally, the preparation of nanoparticles with a low amount of surface chelated 
nickel for high affinity binding to histidine-tagged (his-tag) proteins was investigated.  It 
was hypothesized that this strengthened interaction of his-tag protein to the nickel 
chelated nanoparticles (Ni-NPs) would result in a greater uptake of antigen in vivo; 
therefore, enhanced immune responses compared to protein bound to anionic 
nanoparticles.  In vivo evaluation of his-tag HIV-1 Gag p24 bound to Ni-NPs resulted in 
enhanced immune responses compared to protein either adjuvanted with Alum or coated 
on the surface of nanoparticles.   
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 Chapter 1 
 
Introduction and statement of problem 
 
Adjuvants can be defined as any material included as a component in a vaccine to 
aid in producing more robust cellular and/or humoral immune responses to the antigen of 
interest.  Adjuvants can be broadly categorized as immunostimulatory or particulate, 
including particulate delivery systems.  Many of the early developments in vaccines, 
including the use of adjuvants, have been empirically derived on a trial and error basis 
without in depth knowledge of the exact mechanisms involved in generating effective 
immune responses.  As we gain a better understanding of the immune system and its 
components, we can design more effective vaccines.  An important strategy in designing 
more effective vaccines would be to explore the use of novel delivery systems for 
effectively eliciting the immune responses necessary for protection from viral and 
bacterial pathogens.  The need for safe and effective delivery systems is even more 
evident with new generation vaccines where peptides, protein subunits, or DNA are the 
antigens.  Unlike traditional vaccines such as live attenuated or whole killed pathogens, 
new generation vaccines are considered to be much safer; however, new generation 
vaccines produce poor immune responses when administered alone.  Therefore, in many 
cases, adjuvants are typically used in conjunction with the antigen to enhance the immune 
response [1,2]. 
Currently, aluminum-based mineral salts (Alum) are the most widely used 
adjuvants for human vaccination.  Alum has proven to be safe and effective for antibody 
 1
 production (humoral response); however, it is not very effective for generating strong 
cellular responses with recombinant proteins [3], which are considered to be important in 
providing protection from many viruses such as the human immunodeficiency virus 
(HIV) [4].  While many new adjuvants have entered clinical trials, most have been 
proven too toxic to be used routinely in humans [1]. Ideal adjuvants for routine human 
vaccine applications should be safe, cost-effective, relatively simple to manufacture and 
scale-up, versatile, and should produce balanced (humoral and cellular) immune 
responses.   
Particulate delivery systems such as microparticles and liposomes have been 
extensively investigated for enhancing immune responses to protein-based vaccines [5-9].  
These systems offer several advantages over other adjuvants for enhancing immune 
responses since:  1) they are naturally targeted for uptake by APCs due to their similar 
size to pathogens; 2) targeting ligands for APCs can be incorporated on the surface of the 
particles; and 3) immunostimulatory molecules can be incorporated with the particles for 
synergistic enhancements in immune responses.  Moreover, a number of studies suggest 
that smaller particles (<1 micron) are more effective at generating immune responses 
compared to larger particles (>10 microns) [10-13].    
Nanoparticles prepared from oil-in-water microemulsion precursors have been 
shown to be effective at enhancing immune responses to plasmid DNA [14,15] and a 
model protein, β-galactosidase [16].  The present research was focused on further 
investigating the utility of these nanopariticles for enhancing immune responses to two 
HIV proteins, Tat and Gag p24.  Both proteins are of significant interest for HIV vaccine 
development since they have been reported to be relatively conserved and critical in the 
 2
 HIV life cycle.  In addition, both proteins are currently being evaluated in clinical trials 
[17-19].  In vitro and in vivo studies evaluating parameters such as uptake and cell 
activation by nanoparticles were carried out to gain a better understanding of the 
mechanism by which nanoparticles may be enhancing immune responses.  These types of 
studies are considered to be important as they would have implications on improvements 
that could be made to develop of more effective vaccine delivery systems.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Jigna D. Patel 2006 
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 Chapter 2 
 
Plan of research 
 
The overall goal of this research was to investigate the application of pharmaceutically 
engineered nanoparticles for HIV-1 Tat and Gag p24 proteins to elicit enhanced as well 
as balanced immune responses compared to protein adjuvanted with Alum.  This research 
was guided by three main hypotheses: 
 
Hypothesis 1.  Mice dosed with anionic nanoparticles coated with HIV-1 proteins will 
result in enhanced humoral and cellular immune responses compared to those dosed with 
protein adjuvanted with Alum. 
Hypothesis 2.  Increasing the affinity of the protein antigen for the nanoparticles will 
result in a more stable attachment and lead to a corresponding enhancement in the 
immune responses in vivo compared to antigens coated on anionic nanoparticles by 
charge interaction. 
Hypothesis 3. Mice dosed with nanoparticles co-formulated with protein antigen and an 
immunostimulatory molecule will produce enhanced immune responses compared to 
those dosed with protein antigen with nanoparticles or immunostimulatory molecule 
alone. 
 
To evaluate these hypotheses, the research plan described in sections 2.1 to 2.4 was 
carried out. 
 
 4
 2.1 Formulation and in vivo assessment of anionic nanoparticles 
The main objectives of this section were: 1) to demonstrate that stable anionic 
nanoparticles could be prepared; 2) to formulate Tat with anionic nanoparticles; and 3) to 
evaluate the in vivo responses of Tat-coated nanoparticles compared to Tat adjuvanted 
with Alum.  Anionic nanoparticles in this study were prepared from oil-in-water 
microemulsion precursors using emulsifying wax as the oil phase and Brij 78 and sodium 
dodecyl sulfate (SDS) as the surfactants.  The nanoparticles were characterized by 
particle size, charge, and transmission electron microscopy.  Tat was formulated with 
anionic nanoparticles and further characterized by measuring the resulting size and 
charge of the particles.  The in vivo immune responses to Tat were evaluated by dosing 
BALB/c mice with 0.2 to 5 μg Tat either coated on anionic nanoparticles or adjuvanted 
with Alum.  The Tat-specific immune responses were evaluated by measuring the serum 
IgG levels, the ability of the anti-sera to neutralize extracellular Tat, and mapping the 
antibody epitopes generated to Tat.   
 
2.2 Formulation and in vivo assessment of immunostimulatory molecules and 
Ovalbumin (OVA) coated on cationic nanoparticles 
The immunostimulatory molecules investigated for use with nanoparticles are 
classified as Toll-like receptor (TLR) ligands.  The aims of this section were as follows:  
1) demonstrate the preparation of cationic nanoparticles; 2) demonstrate that OVA could 
be coated on cationic nanoparticles; 3) demonstrate that TLR ligands and OVA could be 
coated on cationic nanoparticles; 4) evaluate the TLR ligands and OVA formulations in 
BALB/c mice to identify the optimal TLR ligand formulation for future studies with 
 5
 nanoparticles.  Cationic nanoparticles were prepared from oil-in-water microemulsion 
precursors using emulsifying wax and Brij 78 and cetyl trimethyl ammonium bromide 
(CTAB) as the surfactants.  The TLR ligands evaluated in this section were lipoteichoic 
acid (LTA), a synthetic double stranded RNA analog (Poly I:C), and a 20-mer synthetic 
oligonucleotide containing CpG motifs (CpG).  The nanoparticles were characterized 
before and after coating with OVA or the TLR ligands by measuring the size and charge 
of the particles.  Initially, a short-term in vivo study was carried out in mice to identify 
the best TLR ligand for further evaluation.  For this study, mice were dosed once with 50 
μg of the various TLR ligands and 5 μg OVA coated on nanoparticles.  The immune 
responses were evaluated on day 8 by measuring T cell proliferation in the lymph nodes.  
Based on the results of this study, the TLR ligand CpG was chosen for further evaluation 
and a follow up in vivo study was carried out to evaluate the immune responses to CpG 
(10 μg) and OVA (5 μg) coated on nanoparticles compared to CpG or nanoparticles alone 
formulated with OVA.  The immune responses in this follow up study were evaluated by 
measuring OVA-specific serum IgG titers and OVA-specific splenocyte proliferation. 
 
2.3 In vitro and in vivo assessment of mechanism(s) of immune response 
enhancement by nanoparticles 
This main objective of this section was to elucidate possible mechanism(s) by 
which nanoparticles may be enhancing immune responses to antigens in vivo.  These 
studies were separated into two parts.  In the first part, in vitro studies were carried to 
evaluate: 1) the uptake of various types of nanoparticles (neutral, anionic, and cationic) 
by murine bone-marrow derived dendritic cells (BMDDCs); 2) the release of pro-
 6
 inflammatory cytokines in human DCs and BMDDCs; and 3) the release of IL-12 from 
BMDDCs using CpG-coated NPs compared to CpG alone.  The second part of this study 
involved the use of a MHC class I restricted OVA transgenic mouse model (OT-1) for 
evaluating the uptake and presentation to T cells in vivo of OVA-coated nanoparticles 
compared to OVA alone.  For these studies, T lymphocytes from the spleens of OT-1 
mice were labeled with a green-fluorescent marker and transferred by tail-vein into 
C57BL/6 mice.  The OVA containing formulations were injected 24 hours later and T 
cell proliferation in the lymph nodes was measured after 3 days. 
 
2.4 Formulation and in vivo evaluation of nickel-coated nanoparticles 
The goal of this section was to strengthen the interaction of antigens with the 
nanoparticles for obtaining greater enhancements in immune responses compared to 
simple anionic nanoparticles.  The use of chelated nickel for purification of proteins 
containing a hexa-histidine tag (his-tag) has been used extensively and this interaction 
has been reported to be extremely strong, in the order of magnitude of biotin-avidin 
interactions.  This approach of incorporating nickel on the nanoparticles for strengthening 
the interaction with proteins was investigated.  More specifically, the aim of these studies 
was to: 1) demonstrate that nanoparticles containing a small amount of chelated nickel 
could be prepared; 2) demonstrate that the nickel coated nanoparticles could bind to his-
tag proteins; and 3) evaluate the immune response to his-tag HIV-1 Gag p24 bound on 
nickel nanoparticles compared to protein adsorbed on anionic nanoparticles or adjuvanted 
with Alum.  Nanoparticles having a small amount of surface-chelated nickel were 
prepared using emulsifying wax, Brij 78, and a nickel chelating lipid 1,2-dioleoyl-sn-
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 glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl].  The resulting 
nickel nanoparticles (Ni-NPs) were characterized by particle size and the amount of 
nickel entrapped in the particles was determined by atomic emission spectroscopy.  Initial 
studies to demonstrate binding of his-tagged proteins to Ni-NPs were performed using 
his-tag green fluorescent protein (GFP).  The optimal binding and stability of his-tag GFP 
bound to Ni-NPs was determined.  Based on the GFP binding results, the optimal binding 
ratios for his-tag HIV-1 Gag p24 were determined and further in vivo immune responses 
to the protein formulated with Ni-NPs, Alum, and anionic nanoparticles were evaluated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Jigna D. Patel 2006
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 Chapter 3 
 
Background and literature review 
 
3.1 Vaccines  
 
3.1.1 A brief history 
Vaccination can be defined as “an overt attempt to use part or all of a microbial 
pathogen to protect against that microbe” [20] with the ultimate goal being the induction 
of appropriate immune responses to provide protection against a pathogen without 
causing serious disease.  Vaccines have proven to be highly effective at controlling many 
infectious diseases and reducing disease related mortality over the last two centuries.  In 
fact, vaccines have been regarded as one of the greatest achievements in the reduction of 
deaths due to infectious diseases, with the exception of safer water [21].   
 The introduction of vaccination is accredited to Edward Jenner, an English 
physician, for his effort in deliberately inoculating a young boy with cowpox and 
demonstrating this as an effective strategy for controlling smallpox infection when it was 
introduced to the boy six weeks later [21].  Jenner referred to the inoculum as vaccine 
(derived from the Latin word for cow, vacca) and termed this procedure vaccination [22], 
entitling Jenner as the father of modern vaccinology in historical records.  However, the 
idea of protection from infectious diseases was long before recognized in China and India 
in the 16th century where a process termed variolation was practiced to reduce severity of 
smallpox.  This process involved the introduction of dried pus from smallpox pustules 
into healthy individuals through the nose or the skin [21].  The process of variolation via 
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 the skin (cutaneous variolation) eventually spread to through the Middle East, Africa, 
Turkey, and finally introduced to Great Britain by Lady Mary Wortley Montagu in 1721 
[20,21,23]. 
 The next major advance in vaccination came about in 1879 with Louis Pasteur’s 
work on the attenuation of chicken cholera bacterium.  Pasteur noted that a culture of 
chicken cholera left exposed to air over a long period provided protection against 
challenge with non-attenuated cholera in immunized chickens.  Based on these initial 
observations with the chicken cholera cultures, Pasteur believed that pathogens could be 
attenuated by exposure to various environmental factors such as elevated temperatures, 
oxygen, and chemicals.  Further experimentation during this period by Pasteur and 
colleagues confirmed his hypothesis and led to the development of both a rabies vaccine 
and an anthrax vaccine in the 1880’s [21].    
These early pioneering efforts by Jenner and Pasteur paved the foundation for 
future developments in vaccines.  A brief historical outline of the major developments in 
vaccines is presented in Table 3.1.  As evident from this Table, since the initial discovery 
of an effective smallpox vaccination strategy, numerous other vaccines have come into 
development.  Moreover, vaccination has been effective in controlling many diseases 
including:  smallpox, diphtheria, tetanus, yellow fever, pertussis, Haemophilus influenza 
type b disease, poliomyelitis, measles, mumps, and rubella [21].  However, the ultimate 
triumph in vaccinology to date has been the global eradication of smallpox, declared in 
1980 by the World Health Organization (WHO) [22]. 
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 3.1.2  Types of vaccines 
Vaccines can be classified into three main categories: live attenuated, whole-
killed, or genetically engineered vaccines.  The use of live attenuated or whole killed 
organisms as vaccine components have been recognized since the 18th century, as 
described above.  These approaches are typically referred to as traditional vaccines.  
Recently, a better understanding of molecular mechanisms and genetic techniques has led 
to the development of a new class of vaccines that are comprised of DNA, peptides or 
proteins, more commonly referred to as new generation vaccines. 
 
3.1.2.a Traditional vaccines 
The first successful vaccines demonstrated by Jenner and Pasteur were based on 
live attenuated organisms.  Live attenuated vaccines are composed of pathogens 
weakened by passage or culture conditions causing the organism to be non-virulent but 
still immunogenic.  Examples of the earliest live attenuated vaccines used in humans 
include the smallpox and rabies virus vaccines.  It took another 40 years after the 
introduction of rabies vaccine by Pasteur for the next major live attenuated vaccine to be 
developed, which occurred in 1920’s with the introduction of the Bacille Calmette-
Guérin (BCG) vaccine for tuberculosis (TB) by Camille Calmette and Alphonse Guérin.  
The first BCG vaccine was developed by repeated passage of the mycobacterium in 
bovine bile and after 13 years and approximately 230 passages, the attenuated BCG strain 
was obtained and evaluated orally in clinical trials with children in 1921, with the 
widespread use in humans initiated in 1927 [21].   The value of BCG vaccines has been 
questioned because of the varying effectiveness observed in controlled trials with the 
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 vaccine where some trials demonstrate benefits while others show no benefit in providing 
protection from the bacteria by vaccination.  Despite this ongoing controversy over the 
use of BCG vaccines, they are still in use throughout the world with the exception of a 
few industrialized countries such as United States and Netherlands [24].  Moreover, 
renewed interests in these vaccines have been stimulated with the emergence of 
tuberculosis associated in human immunodeficiency virus (HIV) infected patients.   
Perhaps the most significant achievement in the use of live attenuated vaccines is the 
introduction of an oral poliovirus vaccine (OPV) in 1962, resulting in a dramatic decrease 
in poliomyelitis – one of the diseases targeted of eradication by WHO [25].  Additional 
examples of live attenuated vaccines that have made significant contributions in reducing 
disease rates include the mumps, rubella, and measles vaccines, which have become the 
foundation of routine pediatric immunization and were licensed as combination vaccines 
(MMR) in 1971 [26,27] .  Although live attenuated vaccines have been used widely and 
are generally more effective than inactivated vaccines, a major disadvantage of these 
types of vaccines is that they tend to pose numerous safety concerns as the organisms 
could revert back to a more virulent strain and cause disease.   
The use of whole-killed vaccines began soon after Pasteur’s initial success in 
generating attenuated strains of chicken cholera.  Daniel Salmon and Theobald Smith are 
credited for demonstrating that whole-killed pathogens retained their immunogenicity 
[28].  In 1896, the work by Wilhelm Kolle demonstrated that agar-grown, heat 
inactivated Vibrio cholerae could be used as a human vaccine for cholera.  Around the 
same time Richard Pfeiffer and Almroth Wright demonstrated that cultures of Salmonella 
typhi could be inactivated with heat and preserved in phenol.  This demonstration led to 
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 the development of a typhoid fever vaccine in 1896 that eventually (1915) became widely 
used in the military in Europe [29].  Some examples of vaccines to infectious agents that 
have been developed in this category include the inactivated poliovirus (IPV) vaccine, 
Hepatitis A vaccine, and the influenza vaccine.  The use of IPV vaccine has replaced the 
more effective OPV vaccine in the U.S. and many European countries due to some safety 
concerns raised by some reported cases of paralysis due to the live attenuated vaccine and 
more importantly, because the disease is very rare in these countries [30]. 
 
3.1.2.b New generation vaccines 
 The majority of early vaccines developed were based on live attenuated or whole 
killed organisms.  However, the growing knowledge of infectious diseases during late 
19th and early 20th century paved the pathway for the identification of pathogen 
components and exploring the use of these individual components for developing 
vaccines.  In the late 1880s, Roux, Yersin, Behring, and Kitasato realized that diphtheria 
bacillus produced an extracellular toxin and that sera from infected animals contained an 
antitoxin able to neutralize the diphtheria toxin in culture.  These discoveries paved the 
foundation for future developments of inactivated toxins, referred to as toxoids, as 
vaccine components.  In fact, as early as 1923 it was realized that the diphtheria toxin 
could be inactivated by formalin and enabled Gaston Ramon to develop the earliest 
subunit vaccines, namely diphtheria and tetanus vaccines [21].  With additional 
technological advancements, the ability to separate and extract bacterial components led 
to the development of polysaccharides, components of bacterial cell walls, as viable 
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 vaccine strategies in cases such as the early pneumococcal and meningococcal vaccines 
[31].   
 From these early discoveries, it is apparent that advancements in technology as 
well as an understanding of both pathogens and immune functions have contributed 
immensely to the development of safer, more effective vaccines throughout their history.  
This is even more apparent in the recent years where genetic engineering techniques have 
contributed immensely in developing safer vaccines.  For example, the use of 
recombinant DNA has enabled production of large quantities of well-defined, purified 
proteins that have been used for a variety of applications including the development of 
safer protein-based vaccines.  In fact, the earliest success in using genetic engineering for 
vaccine development came about in the early 1980’s with the introduction of a yeast 
derived Hepatitis B subunit vaccine, which had previously been obtained from 
purification of infected individual’s plasma [32,33].  Genetic engineering techniques have 
also opened up avenues in the rational design of proteins using site-directed mutagenesis 
to produce proteins with altered properties that are not naturally occurring in the 
pathogen and thus, may be less detrimental or reactogenic in the host, i.e. toxoids.  One 
example of this application is in the improvement of an existing pertussis vaccine, where 
pertussis toxin was detoxified by a double mutations to the protein which rendered it 
safer while still retaining its antigenic conformation and immunogenicity in vivo [34,35].  
This protein-based pertussis vaccine is approved for human use and has replaced the 
whole-cell pertussis vaccine in many countries [36]. 
 Another advancement in vaccines permitted by genetic engineering technology 
occurred in 1992 when Johnston’s group reported that plasmid DNA (pDNA) was 
 14
 effective for immunization, referred to as genetic immunization [37].  Genetic vaccines 
take advantage of the use of plasmid DNA for expression of a gene encoding for a 
specific antigen(s) under the control of a eukaryotic or viral promoter (such as a CMV 
promoter) [38].  DNA vaccines, once administered, allow for the expression of protein 
inside the cells leading to processing and presentation by the major histocompatability 
(MHC) class I pathway and generating strong cellular responses.  Indeed, strong 
cytotoxic T lymphocyte (CTL) responses have been reported with genetic vaccines in 
several different animal models [39-41].  Genetic vaccines enable the delivery and co-
expression of multiple antigens or epitopes of a pathogen on one plasmid [42].  
Moreover, the delivery of antigen-cytokine fusions encoded on the same plasmid has also 
been investigated as a method for obtaining robust enhancements in immune responses 
[43-45].  The most common route of administration for delivery of genetic vaccines has 
been via intramuscular injection; although, many new devices and alternative approaches, 
such as topical application and use of gene gun delivery devices, have been investigated 
more recently in effort to enhance immune responses by targeting dendritic cells (DCs) 
[14,42,46-48].  Unlike many of the approaches to vaccines discussed so far, genetic 
immunization has proven to be successful in mice; however, it has demonstrated limited 
effectiveness in non-human primates and humans after conventional intramuscular 
administration, requiring extremely high doses of pDNA and in some cases failing to 
induce antibody responses [38].  More recently, genetic immunization using low doses of 
DNA in humans has been reported with the use of gene gun devices as an alternative to 
intramuscular injection by PowderMed, Inc. (http://www.powdermed.com).  This success 
has been brought about by the PMED™ technology, which involves the delivery of DNA 
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 coated onto gold particles (1-3 micron in size) into the epidermis using a high pressure 
helium gene gun.  Phase I clinical trials with PMED™ for influenza vaccine resulted in 
100% seroconversion with as little as 4 μg dose of DNA.  This approach is currently 
being explored for cancer, genital herpes, Hepatitis B, and HIV vaccines in phase I 
clinical trials.  In addition, genetic immunization show promising applications in prime-
boost vaccine strategies, where the pDNA vaccine may be used for initial immunization 
followed by boosting with another type of vaccine, i.e. viral vectors or subunit-based 
vaccines [49].  Thus, genetic immunization may prove successful with the development 
of more effective delivery devices in combination with heterologous prime-boost 
immunization strategies.  A major safety concern raised with the use of pDNA based 
vaccines is the potential of the plasmid to integrate into the host genome [42]. 
The candidate subunit or pDNA based vaccines deem themselves much safer than 
traditional approaches as they are purified and well-defined entities; however, they are 
less immunogenic than their counterparts due to removal of various components of the 
whole pathogen which can function as recognition elements in the body and trigger the 
innate immune system – naturally mediating enhanced immune responses.  Therefore, 
one downfall of new generation vaccines is that they are not very immunogenic when 
administered by themselves and many of these approaches require the use of adjuvants to 
generate strong immune responses.   
 
3.1.3 Trends and future developments in vaccines  
Although significant developments have been made in vaccines, a number of 
challenges still lie ahead for the prevention of numerous diseases.  The growing 
 16
 knowledge and technological advancements in various areas of vaccinology have made 
this an exciting and prevailing field.  It has become evident from past experiences that a 
greater understanding of immunological functions and viral pathogenesis for many 
organisms will be essential in developing effective vaccines for chronic infections such as 
HIV, human cytomegalovirus, herpes simplex virus (HSV) and hepatitis C virus (HCV).  
Moreover, vaccines have been traditionally used for preventing infectious diseases; 
however, current trends demonstrate a shift in their application as there is a great deal 
effort being focused on designing vaccines for non-infectious diseases such as 
Alzheimer’s, cancer, autoimmune diseases, and for therapeutic applications for 
controlling progression on to disease as in the case of HIV, HSV, and human 
papillomavirus (HPV) [28]. 
Whereas the historical basis for vaccines was largely empirical, technological 
advancements, in particular genetic engineering techniques, can potentially lead to a 
more rational approach in design of vaccines.  Several examples of the application of 
genetic engineering techniques in generating safer, more effective vaccines have already 
been presented in the previous section in the discussion of new generation vaccines.  
Additional examples of the benefits of these techniques include, 1) attenuation of live 
vaccines via gene deletions or mutations, 2) engineering bacterial or viral vectors to 
express foreign proteins of interest, 3) generating reassortant viruses (i.e. influenza 
vaccines) by combination of genes from two or more different viral strains, and 4) 
generating T cell epitope based vaccines [50].  In spite of the successes of generating 
more stable, less virulent live attenuated vaccines with these techniques, there is still a 
significant concern in using this approach for many diseases.  Moreover, the growing 
 17
 requirement for safer and molecularly well-defined entities imposed by regulatory 
agencies lends future developments in this area towards the use of subunit based 
vaccines.  Therefore, a great deal of focus in this area has been placed on identifying the 
key antigens in preventing or controlling infection as well as on finding newer, more 
effective adjuvants due to their inherent need for enhancing immune responses with these 
purified antigens [51].  Other key considerations for developing new vaccines include: 
storage, stability, ease of manufacture and scale up, ease of administration or needle free 
administration, and feasibility of single dose.  The use of needle-free devices and single-
dose vaccination are particularly important for increased patient compliance. 
 
3.2 Vaccinology and key mediators of immunity 
Despite the successes of some of the earliest vaccines such as smallpox and polio, 
many of these developments have been made empirically without much knowledge on 
the functions of immune system and its components in regard to generating an effective 
immune response.  The most successful vaccines developed to date have been made for 
pathogens that cause acute infections and that could be potentially cleared from the body 
by the host’s immune system.  Moreover, the effectiveness of many of these vaccines has 
largely relied on the generation of high levels of neutralizing antibodies.  An 
understanding of the immune system and its components has greatly advanced with 
emerging chronic infections such as HCV, HIV etc. that cause persistent infections that 
cannot be cleared by the body’s immune system even in the presence of strong immune 
responses.  Many, if not most, of these infections are intracellular and offer additional 
challenges due to mutations in the virus, giving rise to varying strains.  Thus, with the 
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 aim of developing effective vaccines for these more challenging infections, a greater 
understanding of the immunological functions has been and continues to be gained.  The 
contributions of immunology to this area will be necessary for developing safer and more 
effective vaccines, adjuvants, and delivery systems. 
The immune systems and its functions can be divided into two categories: the 
innate and adaptive immune system [52,53].  Both are essential in providing protection 
from organisms and have specialized components that are involved in generating an 
immune response.  Although both systems are generally thought of as distinct, there is 
considerable interplay in the two systems in fighting infections and they in fact share 
some of components (i.e. antigen presenting cells).  Key features of each system are 
presented in Table 3.2.   
 
3.2.1 Innate immune system 
The innate immune system is often referred to the non-specific component of the 
immune system [53].  This system is the first line of defense against pathogens and is 
activated through recognition of non-specific, conserved molecular structures commonly 
present on pathogens or groups of pathogens, but not found in the host, called pathogen-
associated molecular patterns (PAMPs) [54,55].  Some examples of PAMPs include the 
lipopolysaccharides (LPS) found in gram-negative bacteria and double-stranded RNA 
produced by many viruses.  These PAMPs are recognized by a limited number of 
pathogen recognition receptors (PRR), which are germline-encoded receptors present in 
cells comprising the innate immune system [55,56].  Activation of the innate immune 
system occurs within hours of encountering an organism and results in the production of 
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 pro-inflammatory cytokines such as interferons (IFN-α, β, and γ), interleukins (ILs), and 
activation of complement pathway [52,55].  The immune response generated mediates 
the clearance of the pathogen from the host; however, the immune response to the 
pathogen is constant – no heightened immune response is generated with successive 
exposures to the pathogen [52,53].   
 The activation of innate immune system is mediated by the recognition of 
pathogens by PRR including Toll-like receptors (TLRs), scavenger receptors, and Fc 
receptors.  A detailed review of the recognition, binding, and signaling processes 
involved in the innate immune response is presented elsewhere (see references 
[55,57,58]). 
 
3.2.2 Adaptive immune system 
Hallmarks of the adaptive immune system include high specificity and memory of 
the specific immune responses generated [52].  Unlike the innate immune system, the 
adaptive immune system is capable of generating stronger and higher immune responses 
with successive exposures to the pathogen. Thus, it is possible to prevent or reduce the 
course of infection upon re-exposure to the same pathogen – via the generation of a 
memory response.  This branch of the immune system is composed of three main cells: 
antigen presenting cells (APCs), B lymphocytes (B cells) and T lymphocytes (T cells).  
The APCs provide a key bridge between the innate and adaptive immune systems, 
whereas, the lymphocytes are the mediators of the high specificity and memory 
components unique to the adaptive immune system.  Both lymphocytes involved in the 
adaptive immune response are derived from a common lymphoid progenitor cell in the 
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 bone marrow; however, their maturation at different sites in the body raises these two cell 
types [52].  Moreover, both naïve lymphocytes are located in specialized areas in 
secondary lymphoid organs (i.e. the mucosal lymphoid tissues, draining lymph nodes and 
spleen) where antigen recognition by these cells occurs, generating effector cells that can 
participate in the antigen-specific response.  Therefore, unlike innate immune system 
which initiates responses at the site of infection, the adaptive immune responses are 
initiated in the secondary lymphoid organs.   In addition, memory cells that are able to 
respond more robustly to subsequent exposures to the same pathogen are generated 
during adaptive immune responses.  One major difference between the two lymphocytes 
for antigen recognition is that B cells can directly recognize the antigen or pathogen 
through receptors present on the cell surface, whereas T cells do not have the ability to 
directly recognize the antigen and one of the functions of APCs is to process the antigen 
and present peptide fragments bound to cell surface molecules for recognition by T cells.  
The main interactions between the cells of the adaptive immune system leading to the 
production of antigen specific immune responses are summarized in Figure 3.1.  A brief 
description of the various functions of the cells in generating an adaptive immune 
response is given in the sections below (see references [52,53] for a comprehensive 
review).  
 
3.2.2.a Antigen presenting cells 
Pathogens taken up and processed by APCs initiate a sequence of events that 
ultimately leads to the activation of APCs and naïve T cells.  APCs are found on most 
tissues (i.e. skin and mucosa) and circulating throughout the body, constantly surveying 
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 the environment for invading organisms.  The ingested pathogens are then processed into 
peptide fragments (peptides of 9-15 amino acids), are conjugated to molecules encoded 
by genes of the major histocompatability complex (MHC) and are presented on the 
surface of APCs for T cell recognition.  This process is referred to as antigen 
presentation.  Two types of MHC molecules are present: MHC class I, which are present 
on all cell types, and MHC class II, which are specifically expressed on APCs.  MHC 
class I molecules bind peptides of 9-10 amino acids, whereas MHC class II molecules 
bind to longer peptide fragments of 10-15 amino acids in length.  The processing 
pathway for the peptide fragments binding to these two MHC molecules is also distinct.  
MHC class I molecules are generally thought to bind to processed fragments of a protein 
synthesized in the cytoplasm, such as those resulting from infection from a virus.  On the 
other hand, MHC class II molecules primarily bind to peptide fragments of exogenously 
derived proteins, which have been processed in the lysosomes.  Naïve T cells possessing 
receptors of the same specificity as the epitopes presented on these peptide-MHC 
complexes can then bind to the cell surface; however, this interaction alone will not result 
in activation of naïve T cells.  Recognition of other cell surface molecules on the APCs 
commonly referred to as co-stimulatory molecules by the T cell receptors is also 
necessary to result in activation of the naïve T cells.  While all APCs have the potential of 
stimulating naïve T cells by up-regulating expression of MHC class II and co-stimulatory 
molecules during infection, the most efficient APC and the primary APC responsible for 
activation of naïve T cells are the dendritic cells (DCs) (discussed in detail in section 
3.4). 
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 3.2.2.b T lymphocytes 
Immature lymphocytes that leave the bone marrow and mature in the thymus give 
rise to mature T lymphocytes or T cells.  These cells can be further subdivided into two 
categories depending on the expression on cell surface markers as CD4 and CD8 positive 
T lymphocytes.  Both T cells also express the T cell receptor (TCR), which has 
specificity for certain peptides and is involved in recognition of the MHC-peptide 
complex presented on APCs.  Immune responses mediated by T cells are generally 
referred to as cell-mediated immune (CMI) responses.   
The CD8 positive (CD8+) T cells also called cytotoxic T lymphocytes (CTLs) are 
activated by the recognition of peptides presented on MHC class I molecules.  Activation 
of CTLs results in lysis of infected cells by recognition of the MHC class I-peptides on 
these cells.  The CD4 positive (CD4+) T cells are referred to as the T helper cells (Th) 
and these cells can be further subdivided into Th1 and Th2 cells.  T helper cells are 
activated by the recognition of peptides presented on MHC class II molecules and the 
type of Th cell formed is influenced by various factors (i.e. cytokines) during an 
infection.  For example, the release of pro-inflammatory cytokines such as IL-12 by 
APCs during the innate immune response causes differentiation of naïve Th cells into 
Th1 cells.  The two Th cell types also result in production for distinctly different cytokine 
profiles which are associated with mediating either cellular or humoral based immune 
responses.  Th1 cells release IL-2, IL-3, and IFN-γ and are associated with enhancing 
cellular responses, which are necessary for combating intracellular pathogens.  On the 
other hand, Th2 cells mediate humoral responses by releasing the cytokines IL-4, IL-5, 
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 IL-6 and IL-10.  Th2 responses are most effective at eliminating extracellular pathogens 
such as bacteria. 
 
3.2.2.c B lymphocytes 
B lymphocytes, more commonly referred to as B cells, mature in the bone marrow 
and are primarily responsible for producing antibodies (immunoglobulin, Ig) referred to 
as the humoral immune response.  Mature B cells express two types of Ig receptors on 
their cell surface: IgM and IgD, which can directly recognize and bind to antigens.  The 
binding of an antigen to the B cell receptor results in endocytosis of the antigen-receptor 
complex and processing of the antigen.  This process also ultimately leads to the 
activation and differentiation of B cells into plasma cells, which are able to secrete 
antigen specific antibodies that can circulate in the blood.  The initial antibodies secreted 
in an immune response are IgM and upon interaction with cytokines released from 
activated Th cells, the isotypes of antibody produced by plasma cells can be varied to 
IgG, IgE or IgA (a process referred to as isotype switching).   
The uptake and processed antigen can also be presented on the surface of MHC 
class II molecules on B cells.  Although they are not very efficient stimulators of naïve T 
cells, B cells that have been induced to express the necessary co-stimulatory molecules 
can function as APCs, stimulating naïve T cells. 
 
3.3 Adjuvants and mechanism of action  
Adjuvants, derived from the Latin word adjuvare which means to help, have been 
described as any material used with antigens in immunization that aid in enhancing the 
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 cellular and/or humoral immune responses [2,59].  The use of adjuvants was first 
introduced by Ramon in 1925, who demonstrated that immune responses to diphtheria 
and tetanus toxoid could be enhanced by injection with other compounds such as agar, 
tapioca, lecithin, starch oil, saponin, and breadcrumbs [60].   In the recent years, a great 
deal of attention has focused on the development and application of new adjuvants.  This 
trend has been introduced partially by the interest in using new generation vaccines, 
which are purified and lack many of the components of pathogens recognized by the 
innate immune system and therefore, tend to produce poor immune responses when given 
alone.  Adjuvants can also be used to modulate the type of immune response generated to 
the antigen.  Appropriate selection of the adjuvant with the antigen can result in primarily 
cellular (CTL and Th1) or humoral based immune responses.  For example, aluminum 
salts (commonly referred to as Alum) tend to produce predominantly humoral based 
immune responses [61-63] where as bacterial derived components such as Lipid A and 
Saponins (QS21) are associated with producing cellular type responses [1,64].  Thus, the 
selection of the appropriate adjuvant has to be made based on the type of immune 
response desired or that is necessary for providing protection.  However, the selection is 
often empirical in many cases because the exact immune responses necessary to provide 
protection from pathogens in many diseases are not known.    
Alum was first introduced as an adjuvant in 1926 and continues to be the only 
FDA approved adjuvant for routine human vaccination in the U.S. [65].  It has been used 
widely and proven effective for enhancing humoral immune responses.  Although Alum 
has been used extensively in vaccines for over 70 years, the exact mechanisms by which 
they enhance immune responses have not been fully elucidated.  Proposed mechanisms 
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 include:  1) enhancing the uptake of associated antigen into APCs, 2) forming a depot in 
macrophages present in muscle, and 3) causing a local inflammatory response due to 
necrosis at the injection site possibly resulting in the release of inflammatory cytokines 
and activation of APCs [66-69]   Alum is a weak adjuvant for mediating cellular 
immunity and is associated with generating the production of immunoglobulin E 
associated with allergic reactions [3,62,70].  Thus, there is a great need for more effective 
adjuvants to enhance cell-mediated responses with protein-based vaccines, as these are 
regarded to be important for many chronic infections such as HIV.  Many new adjuvants 
have been evaluated in clinical trials; however, most have proven too toxic for routine 
human vaccination.  In addition to demonstrated safety and biocompatibility, other ideal 
adjuvant properties for consideration include ease of manufacture, wide applicability, 
cost effective, and stability.   
Although the exact mechanisms by which adjuvants enhance immune responses 
are not completely understood, the three general mechanisms proposed by which 
adjuvants enhance immune response [2,65,71] are listed below. 
1.  Adjuvants may be used to form a depot of the antigen at the site of injection, 
avoiding rapid clearance of the antigen from the body.  The antigen can then be 
slowly released over a period of time.  Some examples of adjuvants that are 
thought to enhance immune responses by depot formation include water-in-oil 
emulsions (CFA and IFA), Alum, and PLGA microparticles (>10 microns in 
size). 
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 2. Adjuvants can promote uptake of the antigen by APCs leading to higher 
antigen-specific immune responses.  Adjuvants of particulate nature, as in the 
case of pathogens, are naturally targeted for uptake by APCs.  
3. Adjuvants can induce release of pro-inflammatory cytokines and induce 
expression of cell-surface molecules on APCs, causing them to become more 
efficient at stimulating naïve T cells.  Some examples of adjuvants exerting their 
effects via this mechanism include:  PAMPs or cytokines such as IL-2 or IL-12, 
which is induced during inflammation.  
A general list of adjuvants used for enhancing immune responses is presented in 
Table 3.3.  These adjuvants can be more generally classified as immunostimulatory or 
particulate. 
 
3.3.1   Immunostimulatory adjuvants 
 Immunostimulatory adjuvants enhance immune responses by initiating 
intracellular signaling pathways that lead a number of events including: maturation of 
APCs, the release of pro-inflammatory cytokines or upregulation of cell surface 
molecules such as MHC class II and co-stimulatory molecules on APCs.   
 
3.3.1.a Cytokines 
  Cytokines are small, secreted proteins that are naturally found in the body and 
play a critical role in antigen-presentation, activation and proliferation of antigen-specific 
lymphocytes during an immune response. In addition, many cytokines are involved in 
biasing an immune response to Th1 or Th2 and can be used to selectively modulate the 
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 immune response generated.  For example, IL-12 released by APCs during an innate 
immune response is associated with biasing the development of naïve CD4+ T cells into 
Th1 cells.  Moreover, the release of IFN-γ by Th1 cells mediate cellular responses by 
causing activation and proliferation of CD8+ T cells [72,73].  On the other hand, the 
presence of IL-4 or IL-10 during an immune responses directs development of Th2 cells 
[74].  Thus, the use of cytokines has been attractive for manipulating or directing the 
types of immune responses obtained.  In addition, cytokines may also enhance immune 
responses via recruitment of APCs at the site of injection for antigen uptake and 
influencing expression of MHC II and co-stimulatory molecules on these cells.   The 
most extensively evaluated cytokines include:  IFN-γ and IFN-α, IL-2, IL-4, IL-7, IL-12, 
IL-15, IL-18, TNF-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[75].    The main disadvantages in using cytokines are that the proteins can be degraded 
rapidly in vivo and/or dose-related toxicity is associated with cytokine use [76,77].  To 
overcome these issues, the use of particulate delivery systems for slow release at the site 
of injection as a means to minimize toxicity has been investigated [78-82].  In addition, 
cytokines encoded on pDNA alone or encoded along with an antigen have been 
investigated for enhancing immune responses [43,44,77].  
 
 
3.3.1.b Bacterial derived adjuvants: PAMPs and TLRs 
 PAMPs are naturally recognized by cells of the innate immune system and upon 
binding to the PRRs initiate a signaling pathway resulting in the production of cytokines 
or upregulation in the expression of costimulatory molecules.  This activation of the 
innate immune system subsequently triggers adaptive immune responses.  TLR ligands 
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 have been evaluated as adjuvants for enhancing immune responses [56].  Currently, there 
are 10 identified TLRs and they are located either intracellularly (TLR3, 7, 8, 9) or 
expressed on the cell surface (1, 2, 6, 4, 5, 11).  Ligands for many of the TLRs have been 
identified [57].  The binding of ligands to TLRs on DCs modulates the expression of 
chemokine receptors and causes immature DCs to undergo maturation as well as 
migration from peripheral tissues into the draining lymph nodes where they can stimulate 
naïve T cells and initiate the adaptive immune responses.  Many of the TLR ligands are 
associated with generating strong cellular type immune responses [56,83-85].  Two 
bacterial derived immunostimulatory adjuvants that have been extensively investigated 
will be discussed.  Both mediate their effects via binding to TLRs, initiating the innate 
immune response. 
 
Lipopolysaccharide derivatives 
LPS is derived from the cell wall of gram negative bacteria and is composed of 
two domains: a hydrophilic polysaccharide portion which extends out from the cell 
surface and a hydrophobic domain known as Lipid A embedded in the cell wall [86].  
LPS binds to TLR 4 and has shown to be extremely strong adjuvant for generating 
cellular responses [56,87,88].  However, LPS can cause septic shock and this severe 
toxicity limits it’s use as an adjuvant for humans [56,88].  The adjuvant activity of LPS is 
contributed to Lipid A and a chemically modified derivative of LPS called 
monophophosphoryl Lipid A (MPL) has demonstrated to retain the adjuvant properties 
with dramatically decreased toxicity [89].  MPL has been shown to generate strong Th1 
type responses [90] and has been extensively investigated in clinical trials [91-93].  MPL 
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 is currently under investigation for use with Leishmania, malaria, TB and cancer antigens 
and has been evaluated in more than 30,000 humans.  Moreover, MPL is approved for 
use in Canada for a melanoma vaccine called Melacine®.  Synthetic MPL derivatives 
(RC-529) have also been evaluated in phase II clinical trial for Hepatitis B vaccine.  
Additionally, the Lipid A derivative OM-174 has been evaluated in cancer patients and 
demonstrated acceptable safety profile [77,94].   
 
CpG 
Bacterial DNA has demonstrated potent immunostimulatory activity due to the 
presence of unmethylated CpG (cytosine phosphate guanosine) dinucleotides in a 
particular sequence context, referred to as CpG motifs.  Unlike bacterial DNA, CpG 
motifs are not as prevalent or usually methylated in mammalian DNA, making them 
unable to stimulate the immune system [95].  Bacterial DNA containing CpG motifs are 
recognized by TLR9, which is expressed in the endoplasmic reticulum.  Recognition by 
TLR9 results in signal transduction once the receptor translocates to the lysosomal 
compartment, where it can bind to bacterial DNA taken up by cells [96].  The binding of 
CpG motifs to TLR9 triggers the production of various pro-inflammatory cytokines such 
as IL-6, TNF-α as well as the Th1 promoting cytokine, IL-12, and induces the expression 
of co-stimulatory molecules on APCs, enabling them to mature into professional APCs 
and become more efficient at antigen presentation [97].  More importantly, the 
identification of synthetic oligodeoxynucleotides (ODN) containing CpG motifs (referred 
to as CpG ODNs) that mimic the potent immunostimulatory properties of bacterial DNA 
has generated considerable interest to investigate them as potential adjuvants.  Extensive 
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 in vivo experiments in mice have shown that CpG ODNs provide significant 
enhancements in immune responses to various antigens using various routes of 
administration [98-104] .  In addition, studies with CpG ODNs demonstrate the ability to 
generate strong Th1 and cellular immune responses [105-107].  As with most 
immunostimulatory adjuvants, adverse side effects such as enlarged spleen [108] and 
lymph nodes [109] have been reported in mice; however, these were reported to be 
sequence- and dose-dependent [108].  Moreover, some concern has been raised that CpG 
ODN use may generate autoimmune diseases due to over stimulation of the innate 
immune system; however, repeated doses administered in vivo in mice and non-human 
primates to date have shown no toxicity [110].  Therefore, the concerns raised with the 
use of CpG ODNs may be prevented by judicious selection of the appropriate CpG 
sequence and dose.  It is important to note that the strength of the immune response 
generated by each CpG ODN can vary and the optimal sequences differ from species to 
species.  However, optimal CpG ODN have been identified for a number of different 
species including mice, rabbit, sheep, goat, cattle, swine, horse, rhesus monkey, 
chimpanzee, and humans [111].  Clinical trials evaluating the use of CpG ODNs for 
adjuvants in hundreds of patients have reported no adverse reactions due to CpG [110].  
In fact, Phase I clinical trials have demonstrated that hepatitis B surface antigen (HBsAg) 
adjuvanted with CpG ODN resulted in stronger, more robust immune responses 
compared to the HBsAg alone [94,112].   
 
 
 
 31
 3.3.1.c Saponins 
Saponins, isolated from the tree Quillaja saponaria Molina, have demonstrated to 
possess potent immunostimulatory activity.  Saponins are amphipathic molecules 
possessing a hydrophilic carbohydrate and hydrophobic steroid or triterpene moiety 
[113].  A major disadvantage of saponins is their surface-active character which causes 
hemolysis of red blood cells in vitro [114].  Quil A, the active component of saponins, 
has been widely investigated as adjuvants in veterinary vaccines for years; however, its 
hemolytic activity has limited its use in human vaccines [2,115].  HPLC analysis of 
saponins led to the identification of a heterogeneous group of triterpene glycosides with 
varying adjuvant activity and toxicity [113].  Among these highly purified saponins, QS-
21 has been the most extensively evaluated and has demonstrated to possess reduced 
toxicity (considerably reduced hemolytic activity) while retaining the potent adjuvant 
properties [113,116-120].  QS-21 has been demonstrated as a strong adjuvant for both 
cellular, CTL and Th1, and humoral immune responses including enhancements in IgG2a 
isotype with subunit-based vaccines [114,121-123].  The application of QS-21 with HIV-
1 DNA for systemic and mucosal immune response enhancements has also been 
demonstrated [124]. 
The adjuvant activity of QS-21 has not been fully elucidated.  Saponins can 
interact with cholesterol on cell membranes resulting in pore formation, which may be 
one way antigens could gain access to the cytoplasm for antigen presentation via the 
MHC class I pathway to generate CTL responses [125].   In vitro studies have 
demonstrated that murine macrophages stimulated with QS-21 result in cytokine 
production [77].  Moreover, in vivo evaluation in BALB/c mice has demonstrated the 
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 ability of QS-21 to initiate innate immune responses by enhancing the activity of natural 
killer cells in a dose-dependent manner [77].  QS-21 has been evaluated in numerous 
clinical trials as an adjuvant for cancer [126-129], malaria [130], HIV-1 [131], and 
pneumococcal [77] vaccines.  QS-21 has now been administered to over 3500 patients in 
over 90 clinical trials, including some children [77,94] and the most common side effect 
is reported to pain or tenderness at the site of injection [131,132].  Doses of QS-21 
equivalent to or greater than 200 μg have been reported with significant local reactions 
raising concerns of adverse effects with this adjuvant [77,133].  Hence, a fine balance 
between the QS-21 dose and the adverse effects must be determined for each antigen and 
taken into consideration for each vaccine application. 
 
 
3.3.2 Particulate delivery systems   
Particulate delivery systems have been investigated extensively for enhancing 
immune responses with new generation vaccines.  This class of adjuvants exerts their 
effect mainly through formation of an antigen depot at the site of injection or by 
enhancing the uptake of the associated antigen by APCs.  Particulate delivery systems are 
passively targeted for uptake by APCs since they have dimensions that are comparable to 
naturally occurring pathogens (Table 3.4) [125].  The use of emulsions, immune 
stimulating complexes, liposomes, microparticles, and nanoparticles as adjuvants will be 
reviewed.   
 
 
 
 
 33
 3.3.2.a Emulsions 
Emulsions are one of the oldest adjuvants investigated for enhancing immune 
responses, with the first reported use in 1916 [134].  Emulsions are generated by mixing 
antigen solubilized in the aqueous phase with an oil phase in the presence of surfactant.  
Emulsions can be classified into two types depending on the continuous phase:  oil-in-
water emulsions are oil droplets dispersed in the water phase and water-in-oil emulsions 
are water droplets dispersed in the oil phase.  Interest in using emulsions as adjuvants was 
stimulated by the initial demonstration of Freund in 1937 that a water-in-oil emulsion 
composed of mineral oil mixed with killed mycobacteria could serve as a potent adjuvant.  
This adjuvant is more commonly referred to as complete Freund’s adjuvant (CFA) and it 
has been used extensively in laboratory animal research for generating strong cellular and 
humoral immune responses.  However, the use of CFA is associated severe side effects 
[135-138] and is too toxic to be used as an adjuvant in humans.  An alternative adjuvant 
preparation without killed mycobacteria, incomplete Freund’s adjuvant (IFA), has been 
used in a number of veterinary vaccines and has been evaluated in humans with influenza 
and killed poliomyelitis vaccines [134,139].  However, localized toxicity such as 
formation of abscesses and granulomas at the site of injection prevented further 
evaluation of IFA for human vaccines.  It is thought that many of these localized 
reactions were due to impurities in the antigen or the formulation components, i.e. the oil 
or emulsifier, and that the use of highly purified mineral oils and surfactants available 
may reduce the side effects of IFA [139]. 
In attempt to replace Freund’s adjuvant, the use of an oil-in-water emulsion based 
on the biodegradable oil squalene was reported in the 1980s [1].  One adjuvant 
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 formulation based on this system, syntax adjuvant formulation (SAF), induced strong 
cellular responses [140-142]; however, it was too toxic for human vaccination due to the 
inclusion of an immunostimulatory muramyl dipeptide (MDP) derivative [1]. These 
studies led to the development of MF59, a squalene-in-water emulsion without MDP, as 
an adjuvant (see refs [143,144] for detailed review).  MF59 has been investigated with 
numerous antigens including influenza [145-148], hepatitis B [149,150], HIV-1 [151], 
HSV [152] and HPV [153].  In vivo studies in mice suggest that MF59 is taken up by 
macrophages and DCs at the site of injection and in the draining lymph nodes [154]; 
however, a second study evaluating the distribution of the co-administered antigen 
demonstrated that clearance of the antigen from the injection site was independent of 
MF59 [155].  MF59 was shown to be safe and well tolerated with several vaccines in 
clinical trials involving over 32,000 patients, including elderly patients, toddlers, and 
infants [143].  MF59 is currently approved as an adjuvant (in the influenza vaccine 
FLUAD®) in many European countries – the only other adjuvant besides Alum to be 
approved for use in routine human vaccination [156]. 
 
3.3.2.b Liposomes 
 Dispersion of phospholipids and other polar ampiphiles in aqueous buffers result 
in the formation of closed, concentric bilayer vesicles called liposomes.  These systems 
contain an aqueous core and a lipid bilayer, thus allowing for delivery of both hydrophilic 
and hydrophobic molecules.  Liposomes can vary in size from 20 nm to several microns 
and can be classified into two groups depending the number of concentric lipid bilayers:  
small or large unilamellar vesicles (SUV or LUV, respectively) consist of one lipid 
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 bilayer and large multilamellar vesicles (MLV) consist of multiple lipid bilayers [7]    
Liposomes have been investigated for numerous drug delivery applications, are marketed 
for delivery of cancer drugs [157] and have demonstrated to be relatively safe with no 
reports of granulomas after parenteral administration [7,134].  The application of 
liposomes as adjuvants was first reported with diphtheria toxoid in 1974 [158] and have 
since been shown to be effective for enhancing immune responses to numerous other 
antigens [6,159-161] .   Moreover, liposomes have been reported to generate good CTL 
responses with various antigens in animal models [162-166].  Studies to elucidate the 
mechanism of immune response enhancement using liposomes suggest that liposomes 
taken up into endosomes release part of the encapsulated antigen directly in the 
cytoplasm, allowing the antigen to gain access to the MHC class I pathway and leading to 
stronger CTL responses [167]. 
The stability of liposomes in vivo is dependent on the fluidity of the lipid bilayer, 
which is determined by the type of phospholipids used in preparation.  Many preparations 
include the use of cholesterol to improve stability of the liposome formulations.  
However, the use of phospholipids also poses limitations because they can be rapidly 
degraded in the host by phospholipases [2].  In addition, the composition and physical 
characteristics of liposomes are critical parameters influencing particle uptake by 
macrophages [168] and dendritic cells [169] and could potentially affect the immune 
responses obtained in vivo [170].  The use of stable polymerized liposomes have been 
investigated for enhancing immune responses to encapsulated antigens via the oral route 
[171].  More recently, different types of liposomes have been prepared using alternative 
amphipathic molecules to phospholipids and are classified based on their composition as 
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 [172]:  Virosomes (fusogenic liposomes), Transferosomes, Archaeosomes, Niosomes, 
Chochleates, and Proteosomes.  These systems have been evaluated in animal models and 
demonstrate to be as effective or superior to conventional liposomes at enhancing 
immune responses [160,173-179].  In some cases, these alternative liposomes show 
enhanced stability compared to the conventional liposome formulations [179,180].  Of 
these alternative liposomes, virosomes, which resemble SUVs and contain influenza 
hemagglutinin (HA), have demonstrated greatest potential for use in human vaccines 
[51,164,176]. 
 
3.3.2.c Immune stimulating complexes (ISCOMS) 
 Immune stimulating complexes, ISCOMS, were introduced by Morein et al. in 
1984 as an antigen delivery system with immunostimulatory properties [181].  ISCOMS 
form spontaneously upon mixing appropriate ratios of phospholipids, cholesterol, Quil A, 
and an amphipathic antigen (i.e. viral membrane proteins).  Electron micrographs of 
ISCOMs demonstrate characteristic, rigid cage-like structures of about 40 nm size [172].  
This adjuvant has been shown to be effective at enhancing immune responses by both the 
parenteral and mucosal routes [182,183].  The use of ISCOMs has been investigated in 
small animals with antigens for measles [184-186], influenza [187,188], and HIV 
[189,190] vaccines and both humoral and cell mediated immunity were induced.  More 
importantly, these strong, protective immune responses were maintained when tested in 
larger animal models including non-human primates [182] and ISCOMs has been 
licensed for use in an anti-influenza vaccine for horses [172].  The hemolytic activity and 
toxicity normally associated with Quil A is greatly reduced in this system due to the 
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 hydrophobic interactions with cholesterol, preventing significant interactions with the cell 
[191].  Recent studies suggest that IL-12 plays a vital role in the strong cell mediated 
responses observed in vivo with ISCOMs and found that the main APCs involved in 
priming CD4+ and CD8+ T cells are DCs [192,193].    ISCOMs are currently being 
evaluated in phase I clinical trials with influenza, HPV, and human cytomegalovirus 
[94,172].  The major limitation of this approach is its applicability to different antigens.  
ISCOMs typically involve the use of membrane proteins; however, inclusion of antigens 
that do not possess this hydrophobic character may prove difficult and require extensive 
modification for efficient incorporation into ISCOMS.  
 
3.3.2.d Nanoparticles and microparticles 
 Solid colloidal particles can be classified depending on their size as nanoparticles 
for particles in the 10-1000 nm in size range or microparticles for those particles greater 
than 1 μm in size.  The preparation of nanoparticles and microparticles has been reported 
using a wide range of materials [194].  Moreover, numerous methods have been reported 
for preparation of nanoparticles and microparticles; however, the most commonly 
practiced techniques include emulsion and interfacial polymerization, high-pressure 
homogenization, solvent extraction/evaporation (including the double-emulsion-solvent 
evaporation technique used for entrapping proteins) and microemulsion precursor 
technology.  In addition to parameters such as cost-effectiveness, applicability, ease of 
scale up, the method used for preparing the particulate delivery system is extremely 
critical and must be carefully selected as this can potentially influence the stability of the 
antigen and ultimately affect the quality of immune response obtained. 
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 The interest in using solid colloidal particles for enhancement in immune 
responses was stimulated by studies reported by Kreuter and Speiser on the adjuvant 
properties of polymeric nanoparticles [195-197].  These studies reported the use of 
poly(methyl methacrylate) (PMMA) nanoparticles for enhancing immune responses to 
both adsorbed and entrapped vaccines.  Although the use of PMMA nanoparticles was 
shown to enhance immune responses to a number of different antigens by Kreuter [198], 
the utility of these particles is limited by their accumulation in the body due to the 
extremely slow rate of degradation of the polymer [199].  The use of biodegradable 
poly(alkylcyanoacrylates) (PACA) for preparing nanoparticles was introduced by 
Couvreur et al. [200] and their use has been investigated for delivery of various 
hydrophilic and lipophilic drugs; however, the use of these nanoparticles has not been 
reported in vaccines and controversy over the toxicity due to alkylcyanoacrylate 
monomers exists.   
 The idea of using solid colloidal particles was further advanced by O’Hagan et al. 
[201,202] and Eldridge et al. [11,203] by demonstrating that antigens entrapped in 
poly(lactide-co-glycolide) (PLGA) microparticles resulted in similar enhancements in 
immune responses as the antigen emulsified with Freund’s adjuvant.  Although other 
polymeric materials such as chitosan [48,204,205], poloxamers [206], polyphosphazenes 
[207], and polyanhydrides [208,209] have been investigated for enhancing immune 
responses, the use of PLGA polymers has been most preferred due to the extensive 
history of use and biocompatibility in humans.  PLGA polymers have been found 
numerous applications in humans for medical purposes such as surgical sutures, have 
demonstrated excellent biocompatibility and safety, and have been approved for use as 
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 drug delivery devices for a number of therapeutic products [210].   A detailed review of 
the various methods used for preparation of PLGA microparticles and nanoparticles is 
presented elsewhere [211].  PLGA microparticles have been effective at entrapping a 
range of different antigens and in vivo evaluation in animals have demonstrated them to 
be effective at enhancing both cellular (Th1/CTL) and humoral immune responses using 
various routes of administration [8,212-217].  More recently, the utility of PLGA 
microparticles has been attractive for enhancing immune responses to pathogens that may 
be used as potential biowarfare agents [218].  In addition, PLGA microparticles have also 
been investigated for enhancing mucosal immune responses, which are regarded to be 
important for many diseases as the nasal, rectal, and vaginal sites are the routes of entry 
for most pathogens [171,219,220].  The potential of PLGA microparticles for oral 
delivery of entrapped antigens has also been evaluated and shown to induce both 
systemic and mucosal immune responses [213,217,221-225].  This enhanced immune 
response via the oral route is speculated to be due to uptake of the microparticles by 
mucosal associated lymphoid tissue (MALT) [226].  Although microparticles have 
demonstrated good enhancements in mucosal immune responses in small animal models, 
generating these responses non-human primates and humans has been challenging [227]. 
The use of PLGA polymer for preparation of controlled release drug delivery 
systems has been of great interest and currently there are a number of products on the 
market using this technology.  The release rate of the entrapped molecule from the 
microparticle can be modified by altering the co-polymer composition, molecular weight, 
crystallinity of the polymer, and the size of the microparticles [228,229].  This property 
has made PLGA microparticles extremely attractive for development of single-dose 
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 vaccines [230-234].  The concept of oral delivery and single-dose vaccines using 
microparticles rely on the antigen being entrapped within the microparticle.  However, it 
must be realized that a great deal of work is necessary to ensure the stability of the 
entrapped antigen as this can influence the in vivo results [235].  The entrapment of the 
protein in microparticles is associated with a number of issues such as protein stability 
during encapsulation, storage and hydration, as well as the environment experienced in 
vivo during antigen release [229].   
As an alternative to antigen entrapment, the surface characteristics of PLGA 
microparticles have been modified by incorporation anionic or cationic surfactant during 
the microparticle preparation for adsorption of the antigen on the surface of the particle 
via electrostatic and van der waals interactions [9,212,236].  Antigens adsorbed to the 
surface of microparticles have shown enhanced immune responses in vivo in mice 
[237,238] and these systems are undergoing evaluation in phase I clinical trials 
(http://www.iavireport.org/trialsdb/vaccinedetail1.asp?i=82). 
As noted before, one of the main mechanisms by which particulate delivery 
systems are thought to enhance immune response is by enhanced uptake into APCs.  In 
vitro studies demonstrate both nanoparticles [239,240] and microparticles [241,242] are 
taken up by APCs.  In addition, the efficiency of antigen presentation was found to be 
enhanced by 10-100 fold using PLGA microparticles [241].   The uptake of particles by 
APCs is influenced by several factors including charge, hydrophobicity/hydrophilicity, 
and size [168,242].  The increase in hydrophobicity of particles was reported to have 
greater adjuvant activity in vivo in one study [243].  Interestingly, in vivo studies have 
demonstrated that smaller particles are taken up into lymphatics better than larger 
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 particles [11,12,244]; thus, having greater chances of being taken up by residing APCs.  
Combined, these two factors, size and drainage into the lymphatics, correlate with 
enhanced immunogenicity of smaller microparticles compared to larger microparticles 
[11-13].  The inverse correlation of particle size and immune response has also been 
reported by Kreuter with nanoparticles in the 62-306 nm range [10].    
 The superior immune responses obtained in vivo using smaller particles have 
stimulated a great deal of interest in further investigating nanoparticles for subunit-based 
vaccines.  To this end, PLGA nanoparticles have been shown to enhance immune 
responses in mice [245-247].  The potential of cationic nanoparticles adsorbed with 
hepatitis B surface antigen and β-galactosidase to induce antigen-specific systemic (IgG, 
Th1/Th2) and mucosal (IgA) responses was demonstrated after intranasal administration 
[248].  More recently, a novel method for preparation of nanoparticles from oil-in-water 
microemulsion precursors was demonstrated by Mumper et al. [14-16,249,250].  The 
microemulsion precursors are prepared by mixing appropriate ratios of oil, water, and 
pharmaceutically acceptable surfactant(s) at an elevated temperature and by simply 
cooling these microemulsions to room temperature nanoparticles approximately 100 nm 
in size are obtained.  These nanoparticles have the advantage of being prepared in a 
single step, one vessel process without the use of organic solvents and with relative ease 
in modifying the physical characteristics of the particles by choosing the appropriate 
surfactants.  In addition, the nanoparticles are potentially biocompatible as the oil phase 
used for preparation of these nanoparticles is comprised of cetyl alcohol and polysorbate 
60, both found in many pharmaceutical products.  More importantly, these nanoparticles 
are hemocompatible [251] and shown to be degraded via the alcohol dehydrogenase 
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 system [252].  In vivo evaluation in mice have demonstrated enhanced Th1 and humoral 
responses to the model antigen β-galactosidase [16] and HIV-1 Tat protein [253] coated 
on the surface of anionic nanoparticles after subcutaneous administration. 
 
3.3.3 Combined adjuvant formulations  
With the exception of ISCOMs and CFA, the adjuvants described up to this point 
involve the use of individual systems, i.e. particulate or immunostimulatory, for 
enhancing immune responses.  Many researchers have investigated the combination of 
various adjuvant systems as a means for obtaining synergistic enhancements in immune 
responses.  For example, the use HIV-1 gp120 and Gag p24 entrapped in microparticles 
that were dispersed in MF59 demonstrated significantly stronger antigen-specific 
humoral and Gag p24-specific CTL responses compared to either adjuvant alone [254].  
Alving et al. reported the use of lipid A entrapped liposomes adsorbed to Alum as a safe 
and effective method for enhancing humoral and antibody responses to surface bound or 
co-entrapped antigen in human clinical trials [166].   The use of QS-21 with low doses of  
IL-12 was effective for synergistic enhancement in immune responses to respiratory 
syncytial virus, demonstrating the combined adjuvant formulation was effective while 
reducing the dose-related systemic toxicity of IL-12 [82].  Moreover, the addition of 
MPL to QS-21 adjuvant was effective at directing immune responses to HIV-1 gp120 
from a Th2 to a Th1 type response [255].  The adsorption of IL-12 on Alum has also been 
investigated to enhance Th1 type immune responses to several antigens [78,81,256].   
In the quest for developing safer, more potent adjuvants, a great deal of interest 
has turned towards the investigation of various delivery systems for co-delivery of the 
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 antigen and immunostimulatory adjuvants [8,79,246,257-260].  The use of delivery 
systems entrapping an immunostimulatory adjuvant may provide an avenue for reducing 
the dose of antigen or the dose of immunostimulatory adjuvant by targeting uptake by 
APCs, providing a controlled release environment, and most importantly, decreasing 
toxic side effects, as in the case of ISCOMs.  The entrapment of the immunostimulatory 
adjuvant MDP in microparticles was shown to reduce the toxicity [261] while still 
providing potent immune responses to entrapped antigen [262].  Furthermore, CpG 
entrapped in PLGA nanoparticles was reported to generate potent cellular responses 
using a ten-fold lower dose compared to unentrappped CpG [263].   A particularly 
attractive approach for many investigators involves the use of immunostimulatory 
adjuvants with particulate systems for modulating the immune responses to obtain 
enhanced cellular based responses.  Table 3.5 lists several particulate systems that have 
been investigated with immunostimulatory adjuvants for improving immune responses to 
various antigens.    
 
3.4 Dendritic cells and targeting 
The body’s defense mechanism relies on a coordinated set of actions involving 
the components of the innate and adaptive immune system to generate strong, long-
lasting immune responses to pathogens.  As described in section 3.2, one of the key cells 
involved in this process are the APCs such as DCs.  DCs are regarded as professional 
APCs as they are the only cells capable of inducing primary immune responses [264].  
Although macrophages can function as APCs, their primary function involves 
phagocytosis and clearance of the pathogens from the body.  On the other hand, DCs 
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 primarily function to sense, ingest, and process invading pathogens (innate immune 
response) and present them to naïve T cells present in the secondary lymphoid organs 
(adaptive immune response).  DCs are also considered to play a vital role in naïve CD4+ 
T cell differentiation into Th1 or Th2 type and therefore, controlling both the quality of 
the immune response as well as the strength of the immune response [72,265].  
Moreover, studies have demonstrated that DCs have the ability to present exogenous 
antigens (i.e., from non-replicating pathogens and apoptotic or necrotic cells) on MHC 
class I molecules resulting in stimulation of CD8+ T cells.  This process, referred to as 
cross-priming, demonstrates a non-classical or alternative pathway present in DCs for 
processing and complexing exogenously derived peptides to MHC class I molecules and 
for inducing CTL responses [266].  In addition to the antigen presenting function, DCs 
play an important role in the viability, growth, and differentiation of activated B cells 
[267].  Consequently, the key link DCs provide between the innate and adaptive immune 
responses combined with their ability to cross-prime exogenous antigens have made these 
cells particularly attractive targets for manipulating immune responses and for targeting 
vaccines.   
 
3.4.1 Types of dendritic cells 
DCs are derived from hematopoietic progenitor cells in the bone marrow that give 
rise to DC precursors, which circulate the blood and lymphatics.  These DC precursors 
further develop into a heterogeneous population of DCs that can be classified into 
different subsets based on origin, phenotype, localization, and function.  In mice and 
humans, DC precursors can be derived from two different types of hematopoietic 
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 progenitor cells classified as the myeloid and lymphoid progenitors [268].  Furthermore, 
the DC precursors generated from these two progenitor cells give rise to phenotypically 
distinct subsets of DCs that have been identified in both mice and humans (described in 
detail in [264,268,269]).  For example, three phenotypically distinct DC subtypes have 
been identified in humans:  1) Langerine+ DCs, more commonly referred to as 
Langerhans cells (LCs), 2) myeloid DCs, and 3) plasmacytoid DCs.  Cell culture studies 
with human CD34+ hematopoetic progenitor cells suggest that LCs and myeloid DCs are 
derived from a common myeloid progenitor cell, whereas plasmacytoid DCs are thought 
to be derived from a lymphoid progenitor cell [268].  The complex nature of the DC 
subtypes is even more evident in mice, where DCs can be classified into six subtypes 
based on the expression of different cell surface markers [269].  Regardless of the 
species, the different DC subtypes contain both immature and mature DCs and they 
differentially express PRRs, which affects their ability to recognize and respond to 
pathogens and ultimately influence the quality of immune response generated.  For 
example, plasmacytoid DCs express TLR7 and 9 only, while both the LCs and myeloid 
DCs express TLR1, 2, 3, 4, 5, 8 but not 7 and 9.  Moreover, further differences have been 
reported between LCs and myeloid DCs.  Myeloid DCs have about a 10-fold higher 
efficiency of antigen capture and are more potent stimulators of CD4+ T cells compared 
to LCs [264].  Taken together, these differences in the DC subsets enable them to greatly 
influence the adaptive immune responses generated to various pathogens. 
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 3.4.2 Maturation of DCs into professional APCs 
DC precursors in the blood can migrate to various tissues and in the presence of 
certain cytokines, such as GM-CSF and IL-4, they differentiate into immature DCs, 
which reside in the peripheral tissues surveying for invading pathogens.  Immature DCs 
are extremely efficient at capturing antigens and can do this by the following pathways:  
macropinocytosis, receptor-mediated endocytosis, and phagocytocysis [266].  The uptake 
of the antigen causes immature DCs to undergo a maturation process which involves 
phenotypic and morphological changes, migratory capability from the tissue into draining 
lymph nodes, upregulation of co-stimulatory molecules, and enhancement MHC class II 
molecule synthesis as well as transportation to cell surface.  This entire process ultimately 
leads to the immature DCs being converted into mature DCs that possess antigen 
presentation capability and are referred to as professional APCs.  Morphological changes 
that are associated with mature dendritic cells include the formation of fine, long veils 
(>10 μm) extending from the cell body [267].  Functionally, the mature DCs become less 
phagocytic, migrate to T cell areas of in the secondary lympoid organs, and are highly 
efficient at stimulating the antigen-specific naïve T cells.  The main features of immature 
and mature DCs are summarized in Figure 3.2.  Several factors can trigger immature DCs 
to undergo maturation including binding of bacterial or viral components to TLRs (LPS 
or dsRNA), inflammatory cytokines (TNF-α, IL-1, IL-6), T cell derived signals (CD40), 
binding of immune complexes to Fc receptors, and other endogenous factors or cell 
death.  The presence of IL-10 during an immune response inhibits the maturation of DCs; 
thus, they become less efficient stimulators of naïve T cells and could lead to antigen-
specific tolerance [270]. 
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 3.4.3 Receptor-mediated targeting of DCs  
The unique properties of DCs (discussed in the previous sections) have made 
them attractive and widely investigated for targeting antigens to obtain enhanced immune 
responses.  In addition to TLRs, DCs express several endocytic receptors, such as the C-
lectin and Fc receptors [74] that could be utilized for enhancing immune responses to 
protein-based vaccines.  The main challenge in targeting DCs is that many of these 
receptors have only been recently identified and therefore, have not been extensively 
studied.  In addition, the ligands that could be utilized for targeting some of these 
receptors are yet to be determined. 
 
3.4.3.a C-lectin receptors 
The various DC subsets express a family of C-lectin type receptors that recognize 
their targets via single or multiple carbohydrate recognition domains (CRDs).  C-lectin 
receptors bind to their ligands in a calcium-dependent manner [271].  There are two types 
of C-lectin receptors: Type I consisting of the mannose and DEC-205 receptors; Type II 
consisting of Langerin, DC-SIGN and Dectin-1 receptors [272].   
 
Mannose receptor 
 
The mannose receptor (MR) has been most investigated for targeting antigens to 
DCs and macrophages for obtaining enhanced immune responses [273-276].  The MR 
contains 8 carbohydrate recognition domains (CRD), of which CRD 4-8 are involved in 
binding and recognition of terminal mannose containing ligands [277,278].   The 
captured antigen is transported to early endosomes and the MR is recycled back to the 
cell surface, allowing large amounts of antigen to be captured via the MR [279].  
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 Mannosylation of proteins resulted in a 200-10,000 fold increase in simulation of CD4+ T 
cells compared to non-mannosylated proteins in vitro [280].  Many groups reported the 
use of hydrophobized mannan for enhancing cellular and humoral immune responses to 
antigens when formulated with particulate delivery systems such as liposomes and 
nanoparticles [15,163,281-283].   Moreover, mannan conjugated to the cancer antigen 
HER2 was reported to induce strong enough CTL responses to reject HER2+ tumors in 
vivo [284].  One limitation reported to using mannan is its in vivo toxicity (in mice by iv) 
and high immunogenicity [283].  More recently, Mizuochi et al. have investigated 
various alternative oligosaccharide ligands and demonstrated that mannopentaose [has 
five mannose (Man) residues linked in the following order: Manα1-6(Manα1-3)Manα1-
6(Manα1-3)Man] attached to the surface of liposomes generated enhanced cellular 
responses compared uncoated liposomes [283,285,286].  Therefore, alternative mannose 
type ligands may have potential applications for targeting antigen uptake into DCs and 
for enhancing cellular immune responses with particulate delivery systems.    
 
DEC-205 
DEC-205, composed of 10 CRDs, is significantly homologous to the MR 
[287,288]; however, no specific ligands have been defined for DEC-205 [287].  Targeting 
to DEC-205, similar to MR, results in the antigen-receptor complex being endocytosed 
and recycled back to the cell surface; however, endocytosis via DEC-205 targets the 
antigen to the late endosomal compartment [279].  In vitro and in vivo targeting to DEC-
205 using an anti-DEC 205 antibody-antigen complex was reported to enhance the 
antigen presentation on MHC class I and II molecules (by 100 to 400 fold) compared to 
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 non-targeted antigens [279,289].  Moreover, targeted liposomes coated with an anti-DEC 
205 antibody were reported to induce strong CTL responses to an anti-tumor antigen 
when co-delivered with immunostimulatory adjuvants [290].  Furthermore, a more recent 
study reported that DEC-205-targeted HIV-1 Gag p24 was effective at inducing potent 
CD4+ T cell responses and long-lived memory T cells in mice compared to untargeted 
protein or adenovirus expressing Gag p24 [291].   
 
3.4.3.b Fc receptors 
DCs express surface immunoglobulin receptors called Fc receptors (FcR) that 
recognize the constant portion (Fc) of IgG.  One type of FcR, FcγR, has been investigated 
for targeting antigens to DCs.  Unlike MR and DEC-205 receptor, FcγR is not transported 
back to the cell-surface after endocytosis and thus, have a lower uptake capacity 
compared to MR and DEC-205 [275].  In vitro studies demonstrating that antigen 
presentation can be enhanced by 100-1000 fold by targeting them to the FcR have been 
reported [292,293].  In addition, antigen entrapped in FcγR-targeted liposomes was 
reported to be 1000 to 100,000 fold more efficient at stimulating antigen-specific T cells 
in vitro compared to free antigen or untargeted liposomes [294,295].   In vivo studies 
targeting FcγR using a antibody-antigen conjugate demonstrate enhanced cellular and 
humoral immune responses compared to antigen alone [296,297].  Moreover, targeting 
FcγR has been demonstrated to result in efficient cross-priming of the antigen [298,299] 
and thus, have the potential to enhance CTL responses to antigens.  Targeting antigens to 
FcγR could be limited by potential competition with other IgG and B cells present in 
vivo. 
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 3.4.4 Targeting DCs by route of immunization 
Traditionally, vaccines have been administered by the parenteral route, with 
intramuscular (i.m.) and subcutaneous (s.c.) routes being most utilized.  The choice in 
immunization route is of important consideration as it can significantly affect the type of 
immune responses generated and side effects, such as local reactions [124,300-304].  The 
immunization route may influence the uptake of the antigen by APCs, affecting the 
strength and type of responses obtained.  For example, i.m. injection is considered to 
enhance immune responses by offering a depot site for the antigen as few APCs are 
present at the muscle sites [301].  The use of s.c. route has been investigated for targeting 
colloids to draining lymph nodes, with the size of the colloid being a major factor in 
determining drainage [244].  Therefore, antigens formulated with nanoparticles, as 
described previously in section 3.3.2.d, are potentially targeted for passive uptake into 
APCs residing in the lymphatic system after s.c. injection.   
The use of mucosal routes for immunization has been of particular interest as it 
can generate both systemic and mucosal immune responses (secretory IgA), providing an 
additional barrier of protection at the site of infection for pathogens that are transmitted 
via mucosal routes.  Traditionally, the oral and nasal routes have been the most 
investigated for mucosal immunization [124,220,305].  Non-toxic derivatives of cholera 
toxin (CT) and heat labile enterotoxin (LT) adjuvants have been often investigated for 
enhancing immune responses to antigens via mucosal immunization [306].  Moreover, 
the use of a genetically modified LT, LTK63, is being evaluated for intranasal delivery of 
an influenza vaccine human clinical tirals [94].  Although the oral route has been 
investigated extensively with antigens entrapped in particulate delivery systems, the nasal 
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 route is more attractive since it avoids many challenges associated with oral delivery, 
such as the harsh acidic environment of the GI tract experienced by antigens [125,227].  
More recently, there has been a great deal of interest in using the skin as an immunization 
site, referred to as transcutaneous immunization (TCI) [307-310].  As described in the 
earlier section, LCs reside in the viable epidermis and although they compose only 1-4% 
of the cells in the viable epidermis, they cover over 20% of the surface area of the skin 
due to their characteristic DC-like veils that extend from the cell body [308].  Therefore, 
immunization via the skin can be used to passively target the uptake of antigens by LCs, 
potentially leading to strong systemic and mucosal immune responses.  The main 
challenge in targeting the LCs in the viable epidermis is penetration through the stratum 
corneum layer [309].  One system reported the use of a Macroflux® skin, which consists 
of titanium microprojections (~330 μm in length), for delivery of protein-based vaccines 
through the skin [311].  Macroflux® skin patch coated with OVA demonstrated 50-fold 
higher IgG titers compared to i.m. or s.c. routes and comparable to the intradermal route 
(i.d.) at the lowest dose investigated in hairless guinea pigs.  The ability of the 
Macroflux® patch to co-deliver an immunostimulatory adjuvant, resulting in augmented 
OVA-specific antibodies, was also reported [311].   In other animal studies the use of 
detoxified LT and CT mutants is most often investigated to obtain enhanced systemic and 
mucosal immune responses to an antigen after direct application to shaven skin [310,312-
314].  Moreover, TCI  using a patch was demonstrated to be safe in phase I clinical trials 
for immunizing humans with LT, generating robust systemic and mucosal antibodies for 
protection against travelers diarrhea [315].  This technology has been further extended for 
evaluation in numerous clinical trials including anthrax, hepatitis B, and influenza 
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 vaccines using a patch infused with the adjuvant LT [94].  This technology may be a 
viable strategy for advancing the idea of needle-free immunization; however, the 
variability in immune responses generated among individuals due to differences in 
penetration across the stratum corneum layer in larger populations needs to be evaluated.   
Another delivery technology which bypasses the conventional needle-based 
immunization approach involves the use of a high powered helium device (PowderJect®) 
to deliver the antigen of interest into the epidermis, where an abundant population of LCs 
are present [316].  This system has been reported to significantly enhance immune 
responses to hepatitis B surface antigen [317,318], influenza [317], and HIV-1 gp 120 
[319].  Moreover, the hepatitis B surface antigen could be co-formulated with CpG ODN 
and delivered to the epidermis for further enhancements in immune responses, including 
Th1 type responses [318].  The use of this technology has also been extended for delivery 
of DNA coated on gold particles to LCs in the epidermis [316].  Unlike traditional 
approaches for genetic immunization which rely on transfecting muscle cells after 
intramuscular administration, this system allows for direct delivery of the DNA into the 
LCs responsible for generating the immune response.  This technology termed, PMED™, 
has demonstrated success in recent phase I clinical trials with influenza vaccine and is 
currently in phase I clinical trials for a number of additional vaccines 
(www.powdermed.com). 
 
3.5 HIV vaccine development 
Although the cause of acquired immunodeficiency syndrome (AIDS), HIV [320], 
was identified and fully sequenced in the early 1980’s [321], there is still no effective 
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 HIV vaccine and HIV continues to infect millions of people.   The worldwide prevalence 
of AIDS has focused attention on the urgent need to develop a safe and effective vaccine.  
The difficulties in developing an effective HIV vaccine are mainly due to: 1) rapid 
mutations; 2) genetic variability; 3) formation of latent proviral DNA and 4) lack of 
knowledge on the immune correlates of protection [19,322,323].   
 
3.5.1 HIV infection 
HIV is classified as a retrovirus and more specifically grouped with lentiviruses 
that are characteristic of long incubation periods following infection which eventually 
lead to immunosupression and diseased states [52].  It is thought to have evolved from 
the less pathogenic simian immunodeficiency virus (SIV) [324] and studies of SIV in 
simian species have been useful in developing an understanding of the pathogenesis of 
HIV [325,326].  There are two types of HIV viruses identified: HIV-1, the more common 
and main cause of AIDS worldwide, and HIV-2, the less pathogenic strain of HIV and 
more closely related strain to SIV [324].  Rapid mutations in the virus are caused by the 
error prone nature of the reverse transcriptase giving rise to genetically varying strains of 
HIV-1 throughout the world [327].  Currently, there are three main categories of HIV-1: 
group M, N, and O. Group M is prevalent worldwide and consists of various HIV-1 
strains classified as subtypes or clades denoted A to J.  The presence of groups N and O 
are less prevalent and are predominantly identified in Africa and eastern Europe [324].     
HIV can be transmitted by sexual intercourse, exposure to contaminated blood, or 
maternal transmission (mother to child).  The hallmark of HIV infection is depletion of 
CD4+ T cells, which are critical in mediating cellular immunity.  There are several stages 
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 in HIV infection correlated with the presence of specific events during infection 
demonstrated in Figure 3.3 [52,327].  In the early or acute phase of infection (2-8 weeks), 
a burst in viral replication is observed, correlated with a dramatic decrease in the number 
of CD4+ T cells.  During this phase, the first immune responses to emerge are HIV-
specific CTL responses, which eliminate HIV-infected cells and help decrease the viral 
load.  CTL responses are followed by an increase in circulating levels of anti-HIV 
antibodies and the patient is said to have undergone seroconversion at this point.  
Following this phase, an asymptomatic phase is observed during which viral replication 
persists and a gradual decrease in CD4+ T cells occurs.  When the CD4+ T cells drop 
below a certain level (< 200-400 cells/μL) necessary to generate effective immune 
responses to other infections, the onset of AIDS begins [328] and the patient becomes 
susceptible to numerous opportunistic infections – infections that normal, healthy 
individuals can fight but prove fatal in AIDS patients.  These opportunistic infections are 
the ultimate cause of death in AIDS patients.  
The asymptomatic phase in HIV-infected patients is highly variable, lasting from 
a few months to over 16 years.  Individuals that are able to control the infection (>12-16 
years) and progression to disease are referred to as long-term non-progressors (LTNP) 
[327].  Studies of these patients have been of great interest to many scientists in this area 
to gain a better understanding of the immune correlates necessary to prevent onset of 
AIDS.  To this end, many studies with LTNP and HIV-infected patients report an inverse 
correlation between disease progression and the presence of strong CTL responses to 
multiple HIV antigens, suggesting the importance of CTL responses in controlling viral 
replication [329-331]. 
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 3.5.2 HIV life cycle 
The HIV viral genome consists of nine genes flanked by long-terminal repeats 
(LTRs) that are composed of the transcription regulatory elements (Figure 3.4A).  These 
genes translate for the HIV structural, regulatory, and accessory proteins that have 
various functions in the viral life cycle (Table 3.6) [52,327].  A schematic representation 
of the mature HIV virus is presented in Figure 3.4B.  The various stages in the HIV  life 
cycle have been described in detail elsewhere [332,333] and are highlighted in Figure 3.5. 
HIV infection of CD4+ T cells leads to a productive infection of the cell and 
subsequently their demise.  Two receptors, CD4 and chemokine, are necessary for viral 
infection.  The envelope protein first binds to CD4 receptors found on T cells, 
macrophages, and DCs causing conformational changes that allow it to bind to 
chemokine co-receptors (CCR5 or CXCR4) also present on the cells.  The majority of 
HIV infections occur through the use of CCR5 co-receptor; however, viral strains 
utilizing CXCR4 are more pathogenic and the use of this receptor has been observed after 
long periods of infection [324,334].  The differential use of the two receptors during HIV 
infection is likely due to the variability in the envelope proteins, which mediate binding 
to these receptors.  It is important to note that the spread of the virus is also mediated by 
infecting DCs and macrophages, which posses CD4 receptors.  Infection of DCs does not 
result in viral replication.  Instead, they harbor the virus allowing for spread to CD4+ T 
cells by cell to cell contact upon migration into LNs [333].  Moreover, DCs abundantly 
express the C-lectin receptor called DC-SIGN which binds strongly to the envelope 
protein, enabling the virus to enter the cell [335].  Thus, LNs can harbor the virus and act 
as reservoirs for the virus [333]. 
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 3.5.3 Vaccine status 
Initially, it was believed that neutralizing antibodies to HIV would provide 
protection from the virus (sterile immunity) [3].  Therefore, early HIV vaccines were 
based on the env gene encoding for the envelope proteins, gp 160 and gp 120, which 
harbor the neutralizing epitopes.  Envelope based vaccines seem to provide neutralizing 
antibodies strain specific, and thus, broad, cross-reactive neutralizing antibodies are not 
generated [19,322,336-338].  The ineffectiveness of neutralizing antibodies in providing 
protection from infection was even more evident after the reported failures of bivalent 
envelope-based vaccines in two different phase III clinical trials [339].  This is due to the 
high variability in the envelope proteins, which gives rise to the various groups and 
subtypes of HIV mentioned in section 3.5.1.  The envelope proteins can vary by more 
than 30% in their amino acids among the various subtypes [340], with differences greater 
than 50% reported between group M and O [341].  Also, few or no CTL responses are 
observed with the envelope based vaccines [19,322,338].   
Difficulties thus far in achieving sterile immunity based on the envelope vaccines 
have prompted an alternative avenue for developing an HIV vaccine – disease 
prevention.  Studies of LTNP and HIV-infected patients suggest that CTL responses are 
important in preventing disease.  The presence of strong CTL responses correlates with 
low viral loads.  Although it is realized that CTL responses alone will not prevent virus 
entry or replication, many studies suggest that they will aid in maintaining low viral loads 
and controlling viral replication.  Thus, CTL responses may delay or prevent the onset of 
the disease [19,322,337,338,342].   In order to develop a vaccine for controlling infection 
and blocking the onset of disease against various HIV subtypes, the candidate antigen 
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 should be immunogenic, conserved (to produce cross-reactive responses), and critical in 
the virus life cycle.  Currently, numerous candidate HIV vaccines are being evaluated in 
human clinical trials [343].  The vaccine components, unlike early approaches, are 
targeted towards multiple HIV antigens.  Two HIV proteins that have received 
considerable interest for inclusion in potential HIV vaccines are Gag [323,343] and Tat 
[18,344-346].   
 
3.5.4   HIV-1 Gag  
The gag gene encodes for the positively charged Gag poly-protein precursor, p55.  
Non-replicating, non-infectious virus like particles are formed by p55 in the absence of 
viral proteins or RNA.   Gag p55 is composed of four domains, individually known as the 
mature Gag proteins:  p24 capsid (CA), p17 matrix (MA), p7 nucleocapsid (NC), p6 and 
p1.   After virus budding from the host cell, p55 is cleaved by the HIV protease into the 
mature Gag proteins.   The Gag precursor is involved in virus assembly and membrane 
targeting, whereas the mature Gag proteins are involved in virus uncoating and 
disassembly.  In the mature virus, MA is associated with the inner viral protein coat, 
while NC complexes with the viral RNA in the core and CA forms a shell around the 
RNA and core-associated proteins [17].  The Gag proteins are well conserved among 
diverse HIV strains and subtypes.  Furthermore, strong Gag-specific CTL responses have 
been found to correlate with low viral loads in LTNP and HIV-infected patients 
[337,347-349].  In fact, a recent study using peripheral blood mononuclear cells from 
chronically infected patients found that 96% of the patients responded to challenge by 
Gag peptides, found to be the highest response out of all proteins used (Env, Pol, and 
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 Nef).  In addition, the magnitude of the T cell responses to Gag was inversely correlated 
with the viral load in plasma and directly with the CD4+ T cell counts in the patients 
[350].  Numerous studies performed by O’Hagan have demonstrated the ability of 
recombinant Gag p55 or pDNA adsorbed to poly[d,l-lactide-co-glycolide] (PLGA) 
microparticles to induce potent CTL and antibody responses in animals [13,238,351] and 
these microparticles coated with Gag p55 pDNA are being further evaluated in phase I 
clinical trials  (http://www.iavireport.org/trialsdb/vaccinedetail1.asp?i=82).   
One of the most conserved domains of Gag is found in the CA protein, referred to 
as Gag p24 [352-354].  In fact, this Gag p24 contains a region (the major homology 
region) that is conserved among different genera of retroviruses [17].  Cytotoxic T, B, 
and T helper cell eptiopes have been identified in the Gag p24 protein by Ikuta et al. 
[355].  Moreover, other groups have demonstrated Gag p24 to be the target of Gag-
specific CTL responses [238,354,356].  The importance of Gag p24-specific CTL 
responses in controlling viral replication and CD4+ cell counts was further demonstrated 
in a recent study of HIV-infected patients [357].  Combined these features of Gag 
proteins have made them extremely attractive for including them in HIV vaccines.  
Indeed, numerous clinical trials are investigating Gag as vaccine component including a 
phase I clinical trial that is exploring the use of microparticles with Gag (pDNA) [343].              
 
3.5.5  HIV-1 Tat  
The two exons of the tat gene of HIV encode for a small regulatory protein of 86-
102 aa.  The first exon is comprised of the first 72 aa necessary for the HIV 
transactivating activity [358,359] and is composed of four domains:  the amino-terminal 
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 (aa 1-21); the cysteine-rich domain (aa 22-37) representing the transactivation domain; 
the core (aa 38-48); and the basic domain (aa 49-72) containing nuclear localization 
signals and regions mediating cellular uptake of Tat [360].  In addition, the second exon 
contains an RGD sequence required for the interaction with cell surface intergin receptors 
[361] and mediates cellular uptake of extracellular Tat [362].  HIV-1 Tat is expressed in 
the early stages of infection [363] and reported to be necessary for production of an 
infectious virus, with only minute amounts of the structural proteins (Env, Gag, and Pol) 
expressed in the absence of Tat [364,365].  Moreover, Tat released from infected cells is 
found in the extracellular milieu and shown to be taken up by uninfected cells, where it 
can have numerous effects in addition to enhancing virus gene expression.  Biologically 
active Tat was reported to be taken up by APC’s, particularly DCs, more efficiently than 
other cells and promote Th1 type responses [366].  In addition, conjugation of proteins to 
Tat has been shown to be an effective method in presenting exogenous proteins in context 
of MHC class I, and generating antigen-specific CTL responses [367].  Tat induces the 
expression of the chemokine receptors CCR5 and CXCR4, which facilitate the 
transmission of macrophage-tropic and T cell-tropic strains of HIV-1, respectively [368].  
In addition, Tat binds to CXCR4 receptor and prevents viral infection of cells expressing 
this receptor, which may potentially cause the virus to adapt to using the CCR5 receptors 
in the early phase of HIV infection [369].  Tat also plays an important role in 
development of diseases such as AIDS-related Kaposi sarcoma [370], AIDS-related 
vasculopathy [371] and HIV-dementia [372] in infected patients.  Tat has been shown to 
be both immunogenic as well as well conserved among different HIV subtypes [23,26].  
Both antibody [373-376] and CTL responses [377,378] to Tat have been inversely 
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 correlated with disease progression.  In fact, a high frequency of CTL responses to Tat is 
observed in 80% of HIV-infected patients that were able to effectively control the viral 
replication (< 1000 RNA copies/mL) [378].  Extensive work by Ensoli’s group has 
demonstrated Tat to be immunogenic, safe, and effective in inducing humoral and 
cellular responses to Tat [18].  In addition, they reported that 9 out of 12 cynomolgus 
monkeys vaccinated with Tat (protein or DNA) were protected upon challenge with a 
highly pathogenic strain (SHIV89.6P) and the protection correlated with the presence of 
anti-Tat CTLs [379,380].  Studies done by other groups have also found Tat to be safe 
and immunogenic [381-383]; however, two groups have reported failure in controlling 
viral replication upon challenge with SHIV89.6P [382,383].  The authors caution that the 
conflicting results obtained could be due to differences in the study designs including 
different monkey species, dose, immunization schedules, adjuvants, and dose and route 
of challenge with viruses [382-384].  Despite the conflicting data reported in non-human 
primate studies, many researchers agree on the potential of Tat-based vaccines [368,385-
387] and results from phase I clinical trials evaluating Tat for preventative and 
therapeutic vaccines are being compiled [388]. 
 
3.5.6 Therapeutic vaccines for HIV-infected patients 
It is estimated that 14,000 new HIV infections occur every day and even more 
astounding is that greater than 95% of these new infections are in underdeveloped nations 
[389].  Although the use of highly active anti-retroviral therapy (HAART) has been 
greatly effective in controlling viral replication and disease progression, it has not been 
effective at eliminating the virus completely and there are numerous challenges faced 
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 with this therapy regimen.  The regimen itself is complex, often required multiple drugs 
to be taken every day.  Moreover, drug-resistant viruses have been found to develop 
during HAART that require alternative drug combinations for effectively controlling 
HIV, which may ultimately limit the effectiveness of the therapy.  The regimens are also 
often accompanied by complicated side effects such as increased plasma lipids, 
hyperglycemia, and metabolic abnormalities [324].  More importantly, the high cost and 
limited availability of HAART to individuals in underdeveloped countries, where the 
majority of new emerging infections are occurring, is extremely concerning.   
As an alternative to HAART, a great deal of interest has been generated in the 
concept of using therapeutic vaccines for controlling disease progression in HIV-infected 
patients (reviewed in reference [390]).  The goal of therapeutic vaccines would be to 
stimulate appropriate cellular and humoral immune responses in the infected patient 
capable of controlling the viral replication and therefore, eliminating or decreasing the 
need for HAART.  This approach is especially attractive for regions where accessibility 
to HAART is costly and limited because a single dose of the vaccine could be 
administered at appropriate intervals, aiding to reduce viral loads and possibly decrease 
HIV transmission and thus, the number of new infections.  Many therapeutic vaccines 
have demonstrated to be effective in animal models and have entered human clinical 
trials; however, so far the results from these trials have failed to demonstrate significant 
benefits in using this approach.  Some of the challenges that are faced in developing and 
evaluating therapeutic vaccines include: 1) little is known on the immune correlates 
necessary for viral control, 2) the appropriate time to administer the vaccine and to initial 
or cease HAART if used in combination with the vaccine, and 3) limitations in the 
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 current assays available to evaluate responses from patients after vaccination.  
Nonetheless, current work continues to evaluate therapeutic vaccines as a viable 
alternative to HAART due to the potential benefits that could be reaped from this 
approach.  In this respect, the important roles Gag and Tat play in the viral life cycle have 
targeted these antigens as components in therapeutic vaccines [384,390-392].     
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 Table 3.1.  Historical outline for the major developments in vaccines. (Adapted from 
Plotkin and Plotkin [21] and Bramwell [23]) 
 
Vaccine 
Introduced 
Type of 
Vaccine Major Achievements 
18th Century 
Smallpox Live attenuated The idea of vaccination introduced using a closely related animal virus (cowpox) 
19th Century 
Rabies 
Anthrax Live attenuated 
First demonstration of chemical attenuation of 
pathogens for live vaccines 
Typhoid 
Cholera 
Plague 
Whole-killed Demonstration that inactivated organisms could retain their immunogenicity 
20th Century 
(1920s-1940s) 
Whole-cell 
Pertussis Whole-killed - 
BCG Live-attenuated First demonstration of in vitro passage for attenuation using artificial media (bile) 
Yellow-Fever Live-attenuated In vitro passage using mouse brain and chick embryo 
Influenza Whole-killed Production in chick embryo 
Tetanus 
Diphtheria Protein 
First use of inactivated protein vaccines – 
Toxoids 
(1950s-1970s) 
Injected polio 
(IPV) Whole-killed 
Oral Polio (OPV) 
Measles 
Rubella 
Live-attenuated 
Cell culture introduced for producing vaccines 
Influenza Whole-Killed 
Introduction of reassortants – RNA segments 
from attenuated strain combined with RNA 
from circulating strain. 
Pneumococcal 
Meningococcal 
Purified 
Polysaccharides Polysaccharide use for vaccination 
(1980s to date) 
H. Influenzae 
type b Protein 
Conjugation of protein (i.e. bacterial toxins) to 
polysaccharides for enhancing immune response
Hepatitis B Protein First protein-based vaccine produced by genetic engineering technology 
Acellular 
Pertussis Protein 
Genetic engineering for protein modification 
and avoiding side effects associated with 
bacterial cell walls 
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 Table 3.2.  Features of innate and adaptive immune systems.  (Adapted from Janeway 
and Medzhitov [55]). 
 
 
Feature 
 
 
Innate immune system 
 
 
Adaptive immune system 
 
Action Time Rapid (hours) Slow (days-weeks) 
Immune response Invariant Progressive 
Cells 
 
Macrophages 
Dendritic cells 
Mast cells 
Neutrophils 
Eosinophils 
NK Cells 
 
Antigen presenting cells 
B lymphocytes 
T lymphocytes 
 
Receptor 
variability 
 
Germ-line encoded and not 
variable 
Encoded in gene segments and 
variable by rearrangement 
Recognition 
 
Conserved molecular 
patterns present on 
pathogens recognized by 
PRR 
 
 
Details of molecular structure 
and sequences recognized by 
highly specific receptors 
 
 
Outcome of 
Immune Response 
 
1)  Pathogen is cleared 
2)  Adaptive immune system 
is initiated 
1)  Antigen-specific effector 
and memory cells generated 
2) Antigen-specific antibodies 
generated 
3) Pathogen is eliminated or 
infection is controlled 
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 Table 3.3.  Examples of commonly investigated adjuvants for vaccines. 
 
 
Class of Adjuvant 
 
 
Examples 
 
Immunostimulatory 
 
Cytokines:  IL-2, IL-12, IFN-γ, GM-CSF 
QS21 
Bacterial DNA (CpG) 
Lipid A 
Bacterial Toxins:  cholera toxin, 
 heat labile enterotoxin 
 
Particulate 
 
 
Emulsions:  CFA, MF59 
ISCOMs 
Liposomes 
Microparticles 
Nanoparticles 
Virus-like particles (VLPs) 
Mineral Salts:  Aluminum hydroxide, Aluminum 
phosphate and Calcium phosphate 
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 Table 3.4.  Comparison of relative sizes of pathogens with commonly investigated 
particulate delivery systems for vaccines. (Adapted from O’Hagan et al. [125]) 
 
Pathogens Particulate delivery systems 
Bacteria   ~0.5-3 μm Microparticles 1-10 μm 
Herpes virus   ~250 nm Nanoparticles 10-1000 nm 
HIV;  
Influenza virus 
~100 nm Liposomes 50 nm – 10 μm 
Poliovirus ~20-30 nm MF59 ~200 nm 
  ISCOMs ~40 nm 
  VLPs ~20-50 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67
 Table 3.5.  Examples of combined adjuvant formulations investigated for 
enhancement in immune responses.   
Particulate 
System 
Immunostimulatory 
Adjuvant Antigen References 
Malaria antigen [256] 
HIV-1 gp 120 [81] IL-12 
Respiratory syncytial virus [78] 
CpG Hepatitis B surface antigen [107] 
Alum 
Lipid A derivative Herpes simplex virus [91] 
Ovalbumin [393,394] 
Influenza 
Hepatitis B surface antigen 
[258] 
Hepatitis C antigen (NS3) [159,162] 
CpG 
HIV-1 gp 140 [99] 
HIV-1 gp 140 [99] 
Lipid A derivative 
Influenza [395] 
IL-6 HIV-1 gp 120 [79] 
IL-2 Influenza [80,396,397] 
Liposomes 
IFN-γ Influenza hemagglutinin: 
T and B cell epitopes 
[45,79] 
HIV-1 gp120 [398] 
HIV-1 Gag p55 [398] 
Neisseria meningitides type 
B 
[237] 
Anthrax [260] 
CpG 
Tetanus toxoid [111,263] 
Neisseria meningitides 
serotype B (Men B) 
[257] 
HIV-1 gp 120 [257] 
Nanoparticles 
and 
Microparticles 
Lipid A derivative 
Hepatitis B core antigen [246] 
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 Table 3.6.  HIV proteins and their main functions in viral life cycle. 
Gene Protein encoded Major Function(s) 
gag 
Gag p55 precursor;  
capsid (p24); matrix 
(p17); nucleocapsid 
(p7); p6; p1 
Virus assembly and structure 
Viral genome transcription, 
integration into host genome, 
and cleavage of precursor 
proteins in immature virus 
pol 
Reverse transcriptase 
(p66/51); Integrase 
(p32); Protease (p11)
Structural 
gp 160 Envelope 
precursor; 
gp 120; gp 41 
Glycoproteins (gp) required for 
binding and internalization of 
virus 
env 
tat Transactivator (Tat) 
Promotes infection of cells and 
LTR-mediated viral gene 
transcription 
Binds to Rev responsive 
element on HIV mRNA, 
allowing transport of unspliced 
RNA from nucleus to 
cytoplasm and production of 
structural proteins 
Regulatory 
rev Regulator of viral expression (Rev) 
Down regulates expression of 
cell surface molecules (CD4 
and MHC I) in infected cells  
nef Negative-regulation factor (Nef) 
Involved in viral replication by 
stabilizing DNA intermediate 
and  
vif Viral infectivity (Vif) 
Plays a role in transporting 
HIV-preintegration complex to 
nucleus 
vpr Viral protein R (Vpr)Accessory 
vpu Viral protein U (Vpu) 
 
Down regulates CD4 
expression and forms ion 
channels in cell membranes to 
allow release of virons from 
infected cells 
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Figure 3.1 
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Figure 3.1.  Adaptive immune response.  The  key cellular interactions involved in 
generating antigen-specific immune responses are depicted.  Cellular responses are 
mediated by CD8+ and CD4+ T cells and humoral responses are mediated by B cells with 
additional help provided by T helper 2 (Th2) cells.  The cytokines released by the CD4+ 
T cell influence the isotype of antibodies produced by B cells (Adapted from Singh and 
O’Hagan [1]). 
 Figure 3.2 
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Figure 3.2.  Features of dendritic cells.  Immature DCs are triggered to mature by 
environmental factors such as encountering a pathogen or release of inflammatory 
cytokines.  Immature and mature DCs possess different structural, phenotypical and 
functional features.  (Adapted from Banchereau and Steinman [267]). 
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Figure 3.3 
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Figure 3.3.  Adaptive immune responses during HIV infection.  An increase in 
circulating virus correlates with decrease in the CD4+ T cells in the initial phase of 
infection.  The induction of HIV-specific CTL responses helps to maintain CD4+ T cells 
in the asymptomatic phase of infection.  However, the immune system is unable to 
replace the dying CD4+ cells and their subsequent depletion leads to AIDS.   (Adapted 
from Girard and Excler [327] and Parham [52]). 
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Figure 3.4 
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Figure 3.4.  HIV genome and schematic representation of the HIV viron.  A) The 
viral genome consists of nine genes flanked by LTR regions.  B)  Schematic 
representation of HIV viron, showing the location of the various proteins in the mature 
virus.  (Adapted from Girard and Excler [327] and http://hivinsite.ucsf.edu/ 
InSite?page=kb-02-01-01#S2X). 
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Figure 3.5.  HIV life cycle. 1) gp120 interacts with CD4 and chemokine co-receptors 
present on the cell.  2) The virus membrane fuses with cell membrane. 3) Viral contents 
are emptied into cell cytoplasm.  4) The viral RNA is transcribed into double stranded 
DNA by the reverse transcriptase. 5) Viral DNA is transported into the nucleus and 
integrated into host genome by integrase. 6) The DNA is transcribed into RNA. 7) RNA 
is transported to the cell cytoplasm. 8) The viral proteins are synthesized in the 
cytoplasm.  9) The structural proteins are transported to the cell membrane and virus 
assembly begins.  10) The immature virus buds from the cell membrane.  11) The 
protease enzyme cleaves the polyproteins to give the mature virus.  (Adapted from Freed 
[17]). 
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 Chapter 4 
 
HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and 
neutralizing antibodies compared to Alum adjuvant 
 
4.1   Summary 
HIV-1 Tat has been identified as an attractive target for vaccine development and 
is currently under investigation in clinical trials as both a therapeutic and preventative 
vaccine for HIV-1.  It is well known that protein based vaccines produce poor immune 
responses by themselves and therefore require adjuvants to enhance immune responses.  
We have previously reported on the use of anionic nanoparticles for enhancing cellular 
and humoral immune responses to Tat (1-72).  The purpose of this study was to further 
evaluate the immune response of HIV-1 Tat (1-72) coated on anionic nanoparticles (NPs) 
compared to Alum using various doses of Tat (1-72).  Nanoparticles were effective at 
generating comparable antibody titers at both 1 μg and 5 μg doses of Tat (1-72), whereas 
the antibody titers significantly decreased at the lower dose of Tat (1-72) using Alum.  
Anti-sera from Tat (1-72) immunized mice reacted greatest to the N-terminal and basic 
regions of Tat, with the NP groups showing stronger reactivity to these regions compared 
to Alum.  Moreover, the anti-sera from all Tat (1-72) immunized groups contained Tat-
neutralizing antibodies and were able to significantly inhibit Tat-mediated long terminal 
repeat (LTR) transactivation. 
 
 
 75
 4.2   Introduction 
Ideally, an HIV vaccine would be effective at blocking viral entry and thus, 
provide sterilizing immunity.  However, recent failures with the envelope (Env) based 
HIV vaccine have demonstrated that this may be a difficult goal to attain [339].  These 
experiences have prompted investigators to look at alternative strategies in developing an 
HIV vaccine; for example, to limit viral replication and thereby block or delay 
progression onto AIDS.  In pursuit of this secondary goal, it is well recognized that the 
candidate antigen must be conserved among different HIV subtypes, as this is a major 
drawback for Env based vaccines.  In addition, the antigen should be immunogenic and 
play a critical role in the virus life cycle.  To this end, the HIV-1 regulatory protein Tat 
has received considerable interest as a potential HIV vaccine or as a component in a HIV 
vaccine [384,385,399,400].    
 Tat, a small regulatory HIV protein, is encoded by two exons, with the size of the 
full length protein varying from 86 to 102 amino acids (aa) depending on the viral strain.  
The first exon of Tat encodes the first 72 aa of the protein, which includes:  the amino-
terminal (aa 1-21); the cysteine-rich domain (aa 22-37) representing the transactivation 
domain; the core (aa 38-48); and the basic domain (aa 49-72) containing nuclear 
localization signals and regions mediating cellular uptake of Tat [360].  This region of 
Tat has been shown to be necessary for Tat-mediated  transactivation of HIV-1 gene 
expression [358,359] and is highly conserved among different viral subtypes [401,402], 
with the cysteine-rich domain (aa 25-38) being conserved among human, bovine and 
simian species [403].  While the second exon, encoding the C-terminal domain of Tat is 
not required for the transactivation, it contains an arginine-glycine-aspartic acid (RGD) 
 76
 sequence that mediates the binding of extracellular Tat to integrin receptors [361].  
Additionally, the C-terminal domain of Tat is of significant importance in the cellular 
uptake of extracellular Tat [362].  
Tat plays a vital role in the viral life cycle and mediates many processes allowing 
for spread of the virus throughout the body and potentiating disease.  Of these, possibly 
the most significant role of Tat in the virus life cycle is the enhancement of HIV gene 
expression.  Tat is expressed in the very early stages of infection before the expression of 
the structural components (Env, Gag, Pol) [363].  In fact, Tat is necessary for efficient 
viral gene expression and in the absence of Tat, no or only minute amounts of the 
structural proteins are expressed, preventing the production of an infectious virus 
[364,365].  In addition to promoting viral gene expression in HIV-infected cells, 
extracellular Tat released from infected T lymphocytes has numerous effects on 
uninfected cells that aid in the progression of disease.  Tat induces the expression of the 
chemokine receptors CCR5 and CXCR4, which function as co-receptors for HIV-1 and 
facilitate the transmission of macrophage and T cell tropic HIV-1 strains [368].  Some in 
vitro studies have demonstrated that Tat induces the production of Interferon-α, 
inhibiting T cell proliferation, [400] and also promotes apoptosis of T cells by increasing 
the expression of CD95L/Fas ligand on macrophages [381].  Fanales-Belasio et al. have 
demonstrated that biologically active Tat at high concentrations is taken up by antigen 
presenting cells (APCs), particularly monocyte-derived dendritic cells, inducing 
expression of MHC II, co-stimulatory molecules, and causing production of Th1 type 
cytokines such as IL-12 [366].  On the contrary, Izmailova et al. did not observe DC 
activation or maturation in the presence of HIV infection or Tat expression; however, 
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 they reported that Tat was involved in up-regulation of chemoattractant proteins in 
immature DC which are involved in recruiting of T cells and macrophages thus, aiding in 
the spread of infection [404].  The ability of Tat to be efficiently taken up by cells has 
become attractive for the delivery of proteins into cells [405] and conjugation of proteins 
to Tat has been shown to be an effective method in presenting exogenous proteins in 
context of MHC class I, and generating antigen-specific CTL responses [367].   
The importance of Tat in the progression to diseased states has been demonstrated 
in numerous reports [373-378,406-408].  In fact, both strong antibody [373,374,376] and 
CTL responses [377,378] to Tat have been inversely correlated with viral loads and 
disease progression.  Moreover, Tat is involved in the progression of AIDS-related 
Kaposi sarcoma and high serum levels anti-Tat antibodies have been correlated with 
reduced Kaposi sarcoma in HIV-infected patients [387].   Extensive studies carried out in 
mice and non-human primates have demonstrated that immunization with Tat is safe and 
effective at generating humoral and cellular immune responses [18].  However, 
conflicting data exists on the effectiveness of a Tat-based vaccine in controlling infection 
upon challenge with a highly pathogenic strain (SHIV-89.6P) in non-human primates 
[379,381,383,409,410].  In spite of these data, many researchers agree that the potential 
of Tat based vaccines warrant further investigation and Phase I clinical trials evaluating 
Tat for preventative and therapeutic vaccines are currently ongoing in Italy [18,407].   
Moreover, a Tat toxoid (chemically modified Tat) vaccine has already been evaluated in 
both HIV negative and positive patients and was shown to be safe and effective [387].  
Futhermore, other ongoing clinical trials evaluating preventative HIV-1 vaccines include 
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 Tat as component of the vaccine in addition to other HIV-1 antigens (IAVI Report, 
February 2005).    
We have previously reported on the preparation and purification of the first exon 
of  Tat protein (referred to as Tat (1-72)) [362].  We have demonstrated that Tat (1-72) is 
immunogenic and that Tat (1-72) coated anionic nanoparticles were effective at 
generating humoral and cellular immune responses to Tat [253].  In the present study, the 
use of nanoparticles for generating immune responses to various doses of Tat (1-72) was 
further investigated.  More specifically, we sought to determine the lowest effective dose 
of Tat (1-72) that could produce immune responses when administered with anionic 
nanoparticles.  In addition, the antibody epitopes generated in mice immunized with Tat 
(1-72) were mapped and the Tat-neutralizing activity in the sera from immunized mice 
was evaluated.  
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 4.3   Materials and methods 
 
Materials 
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of 
20:1), was purchased from Spectrum (New Brunswick, NJ).  Sodium dodecyl sulfate 
(SDS), PBS/Tween 20 buffer, bovine serum albumin (BSA), triethanolamine, and 
mannitol were purchased from Sigma Chemical Co. (St. Louis, MO).  Brij 78 was 
purchased from Uniqema (New Castle, DE).  Sheep anti-mouse IgG, peroxidase-linked 
species specific F(ab’)2 fragment was purchased from Amersham Pharmacia Biotech 
(Piscataway, NJ).  Goat anti-mouse IgG2a and IgG1 horseradish peroxidase (HRP) 
conjugates were purchased from Southern Biotechnology Associates, Inc. (Birmingham, 
AL).  Tetramethylbenzidine (TMB) substrate kit was purchased from Pierce (Rockford, 
IL).  Incomplete Freund’s adjuvant and mycobacterium tuberculosis were purchased from 
Fisher Scientific (Hampton, NH).  Lipid A from Salmonella Minnesota R595 (Re) was 
purchased from List Biological Laboratories (Campbell, CA).  HIV-1 Clade B consensus 
Tat peptides (15 aa) were obtained through the AIDS Research and Reference Reagent 
Program (Division of AIDS, NIAID, NIH, Bethesda, MA).  Recombinant HIV-1 Tat (1-
72 aa) was prepared as previously described [362]. 
 
Preparation of anionic NPs 
Nanoparticles from oil-in-water microemulsion precursors were prepared as 
previously described previously [253] with slight modification.  Briefly, 2 mg of 
emulsifying wax and 3.5 mg of Brij 78 was melted and mixed at ~60-65oC.  Deionized 
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 and filtered (0.2 μm) water (980 μL) was added to the melted wax and surfactant while 
stirring to form an opaque suspension.  Finally, 20 μL of sodium dodecyl sulfate (50 
mM) was added to form clear microemulsions at 60-65oC.  The microemulsions were 
cooled to room temperature, while stirring, to obtain NPs (2 mg/mL).  The final 
concentration of components in the NP suspension was emulsifying wax (2 mg/mL), Brij 
78 (3 mM), and SDS (1 mM). The NP sizes were measured using a Coulter N4 Plus Sub-
Micron Particle Sizer (Coulter Corporation, Miami, FL) at 90o.  The overall charge of the 
NPs was measured using Malvern Zeta Sizer 2000 (Malvern Instruments, Southborough, 
MA). 
 
Coating of the anionic NPs with Tat  
Varying amounts of Tat were added to NPs (1000 μg/mL) in 5% (v/v) mannitol.  
The suspension was vortexed gently and placed on a horizontal shaker at room 
temperature for a minimum of 30 min to allow for coating.  The coated NPs were diluted 
appropriately in de-ionized water for measuring the size and charge of the particles.  
 
Mouse immunization study 
Two animal studies were carried out to determine the immune response to 
different doses of Tat.  A summary of the experimental design is presented in Table 4.1.  
For both studies, female BALB/c mice (8-10 weeks old) obtained from Harlan Sprague-
Dawley Laboratories (Indianapolis, Indiana) were immunized subcutaneously with 100 
μL of the formulations.  In the initial mouse study (Study 1), mice (n=5-6/group) were 
dosed on day 0, 21 and 28 with 1 μg or 5 μg of Tat-coated NPs or 1 μg or 5 μg of Tat 
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 adjuvanted with Alum. The dose of NPs and Alum administered in both cases was 100 
μg.  As a positive control, mice were immunized on day 0 with 5 μg of Tat adjuvanted 
with complete Freund’s adjuvant (CFA) followed by boost with 5 μg Tat adjuvanted with 
incomplete Freund’s adjuvant (IFA).  On day 35, mice were bled by cardiac puncture and 
sera were separated.  All sera collected were stored at -20oC.   
In the follow up study (Study 2), mice (n=6-8/group) were dosed on day 0, 14 and 
28 with 0.2 μg or 1 μg of Tat-coated NPs or 0.2 μg or 1 μg of Tat adjuvanted with Alum.  
Again, the dose of NPs and Alum given to animals was 100 μg.  Mice were immunized 
with 1 μg of Tat adjuvanted with Lipid A (50 μg) as a positive control.  To assess the 
kinetics of Tat specific antibodies generated using the different treatments, mice were 
bled on day 13 and 34 by tail vein and sera were collected.  On day 42, all mice were bled 
by cardiac puncture and sera were collected.  All sera were stored at -20oC. 
 
Determination of antibody titers 
Tat-specific serum IgG, IgG1 and IgG2a antibody titer were determined using an 
ELISA.  Briefly, 96-well plates (Costar) were coated with 50 μL of Tat (5-8 μg/mL in 
0.01 M phosphate buffered saline, pH 7.4) overnight at 4oC.  The plates were blocked for 
1 hr at 37oC with 200 μL of 4% BSA prepared in PBS/Tween 20.  The plates were then 
incubated with 50 μL per well of mouse serum diluted appropriately in 4% 
BSA/PBS/Tween 20 for 2 hr at 37oC.  The plates were washed with PBS/Tween 20 and 
incubated with 50 μL/well anti-mouse IgG HRP F(ab’)2 fragment from sheep (1:3000 in 
1% BSA/PBS/Tween 20) for 1 hr at 37oC.  For IgG1 and IgG2a determination, the plates 
were similarly incubated with goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP 
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 diluted 1:8000 (1% BSA/PBS/Tween 20). After washing the plates with PBS/Tween 20, 
the plate was developed by adding 100 μL of TMB substrate and incubating for 30 min at 
RT.  The color development was stopped by addition of 100 μL of 2 M H2SO4 and the 
OD at 450 nm was read using a Universal Microplate Reader (Bio-Tek Instruments, Inc.).  
The OD at 450 nm versus log serum dilution for each animal was plotted and fit to a four 
parameter logistic equation using GraphPad Prism software.  The titer was defined as 
0.5*ODmax.    
 
B cell epitope mapping 
 
Tat anti-sera were tested by ELISA to determine reactivity to various regions of 
Tat.  Tat peptides (50 μL of 1 μg/mL Tat peptide in 0.05 M carbonate buffer, pH 9.6) 
were coated onto 96-well Costar plates by incubating overnight at 4oC.  The plates were 
blocked for 1 hr at 37oC with 200 μL of 4% BSA prepared in PBS/Tween 20.  Tat anti-
sera diluted at 1:100 in 4% BSA/PBS/Tween 20 were added to the wells and incubated 
for 2 hr at 37oC.  The wells were washed, reacted with anti-mouse IgG HRP F(ab’)2 
fragment from sheep, and developed as described for total IgG titer.   
 
Tat-mediated LTR-transactivation assay 
 
     SVGA LTR-chloramphenicol acetyltransferase (CAT) was produced by stable 
transfection of the astrocytic cell line SVGA with pHIV-CAT [411].  SVGA LTR-CAT 
cells were seeded into 6-well plates a minimum of 24 hr prior to use in Dulbecco’s 
Modified Eagle Medium (DMEM; GibcoBRL) with 10% heat-inactivated fetal bovine 
serum (FBS; Sigma) and 1% antibiotic-antimycotic solution (penicillin G sodium, 
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 streptomycin sulfate, and amphotericin B in 0.85% saline; GibcoBRL) (DMEM+10% 
FBS+Ab).  Ten (10) µL of sera was mixed with 2 μL (1000 μg) recombinant Tat (1-72) 
derived from the first exon of the HIV-1 tat gene and incubated for 30 min at 37oC in a 
water bath.  During the incubation, medium was replaced on the SVGA LTR-CAT cells 
with 2 mL fresh DMEM+10% FBS+Ab.  The sera/Tat mixtures were then added to the 
cells.  Cells were then lysed at 24 hr post-treatment and CAT levels were quantitated by 
ELISA according to the manufacturer’s directions (Roche).  
 
Statistical analysis 
Statistical analysis was performed using one-way analysis of variances (ANOVA) 
followed by pair-wise comparisons using Newman-Keuls multiple comparison test using 
GraphPad Prism software. 
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 4.4   Results and discussion 
Many researchers have reported on the potential of HIV-1 Tat-based vaccine or 
supported the idea including Tat as a component in a cocktail for vaccine development 
[384,385,399,400].  As new targets for HIV vaccine development are identified, it is also 
important to investigate novel delivery systems for effectively enhancing immune 
responses to the target antigen(s).  Our laboratory has reported on the use of anionic and 
cationic NPs for effectively enhancing immune responses to plasmid DNA and protein 
based vaccines [14-16].  These NPs are prepared from oil-in-water microemulsion 
precursors and form solid stable particles.  The emulsifying wax oil phase used to prepare 
the NPs is comprised of cetyl alcohol and polysorbate 60 (20:1 molar ratio) which are 
both employed as components in parenteral products and are potentially non-toxic 
materials.  We have recently shown that these nanoparticles are hemocompatible and 
metabolized via endogenous alcohol dehydrogenase enzyme systems [251].  In addition, 
these NPs have the advantage of being prepared in a single step, one vessel process with 
relative ease in modifying the physical characteristics of the particles by using 
appropriate surfactants.  We recently reported the use of anionic NPs as effective delivery 
systems for enhancing immune responses to Tat (1-72) [253].  In the present studies, the 
dose-response to Tat (1-72) using NPs compared to standard Alum adjuvanted protein 
was further evaluated.  In addition, the humoral immune responses to Tat (1-72) were 
characterized for reactivity to various regions of Tat and for activity in a LTR-
transactivation assay. 
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 Adsorption of Tat (1-72) on anionic NPs 
The NPs prepared in these present studies are stabilized by the inclusion of Brij 
78 and made to be negatively-charged by the use of the anionic surfactant SDS.  The net 
charge of the NPs prior to coating with Tat is approximately -56 mV (Table 4.2).  Tat, a 
cationic protein, is expected to be coated on the surface of the NPs via ionic interactions.  
It is thought that the negatively charged amino acids of Tat are exposed on the surface of 
NPs while the positively charged amino acids interact with the negatively charged NPs.  
As demonstrated in Table 4.2, there is a slight increase in the zeta potential with 
increasing amounts of Tat coated on NPs; however, the Tat-coated NPs continue to have 
a net negative charge possibly due to the exposed negatively charged amino acids.  The 
coating of Tat on NPs at a 1:100 w/w ratio was found to be approximately 85% by SDS-
PAGE/densitometry (data not shown). 
 
Dose response to Tat in immunized mice 
We previously reported that Tat (5 μg) coated on anionic NPs result in similar 
Tat-specific IgG levels as Alum and Lipid A adjuvanted with Tat [253].  Thus, a dose 
response of Tat was evaluated in these present studies to determine the minimum Tat 
dose that could be administered while maintaining the Tat-specific IgG response.  In the 
first study, use of 1 μg and 5 μg of Tat coated on NPs or adjuvanted with Alum was 
investigated.  Tat (5 μg) with CFA adjuvant was used as a positive control.  The results 
shown in Figure 4.1 demonstrate that Tat-specific IgG antibody titers are maintained at 
both the 1 μg and 5 μg of Tat coated on NPs, while Tat (1 μg) adjuvanted with Alum 
produced significantly lower titers compared to Tat (5 μg) adjuvanted with Alum.  
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 Moreover, both the 1 μg and 5 μg Tat-coated NPs produced comparable Tat-specific IgG 
titers compared to CFA.  Only the higher dose of Tat adjuvanted with Alum produced 
comparable Tat-specific IgG levels to CFA adjuvant.  These results suggested that a 
lower dose of Tat using NPs compared Alum was still effective at eliciting a strong Tat-
specific antibody response.   
In the follow up study, the effectiveness of lower doses of Tat coated on NPs and 
adjuvanted with Alum in generating Tat specific antibodies was evaluated.  Lipid A with 
1 μg of Tat was used as a positive control.  The results (Figure 4.2) indicated that Tat  (1 
μg) coated NPs were able to generate significantly higher IgG levels at all time points 
tested compared to both Alum groups and the NP group receiving the lower dose of Tat.  
These data combined with IgG results from the first study suggest that the total serum 
anti-Tat IgG levels are similar with immunization doses of 1 μg or 5 μg of Tat coated on 
NPs, however, doses of less than 1 μg of Tat, cause a significant decrease in the anti-Tat 
IgG levels.  More importantly, the data taken together demonstrate that the Tat-coated 
NPs were capable of generating stronger and more robust humoral immune responses at 
lower doses of antigen compared to Tat adjuvanted with Alum. 
To evaluate the type of response (Th1- or Th2-type) that was generated using NPs 
compared to the other adjuvants, both Tat-specific IgG2a and IgG1 titers were 
determined using Tat anti-sera from the first study evaluating 1 μg and 5 μg Tat.  The 
Tat-specific IgG2a and IgG1 titers along with the mean IgG2a/IgG1 ratio are presented in 
Figure 4.3.  Significantly lower Tat-specific IgG2a titers were produced using 1 μg Tat 
adjuvanted with Alum compared to Tat (1 μg) coated NPs and the mean IgG2a/IgG1 
ratios were lower for both Alum groups compared to the NP groups.  Interestingly, CFA, 
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 a strong adjuvant for Th1 responses in mice, produced similar Tat-specific IgG2a levels 
as Tat coated NPs or Tat (5 μg) adjuvanted with Alum.  This high level of IgG2a seen 
with all groups may be attributed to Tat, which has been demonstrated to enter the MHC 
class I pathway and enhance Th1 responses [366,367].  These results are consistent with a 
greater stimulation of Th1 responses by NPs compared to Alum. 
 
Tat-specific antibody epitope mapping 
The Tat used in this study only corresponds to the first 72 aa acids of Tat, which 
is encoded by the first exon of the tat gene.  Tat anti-sera collected from both studies 
were analyzed to determine reactivity to overlapping 15-mer peptides spanning aa 1-83 of 
the Tat sequence.  Table 4.3 presents the reactivity pattern for anti-sera collected from 
each animal for each Tat immunized group in Study 1.  Sera from all animals recognized 
aa 1-15 or 5-19, corresponding to the N-terminal region of Tat.  In addition, the sera from 
Tat immunized mice also recognized aa 45-59 and 49-63, corresponding to the basic 
region of Tat; however, this was to a lesser degree than recognition of the N-terminal and 
was only observed in some of the animals.  Interestingly, Tat-coated NPs which 
demonstrated the highest total serum Tat-specific IgG titers also demonstrated the 
strongest reactivity in both the N-terminal and basic regions.  Moreover, the strong 
reactivity to both the N-terminal and basic regions of Tat is maintained using 1 μg of Tat- 
coated NPs compared to the Alum groups.  In fact, Tat (1 μg) coated on NPs showed 
stronger reactivity in the basic region of Tat compared to Tat (5 μg) adjuvanted with 
Alum.  Similarly, evaluation of the Tat anti-sera from Study 2 demonstrated strong 
reactivity of 1 μg Tat-coated NPs compared to Alum at both the N-terminus and basic 
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 region (Table 4.4).  Although the sera from both positive controls in the two studies, CFA 
and Lipid A, demonstrated reactivity across the entire Tat sequence analyzed, the 
strongest recognition was in the N-terminal and basic regions of the protein.   
These data are in agreement with the antibody epitopes reported for Tat (aa 1-86) 
in different species [387,412-414].  Sera from healthy and HIV-infected volunteers 
immunized with a Tat-toxoid vaccine reacted primarily with the N-terminus (aa 1-24) and 
the basic domain (aa 46-60) of Tat [387].  Moreover, sera from mice, rabbits, macaques 
and humans immunized with recombinant Tat, synthetic Tat, Tat toxoid or Tat peptides 
demonstrated reactivity to N-terminus and basic domains of Tat [413].  While both the N-
terminal and basic regions of Tat are highly conserved among different HIV-1 subtypes 
[414], the recognition of the basic region may be of particular importance since it 
mediates the cellular uptake and nuclear localization of Tat [360].  Thus, generating 
antibodies that strongly recognize this region is advantageous for inhibiting Tat-mediated 
HIV-gene expression in infected cells.  It is important to note that that the strongest 
reactivity in the basic domain in the Tat immunized animals was produced by the NP 
groups, suggesting that NPs may be effective at enhancing immune responses to this 
region. 
 
Inhibition of Tat-mediated LTR-transactivation  
Extracellular Tat has been demonstrated to enter HIV-infected cells and promote 
gene expression [358,359].  Tat mediates transactivation of HIV-1 via the long-terminal 
repeat promoter by migrating from the cell cytoplasm into the cell nucleus and binding to 
the Tat responsive element, TAR region [18].  Thus, neutralization of extracellular Tat 
may be crucial in preventing spread of HIV infection and slowing the progression on to 
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 disease.  The anti-sera from Tat immunized mice were evaluated for extracellular Tat 
neutralization activity using SVGA cells (an astrocytic cell line) transfected with pHIV-
CAT plasmid.  Sera from the naïve group were used as controls and the percent inhibition 
in CAT expression for each group compared to the naïve group is presented in Figure 4.4.  
All groups demonstrated significantly higher Tat neutralizing antibody compared to the 
naïve sera.  As shown, the anti-sera from Tat (5 μg) coated NPs group produced 
significantly higher inhibition in CAT expression compared to all groups.  Nonetheless, 
the other groups also demonstrated ability of the anti-sera to neutralize extracellular Tat.  
These data suggest that neutralizing antibodies to Tat (1-72) can be generated with the 
various adjuvants employed.  Interestingly, Moreau et al. have reported that only anti-
sera reacting with the N-terminal and basic regions of Tat were able to block Tat-
mediated LTR-transactivation [413].  In the present studies, a correlation between 
reactivity in these regions of Tat and ability to block extracellular Tat entry into cells was 
not observed.  All the anti-sera were able to neutralize extracellular Tat to some degree 
regardless of the Tat epitopes recognized in the peptide ELISA.  However, Tat (5 μg) 
coated on NPs which demonstrated the strongest reactivity to the basic region in the 
peptide ELISA also demonstrated the highest neutralization activity in the LTR-
transactivation assay.  Moreover, this group also demonstrated the strongest reactivity in 
the basic region of Tat, which may be of significant importance in preventing entry of Tat 
and thus, Tat-mediated LTR-transactivation.  Differences observed between the results 
obtained in this study compared to those observed by Moreau et al. could be due to a 
number of factors.  First, different cell types were used in the two studies which may 
affect the sensitivity of the assay.  Second, the present studies used the first exon of Tat 
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 (aa 1-72) for the LTR-transactivation assay whereas Moreau et al. used full length Tat (aa 
1-86), which has been shown to enter cells more efficiently than Tat (1-72).  Third, the 
Tat concentrations employed in the present LTR-transactivation studies are 
approximately 80-fold greater than those reported by Moreau et al.  Fourth, Tosi et al. 
have shown that only the monomeric form of exogenous Tat is able induce LTR- 
transactivation and took significant precautions using high concentrations of DTT to 
inhibit oligomer formation [415].  Thus, taken together these differences may offer some 
explanation as to why a correlation was not observed between the reactivities of the anti-
sera in the N-terminal and basic regions of Tat and the neutralization activity in the LTR-
transactivation assay.  Further work to optimize the LTR-transactivation assay using a 
HeLa cell line and a difference source of extracellular Tat are on going in our laboratory.  
Preliminary results, presented in Chapter 8, demonstrate that improved sensitivity in the 
assay can be obtained with these modifications. 
It is well recognized that there is an urgent need for a safe and effective vaccine 
against HIV.  Numerous failures to neutralize the virus using envelope-based vaccines 
have caused researchers to look at alternative avenues to provide some protection or to 
slow down the progression of the disease in HIV-infected patients by the development of 
therapeutic vaccines.  One of the requirements for an effective HIV vaccine will be that 
the antigen is conserved among the different viral subtypes.  Thus, many researchers are 
investigating the potential of HIV regulatory proteins Nef, Rev, and Tat, which are 
expressed early in the life cycle and are also fairly well conserved among the different 
HIV subtypes, as alternative targets for vaccine development [406,416,417].  Several 
studies have demonstrated the importance of Tat in the virus life cycle and demonstrated 
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 that anti-Tat antibodies [373,374,376] and CTL responses [377,378] correlate inversely 
with disease progression, making Tat an attractive candidate for HIV vaccine 
development.   
In conclusion, we previously reported that anionic NPs were effective for 
enhancing immune humoral and cellular immune responses to HIV-1 Tat [253].   The 
present studies further demonstrated the advantages of using NPs over Alum as an 
adjuvant for protein based vaccine in that NPs allowed for lower doses of Tat to be 
administered.  Moreover, Tat-coated NPs were able to generate antibodies that strongly 
recognized both the N-terminal and basic regions of the protein.  Tat-mediated LTR-
transactivation studies also revealed that the antibodies generated with all Tat groups 
were able to block Tat entry into cells, with Tat coated NPs showing superior Tat 
neutralization activity over other forms of delivery.  Together the data presented here 
demonstrate the potential of these novel anionic NPs as effective vaccine delivery 
systems for enhancing immune responses to HIV-1 Tat-based vaccines and possibly other 
HIV protein-based vaccines. 
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 Table 4.1.  Experimental design for mouse immunization study. 
Study Treatment Tat Dose 
Immunization 
Schedule 
Sera 
Collected 
Naïve - - 
NPs + Tat 1 and 5 μg 
Alum + Tat 1 and 5 μg Study 1 
CFA + Tat 5 μg 
Day 0, 21, 28 Day 35 
  
Naïve - - 
NPs + Tat 0.2 and 1 μg 
Alum + Tat 0.2 and 1 μg Study 2 
Lipid A + Tat 0.2 and 1 μg 
Day 0, 14, 28 Day 13, 34, 42 
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 Table 4.2.  Physical properties of anionic NPs coated with HIV-1 Tat (1-72).   
 
 
Sample (n=3) 
 
Mean Size (nm) 
 
Mean Charge (mV)
 
Anionic NPs 
 
102.5 + 7.6 
 
-55.7 + 0.7 
 
Tat-coated NPs (1:500 w/w) 
 
130.6 + 3.3 
 
-48.6 + 3.7 
 
Tat-coated NPs (1:100 w/w) 
 
110.9 + 3.3 
 
-43.9 + 1.9 
 
Tat-coated NPs (1:20 w/w) 
 
111.6 + 5.1 
 
-43.6 + 1.7 
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 Table 4.3.  Tat anti-sera reactivity to 15-mer Tat peptides in Study 1.  All sera were 
diluted 1:100.  The reactivity of anti-sera from each animal is presented.  The value in 
parenthesis represents the dose of Tat in μg.  *Cutoff = (AVG Naïve response) + (3*SD). 
(-) indicates no response – ELISA OD values equal to cutoff/background. 
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 Table 4.4.  Tat anti-sera reactivity to 15-mer Tat peptides in Study 2.  All sera from 
mice immunized with 1 μg of Tat were diluted 1:100.  The reactivity of anti-sera from 
each animal is presented.  *Cutoff = (AVG Naïve response) + (3*SD). (-) indicates no 
response – ELISA OD values equal to cutoff/background. 
 
 
 
 96
 Figure 4.1 
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Figure 4.1.  Study 1: Tat-specific total serum IgG titers.  The numbers in parentheses 
refer to the dose of Tat.  BALB/c mice were immunized on day 0, 21, and 28 with 100 
μL of each formulation. Tat-specific total serum IgG Titers were evaluated on day 35 by 
ELISA. Data represent the mean ± SD.   *p<0.05 compared to all groups.   
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 Figure 4.2 
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Figure 4.2.  Study 2: Tat-specific total serum IgG titers.  The numbers in parentheses 
refer to the dose of Tat.  BALB/c mice were immunized on day 0, 14, and 28 with 100 
μL of each formulation. Tat-specific total serum IgG Titers were evaluated on day 13, 34, 
and 42 by ELISA. Data represent the mean ± SD.  *p<0.05 compared to NPs (0.2 μg) and 
both Alum groups at all time points; #p<0.05 compared to all groups at all time points.   
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 Figure 4.3 
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Figure 4.3.  Tat-specific IgG2a and IgG1 titers.  BALB/c mice were immunized on day 
0, 21, and 28 with 100 μL of each formulation.  The numbers in parentheses refer to the 
dose of Tat.  Tat-specific serum IgG2a and IgG1 Titers were evaluated on day 35 by 
ELISA.  The mean IgG2a/IgG1 ratio is indicated on top of the graphed titers for each 
group.  Data represent the mean ± SD. *p<0.05 compared to NPs (1 μg) group.   
 
 
 
 
 
 
 
 
 
 
 99
 Figure 4.4 
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Figure 4.4.  Inhibition of Tat-mediated LTR-transactivation.  BALB/c mice were 
immunized on day 0, 21, and 28 with 100 μL of each formulation.  The numbers in 
parentheses refer to the dose of Tat.   Serum from each mouse was evaluated for Tat 
neutralizing antibodies using a LTR-transactivation assay.  The percent inhibition in CAT 
expression for each group is expressed in comparison to naïve sera.   Data represent the 
mean ± SD.  *p<0.05 compared to all groups.   
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 Chapter 5 
 
Formulation of Toll-like receptor ligands with cationic nanoparticles and in vivo 
evaluation using Ovalbumin as a model antigen 
 
5.1 Summary 
The use of cationic nanoparticles formulated with immunostimulatory adjuvants 
was investigated for obtaining enhancements in immune responses to ovalbumin (OVA) 
compared to either nanoparticles or adjuvant alone.  More specifically, three Toll-like 
receptor ligands were investigated:  lipoteichoic acid (LTA), a synthetic CpG 
oligonucleotide (CpG), and a synthetic double-stranded RNA analog (Poly I:C).  Initial 
studies revealed the strong potency of CpG formulated with nanoparticles for stimulating 
cell responses in the lymph nodes 8 days after initial immunization.  Based on these data, 
further work was carried out to evaluate the humoral immune responses in BALB/c mice 
using nanoparticles coated with OVA and CpG.  The data demonstrated that more robust 
OVA-specific immune responses could be obtained with CpG coated on nanoparticles 
compared to either CpG or nanoparticles alone.   
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 5.2 Introduction 
Unlike traditional vaccines such as live attenuated or whole killed pathogens, new 
generation vaccines, composed of peptides, proteins or DNA, are considered to be 
potentially much safer; however, they produce poor immune responses when 
administered alone.  Thus, the use of immunological adjuvants is crucial with new 
generation vaccines to elicit stronger, more robust immune responses.  Of particular 
importance is the choice of adjuvant used with the antigen, as the adjuvant can greatly 
influence the type of immune response generated, biasing towards either a Th1/cellular or 
Th2/humoral type response.  For example, aluminum-based mineral salts such as Alum 
produce strong humoral responses but Alum is considered a weak adjuvant for mediating 
cellular responses [134].  In contrast, bacterial derived products such as Lipid A typically 
bias the immune response towards a cellular or Th1 type response [64].  Therefore, the 
key to eliciting optimal immune responses with new generation vaccines may lie in the 
selection of an appropriate adjuvant or combination of adjuvants. 
While many new adjuvants have been explored and evaluated in clinical trials, the 
majority of adjuvants have been proven to be too toxic to be used in routine human 
vaccination. Alum continues to be the only approved adjuvant for use in human vaccines 
in the United States [2].   It is well recognized that in order to conquer emerging chronic 
infections, such as HIV, safer and more effective adjuvants that produce cellular in 
addition to humoral immune responses will be necessary [77]. 
Adjuvants can be broadly classified as immunostimulatory or particulate, 
including particulate delivery systems.  Immunostimulatory adjuvants function mainly at 
the cytokine level, enhancing the immune responses via activation and up regulation of 
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 co-stimulatory molecules on antigen presenting cells (APCs).  Immunostimulatory 
adjuvants derived from bacterial components, such as lipopolysaccharides and 
lipoproteins, are recognized by Toll-like receptors (TLRs) expressed on antigen 
presenting cells and mediate enhancement in immune responses through activating the 
innate immune system [418].  Presently, ten TLRs have been identified, denoted TLR1 to 
TLR10, and ligands that bind to most of these receptors have been identified [57].  For 
example, the well-investigated immunostimulant lipopolysaccharide is reported to bind to 
TLR4, whereas lipoproteins bind to TLR2.  Moreover, the cooperation of different TLRs 
in recognition of microbes has been reported.  One example reported includes the 
cooperation of TLR2 with TLR1 [419] and TLR6 [420] in recognition and innate 
immune responses to pathogens.  An additional feature of TLRs is their differential 
expression on different dendritic cell subtypes [269].  Furthermore, TLRs are expressed 
either on the cell surface (TLR1, 2, 4-5, 11) or intracellularly (TLR3, 7-9) [83].    
In contrast to immunostimulatory adjuvants, particulate delivery systems are 
thought to mediate their effects through enhanced delivery and uptake by APCs [1].  
Particulate systems are naturally targeted for uptake by APCs due to the similarity in 
sizes compared to pathogens [125].  The use of immunostimulatory adjuvants in 
combination with particulate delivery systems has been of great interest in obtaining 
more robust enhancements in immune responses to antigens [4,92,257,421,422].  
Particulate delivery systems offer numerous advantages for delivery of 
immunostimulatory adjuvants including: 1) reducing the toxicity or side effects of the 
immunostimulant by providing controlled delivery or release [255], 2) allowing for lower 
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 doses of immunostimulant to be used by enhancing uptake into APCs [263], and 3) 
biasing immune responses toward cellular/Th1 type with particulate systems [99,394].   
To this end, our laboratory has reported on the preparation of nanoparticles (NPs) 
from oil-in-water microemulsion precursors and reported on initial studies demonstrating 
the application of these NPs for enhancing immune responses to plasmid DNA [14,15], 
cationized β-galactosidase protein [16], and the HIV-1 Tat protein [253].  These NPs are 
approximately 100 nm in size and have the advantage of being prepared in a single step, 
one vessel process with relative ease in modifying the physical characteristics of the 
particles by using appropriate surfactants.  More importantly, the oil phase used for 
preparation of these NPs is comprised of cetyl alcohol and polysorbate 60, both which are 
found in many pharmaceutical products and are biocompatible [251].   The present 
studies investigated the potential application of these NPs formulated with three different 
TLR ligands for enhancing immune responses to a model antigen, ovalbumin (OVA).  To 
formulate with cationic NPs, three negatively charged TLR ligands were used: Poly I:C, a 
synthetic analog of double-stranded RNA (dsRNA) that binds to TLR3; lipoteichoic acid 
(LTA), a cell wall component from gram positive bacteria that binds to TLR2; and CpG 
oligonucleotide (CpG), a synthetic 20-mer oligonucleotide containing unmethylated CpG 
motifs typically present in bacterial DNA that bind to TLR9.       
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 5.3 Materials and methods 
 
Materials 
 
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of 
20:1), was purchased from Spectrum (New Brunswick, NJ).  Cetyl trimethyl ammonium 
bromide (CTAB), PBS/Tween 20 buffer, bovine serum albumin (BSA), ovalbumin grade 
VI (OVA), and mannitol were purchased from Sigma Chemical Co. (St. Louis, MO).  
Brij 78 was purchased from Uniqema (New Castle, DE).  Sheep anti-mouse IgG, 
peroxidase-linked species specific F(ab’)2 fragment was purchased from Amersham 
Pharmacia Biotech (Piscataway, NJ).  Goat anti-mouse IgG2a and IgG1 horseradish 
peroxidase (HRP) conjugates were purchased from Southern Biotechnology Associates, 
Inc. (Birmingham, AL).  Tetramethylbenzidine (TMB) substrate kit was purchased from 
Pierce (Rockford, IL).  RPMI 1640, 10% heat-inactivated fetal calf serum, Hanks 
Balanced Salt Solution (HBSS), HEPES, L-glutamine, penicillin, and streptomycin were 
from GIBCO (Carlsbad, CA).  The TLR ligands: murine CpG oligodeoxynucleotide 
(ODN 1826: 5’-tcc atg acg ttc ctg acg tt-3’), synthetic dsRNA (Poly I:C), and 
Lipoteichoic acid (LTA) were purchased from Invivogen (San Diego, CA). Incomplete 
Freund’s adjuvant, mycobacterium tuberculosis and 2-mercaptoethanol were purchased 
from Fisher Scientific (Hampton, NH).  For in vivo studies, Female BALB/c mice (8-10 
weeks old) obtained from Harlan Sprague-Dawley Laboratories (Indianapolis, Indiana) 
were used.  Unless stated otherwise, all water used in experiments was filtered (0.2 μm) 
deionized water. 
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 Preparation of cationic NPs 
Nanoparticles from oil-in-water microemulsion precursors were prepared as 
described previously with slight modification [14,15].  Briefly, 2 mg of emulsifying wax 
and 3.5 mg of Brij 78 was melted and mixed at ~60-65oC.  Water (980 μL) was added to 
the melted wax and surfactant while stirring to form an opaque emulsion.  Finally, 20 μL 
of CTAB (50 mM) was added to form clear microemulsions at 60-65oC. The 
microemulsions were cooled to room temperature while stirring to obtain solid NPs        
(2 mg/mL).  The final concentration of components in the NP suspension was 
emulsifying wax (2 mg/mL), Brij 78 (3 mM), and CTAB (1 mM). The NP sizes were 
measured using a Coulter N4 Plus Sub-Micron Particle Sizer (Coulter Corporation, 
Miami, FL) at 90o.  The overall charge of the NPs was measured using Malvern Zeta 
Sizer 2000 (Malvern Instruments, Southborough, MA). 
 
Coating of the cationic NPs with OVA and TLR ligands  
Varying amounts of OVA were added to NPs (1000 μg/mL) in 5% (v/v) mannitol.  
The suspension was vortexed gently and placed on a horizontal shaker at room 
temperature for a minimum of 30 min to allow for coating.  A similar procedure was 
followed to coat the TLR ligands on cationic NPs.  For formulations where TLR ligands 
and OVA were coated on NPs, the required amount of OVA was first coated on the NPs 
followed by coating with the ligand as described above.  The coated NPs were diluted 
appropriately in water for measuring the size and charge of the particles.  
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 Mouse immunization study evaluating cationic NPs coated with TLR ligands and 
OVA 
Mice (n=5/group) were immunized (s.c.) once, on day 0, with 100 μL of NPs, 
OVA-coated NPs, OVA- and LTA-coated NPs, OVA- and Poly I:C-coated NPs, OVA- 
and CpG-coated NPs, and OVA adjuvanted with complete Freund’s adjuvant (CFA).  
The doses were as follows: 5 μg of OVA; 50 μg of TLR ligand; and 100 μg of cationic 
NPs.  The immune responses in draining lymph nodes (brachial, axillary and inguinal) 
were assessed on day 8. 
 
Lymphocyte proliferation assay for day 8 harvested lymph nodes 
The draining lymph nodes collected for each mouse were prepared individually 
and stimulated in triplicate with media, Con A (2 μg/mL), or OVA (50 μg/mL).  Briefly, 
single cell suspensions were prepared by teasing the lymph nodes apart in 1X Hanks 
Balanced Salt Solution (HBSS).  Single cell suspensions were transferred into 15 mL of 
1X HBSS in a centrifuge tube and spun down at 1,500 rpm for 10 min at 4oC.  The cells 
were resuspended in RPMI 1640 (supplemented with 10% heat-inactivated fetal calf 
serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL streptomycin, 
50 μM 2–mercaptoethanol).  The cells (5x105 cells/well) were incubated with media, Con 
A, or OVA at 37oC, 7% CO2 for 4 days and then pulsed with 1 μCi of 3H-thymidine and 
incubated for an additional 24 hr at 37oC, 7% CO2.  The cells were harvested and counted 
on day 5 to measure T cell proliferation. 
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 Mouse immunization study with cationic NPs coated with CpG and OVA 
Mice (n=4-5/group) were immunized (s.c.) on day 0 and day 14 with either CpG-
coated NPs, OVA adjuvanted with CpG, OVA-coated NPs or CpG- and OVA-coated 
NPs.  CpG was coated on NPs at a 1:10 w/w and the dose of CpG or OVA given to 
animals was 10 μg and 5 μg, respectively.  As a positive control, mice were immunized 
with 50 μg of OVA adjuvanted with CFA on day 0.  On day 14, mice were bled via tail 
vein prior to boosting and blood was collected into Microtainer tubes (BD) and sera were 
separated according to manufacturer’s instructions.  On day 28, mice were bled by 
cardiac puncture and sera were separated.  All collected sera were stored at -20oC.  
Spleens were harvested and used for splenocyte proliferation assay. 
 
Determination of antibody titers 
OVA-specific serum IgG, IgG1 and IgG2a antibody titer were determined using 
an ELISA.  Briefly, 96-well plates (Costar) were coated with 100 μL of OVA (10 μg/mL 
in 0.05 M sodium carbonate-bicarbonate buffer, pH 9.6) overnight at 4oC.  The plates 
were blocked for 1 hr at 37oC with 200 μL of 4% BSA prepared in PBS/Tween 20.  The 
plates were then incubated with 50 μL per well of mouse serum diluted appropriately in 
4% BSA/PBS/Tween 20 for 2 hr at 37oC.  The plates were washed with PBS/Tween 20 
and incubated with 50 μL/well anti-mouse IgG HRP F(ab’)2 fragment from sheep 
(1:3000 in 1% BSA/PBS/Tween 20) for 1 hr at 37oC.  For IgG1 and IgG2a determination, 
the plates were similarly incubated with goat anti-mouse IgG1-HRP or goat anti-mouse 
IgG2a-HRP diluted 1:8000 (1% BSA/PBS/Tween 20). After washing the plates with 
PBS/Tween 20, the plates were developed by adding 100 μL of TMB substrate and 
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 incubating for 30 min at RT.  The color development was stopped by the addition of    
100 μL of 2 M H2SO4 and the OD at 450 nm was read using a Universal Microplate 
Reader (Bio-Tek Instruments, Inc.).  The OD at 450 nm versus log serum dilution for 
each animal was plotted and fit to a four parameter logistic equation using GraphPad 
Prism software.  The titer was defined as the anti-sera dilution giving 0.5*ODmax.   
  
Splenocyte proliferation assay 
The spleens were crushed in 1X HBSS using a stomacher homogenizer for 60s at 
normal speed to obtain single cell suspensions and the suspensions were then transferred 
into centrifuge tubes. Red blood cells were lysed adding 1X ACK buffer (156 mM 
NH4Cl, 10 mM KHCO3 and 100 μM EDTA) and incubating for 1-2 min at RT.   The 
cells were spun down at 1500 rpm, 4oC for 10 min.  Supernatants were decanted and the 
cells were washed 2 more times with 1X HBSS.  The cells were resuspended in RPMI 
1640 (supplemented with 10% heat-inactivated fetal calf serum, 1 mM HEPES, 2 μM L-
glutamine, 10 U/mL penicillin, 100 U/mL streptomycin, 50 μM 2–mercaptoethanol).  For 
splenocyte proliferation assay, cells (5x105 cells/well) were added to a 96-well plate and 
incubated in triplicate with media, Con A (2 μg/mL), or OVA (50 μg/mL) at 37oC, 7% 
CO2 for 4 days.  The cells were pulsed with 1 μCi of 3H-thymidine on day 4 and 
incubated for an additional 24 hr at 37oC, 7% CO2.   
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 Statistical analysis 
Statistical analysis was performed using one-way analysis of variances (ANOVA) 
followed by pair-wise comparisons using Tukey’s multiple comparison test using 
GraphPad Prism software. 
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 5.4 Results and discussion 
 
Preparation and characterization of cationic NPs coated with OVA and TLR 
ligands 
The preparation of NPs from warm oil-in-water microemulsion precursors has 
previously been reported by our laboratory [15,16].  These NPs are approximately 100 
nm in size and have the advantage of being prepared in a single step, one vessel process 
with relative ease in modifying the physical characteristics of the particles by using 
appropriate surfactants.  More importantly, the oil phase used for preparation of these 
NPs is comprised of cetyl alcohol and polysorbate 60, both which are found in many 
pharmaceutical products and are biocompatible [251].   
The NPs used in these present studies were stabilized by the inclusion of Brij 78 
and made to be positively-charged by the use of the cationic surfactant CTAB.  The net 
charge of the NPs prior to coating with OVA or TLR ligands was approximately +50 mV 
(Figure 5.1).  OVA, a negatively charged protein, was expected to be coated on the 
surface of the NPs via ionic interactions.  As demonstrated in Figure 5.1, there was a net 
decrease in the overall charge with increasing concentrations of OVA adsorbed to the 
surface of the NPs.  At a protein concentration of 50 μg/mL, approximately 95% of OVA 
was estimated to be coated on the NPs using SDS-PAGE densitometry (data not shown).  
At this concentration of OVA, it was expected that there was an excess of NPs as the net 
charge of the OVA-coated NPs was still positive and thus, allowed for the adsorption of 
TLR ligands via the negative charges of the molecules.  In the present studies, the 
adsorption of TLR ligands on NPs led to a further decrease in the charge, resulting in an 
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 overall negative charge for the particles (Table 5.1).  The coating of CpG did not 
significantly affect the nanoparticle particle size; however, the coating with LTA and 
Poly I:C resulted in an increase in the mean particle sizes to around 300 and 200 nm, 
respectively. 
 
Lymphoproliferative responses to OVA using TLR ligand-coated NPs 
 Initial in vivo studies were carried out to evaluate the ability of cationic NPs 
coated with three different negatively charged TLR ligands in providing more robust 
immune responses to OVA compared to NPs alone.  The immune responses were 
evaluated on day 8 by measuring T cell proliferation in the draining lymph nodes.  
Lymph node cell counts on day 8 demonstrated the highest activity with CpG-coated NPs 
(Figure 5.2), suggesting that this TLR ligand had extremely potent immunostimulatory 
activity compared to the Poly I:C and LTA.  Interestingly, this response was even 
stronger than the positive control CFA.  As expected, the OVA-specific proliferative 
responses demonstrated the strongest responses with the CFA positive control (Figure 
5.3).  All NP groups with OVA demonstrated positive OVA-specific responses, with the 
OVA-coated NPs showing the strongest response.  However, the responses with the NP 
groups were modest compared to the CFA.  It is possible that day 8 may not be optimal 
for evaluating the T cell responses.  Nonetheless, these data demonstrate the potential 
application of NPs with or without TLR ligands for enhancing immune responses to 
OVA.  The results suggested that CpG was a potent immunostimulatory adjuvant when 
coated on cationic NPs compared to Poly I:C and LTA, and was chosen for further work 
with NPs.  Moreover, the use of CpG has been of great interest to numerous researchers.  
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 The potent activity of CpG does pose potential side effects such as enlarged spleen and 
lymph nodes, which have been reported in literature to be dose-dependent [108,109].  
Thus, the use of cationic NPs coated with CpG may have the advantage in minimizing 
these side effects by enhancing the adjuvant activity of CpG and allowing for lower doses 
of CpG to be used.  In fact, recent reports demonstrated that PLGA nanoparticles were 
able to effectively reduce the doses of CpG required for obtaining more robust immune 
responses to tetanus toxoid compared to CpG in saline [263]. 
 
Immune response to OVA 
In vivo studies in BALB/c mice were carried out to investigate the use of cationic 
NPs as potential delivery systems to improve the adjuvant effect of CpG and thus, obtain 
significant enhancements in the immune responses to OVA.  Mice were immunized with 
either OVA-coated NPs (NPs+OVA), OVA mixed with CpG (CpG+OVA), or OVA- and 
CpG-coated NPs (NPs+CpG+OVA).  As a positive control, mice were immunized with 
OVA adjuvanted with CFA.  Sera collected from mice were analyzed for total OVA-
specific IgG at 2 weeks post initial immunization and 2 weeks post second immunization.  
As expected, animals immunized with OVA (50 μg) adjuvanted with CFA (a 10-fold 
higher dose than all other groups) resulted in the highest total IgG titers at both time 
points (Figure 5.4).  More importantly, 3-4-fold higher IgG titers were observed at both 2 
and 4 weeks using NPs coated with both CpG and OVA compared to CpG with OVA or 
NPs coated with OVA alone.  There were no significant differences at either time point in 
the IgG titers of the CpG with OVA group compared to OVA-coated NP group.  Also, 
the CpG-coated NP control group did not result in significant OVA-specific IgG 
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 compared to naïve animals (data not shown).  The data suggest that NPs coated with CpG 
and OVA can result in robust enhancements in the humoral immune response.  These 
results are consistent with reports from Singh et al. who demonstrated that the immune 
responses to HIV antigens using microparticles coated with CpG are more effective at 
enhancing immune responses than either adjuvant alone [398].  Surprisingly, this study 
demonstrated greatest OVA-specific proliferative responses with the NP group (Figure 
5.5).  This is in line with the initial study; however, it is unclear why the positive control 
group CFA did not produce a positive response in the assay.       
As mentioned earlier, there have been several reports on the use of CpG in 
shifting the immune response to antigens from a Th2 to a Th1 type response 
[105,107,159].  The presence of Th1/cellular response can be inferred by measuring the 
production of different IgG isotypes, as this is directly under the influence of cytokines 
secreted by T helper cells.  Th1 responses are characterized by production of IFN-γ, 
which promotes production of IgG2a isotype, whereas Th2 responses produce IL-4 which 
promotes the presence of the IgG1 isotype [423].  Although no significant differences 
existed among the groups for the OVA-specific IgG2a titers in this study, there is a shift 
in the type of immune response generated using NPs coated with CpG compared to NPs 
alone (Figure 5.6).  It is likely that the route of immunization and dose of CpG and/or the 
antigen may influence these types of responses.  Interestingly, Weeratna et al. have 
reported that the intramuscular route (i.m.) is superior to the subcutaneous route (s.c.) in 
obtaining optimal adjuvant activity with CpG [424].  Nonetheless, Samuel et al. have 
reported significant reduction in the CpG dose can be obtained using nanoparticles after 
subcutaneous injection [111,263].  However, the CpG was entrapped inside the 
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 nanoparticles with the antigen, which may allow for slow release of the antigen at the 
injection site.  Moreover, the antigen in this case is tetanus toxoid and the dose and 
effectiveness of adjuvant, i.e. CpG, may be dependent on the antigen.  Samuel et al. also 
used C57BL/6 mice in their studies, which have been reported to express higher levels of 
TLR9 compared to BALB/c mice, hence affecting the IL-12 production and Th1 
responses in the two strains of mice in response to CpG adjuvant [425].  In fact, this 
difference in the two strains of mice was suggested to be the underlying cause of the 
higher susceptibility of BALB/c mice to Listeria monocytogenes infection compared to 
C57BL/6 mice [425].  Therefore, the data with the current strategy in this study does 
suggest that NPs can be used for enhancing the adjuvant effect with CpG; however, 
further studies evaluating the route of immunization, CpG and antigen doses, as well as 
different antigens may be necessary to truly reveal the range of enhancements in immune 
responses that can be achieved with these NPs. 
As the field moves toward an era where well-defined antigenic components are 
becoming more attractive candidates for vaccines, there is an urgent need for more 
effective and safer adjuvants to aid in generating cellular and humoral immune responses 
to these antigens.  Toxicity is one of the greatest barriers in the development of new 
adjuvants for use in routine human vaccination.  These studies highlight the potential of 
NPs for enhancing immune responses to protein-based vaccines.  In addition, the use of 
an optimal murine CpG coated on NPs was shown to generate more robust immune 
responses than either adjuvant alone, further illustrating the potential of these NPs as 
adjuvants.  Although some concern has been raised that CpG use may generate 
autoimmune diseases due to over stimulation of the innate immune system, repeated 
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 doses administered in vivo in mice and non-human primates to date have shown no 
toxicity.  More importantly, the use of CpG have been evaluated in hundreds of human 
subjects in Phase I clinical trials and no adverse reactions due to CpG have been reported 
[110].  In fact, Phase I clinical trials have demonstrated that hepatitis B surface antigen 
(HBsAg) adjuvanted with CpG resulted in stronger, more robust immune responses 
compared to the HBsAg alone [94,112].  The strength of the immune response generated 
by each CpG oligonucleotide can vary and the optimal sequences differ from species to 
species.  However, optimal CpG oligonucleotides have been identified for a number of 
different species including mice, rabbit, sheep, goat, cattle, swine, horse, rhesus monkey, 
chimpanzee, and humans [111]. 
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 Table 5.1.  Physical properties of cationic NPs coated with TLR ligands and OVA. 
 
 Mean 
Charge 
(mV) 
Sample 
(n=3) 
Mean Size 
(nm)  
 
 
NPs 
 
 
111.9 ± 5.4 48.1 ± 1.6  
 
 
NPs + OVA 
 
 
116.7 ± 5.9 41.8 ± 1.9  
 
 
NPs + OVA + LTA 
 
 
299.1 ± 3.4 -35 ± 6  
 
 
NPs + OVA + Poly I:C 
 
 
220 ± 1.8 -30 ± 10  
 
 
NPs + OVA + CpG 
 
 
107.1 ± 1.1 -26.0 ± 3  
 
 
 
 
All OVA formulations were prepared at a concentration of 50 μg/mL OVA and         
1000 μg/mL cationic NPs.  All TLR ligands were present at a concentration of             
500 μg/mL. 
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 Figure 5.1 
 
 
Ctrl 10 30 50 70 100
0
25
50
75
100
125
0
10
20
30
40
50
60
OVA (μg/mL)
Pa
rt
ic
le
 S
iz
e 
(n
m
)
C
ha
rg
e 
(m
V)
 
 
 
Figure 5.1.  Physical characterization of cationic NPs coated with increasing 
concentrations of OVA.  The particle size ( ) and charge (♦) of cationic NPs (Ctrl) and 
OVA-coated on cationic NPs are shown.  Data reported are the mean ± S.D. (n=3). 
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Figure 5.2 
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Figure 5.2.  Mean number of cells recovered from the draining lymph nodes.  
Brachial, axillary and inguinal lymph nodes were collected from mice 8 days after 
immunization with the appropriate formulations.  The data represent the mean number of 
cells ± S.D. (for n=5/group). *p<0.05 compared to all groups. 
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Figure 5.3 
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Figure 5.3.  T cell proliferation in draining lymph nodes on day 8.  Single cell 
suspensions of the draining lymph nodes were stimulated for 4 days with Con A (2 
μg/mL) or OVA (50 μg/mL).  The cells were evaluated for 3H-thymidine incorporation 
on day 5.  The data represent the mean ± S.D. (for n=5/group). *p<0.05 compared to 
naïve group for OVA-stimulated cells; #p<0.05 compared to naïve group for Con A 
stimulated group; ap<0.05 for NPs+OVA group compared to NPs+OVA+LTA. 
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Figure 5.4 
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Figure 5.4.  OVA-specific serum IgG titers at 2 weeks and 4 weeks post initial 
immunization.  Mice were immunized on day 0 and 14 with OVA (5 μg) adjuvanted 
with CpG, OVA (5 μg) coated on NPs (100 μg) or OVA (5 μg) and CpG (10 μg) coated 
on NPs (100 μg).  As a positive control, OVA (50 μg) adjuvanted with CFA was injected 
on day 0 only.  Titers reported are the mean ± S.D. (n=4-5).  * indicates that the titers are 
significantly higher compared to CpG group and NPs group.    
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Figure 5.5 
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Figure 5.5.  OVA-specific proliferative responses in spleen on day 5.  Spleens were 
harvested four weeks post initial immunization and single cell suspensions of the spleen 
were stimulated with OVA for 4 days.  The incorporation of 3H-thymidine was evaluated 
on day 5.  The data represent the mean ± S.D. (for n=4-5/group).  *p<0.05 compared to 
all groups. 
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Figure 5.6 
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Figure 5.6.  OVA-specific serum IgG1 and IgG2a titers.  The IgG1 and IgG2a titers in 
sera were analyzed at four weeks post initial immunization. The mean IgG2a to IgG1 
ratio for each group is indicated on top of the graphed titers.  Data for each group 
represents the mean ± S.D. (n=4-5). 
. 
 
 
 
 
 
 
 
 123
  
Chapter 6 
 
Mechanistic investigation of immune response enhancement using nanoparticles  
 
6.1 Summary 
Nanoparticles prepared from oil-in-water microemulsion precursors have been 
shown to be effective for enhancing immune responses to pDNA and protein-based 
vaccines in mice.  The in vitro and in vivo studies in this chapter were carried out to 
assess the mechanism(s) by which nanoparticles may be enhancing immune responses.  
In vitro studies demonstrated that nanoparticles were taken up efficiently by murine 
bone-marrow derived dendritic cells (BMDDCs) and the presence of nanoparticles 
intracellulary was confirmed by confocal microscopy.  Furthermore, the release of pro-
inflammatory cytokines from human dendritic cells and BMDDCs was not observed after 
incubation with nanoparticles for 24 hr; however, nanoparticles coated with the 
immunostimulatory adjuvant, CpG, resulted in the release of IL-12, which was higher 
than the cytokine levels with CpG alone.  Adoptive transfer experiments using cells from 
OT-1 mice, MHC class I restricted Ovalbumin (OVA) transgenic mouse model, 
demonstrated higher proliferation of the OT-1 cells using OVA-coated nanoparticles 
compared to OVA, especially at lower doses of OVA.  Taken together, these data suggest 
that nanoparticles may be enhancing immune responses by promoting uptake of antigen 
by antigen presenting cells and by facilitating the delivery of antigen into MHC class I 
restricted antigen presentation pathway. 
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 6.2 Introduction 
The need for safer, more effective adjuvants is clearly recognized for 
development of vaccines comprised of proteins, peptides and pDNA [4,5,218,426].  One 
of the major limitations in development of vaccines is their toxicity or adverse side 
effects [134].  Many of the adjuvants evaluated have been empirically chosen for use and 
the mechanisms by which these adjuvants enhance immune responses are not fully 
understood and continue to be evaluated.  For example, although Alum has been used in 
routine human vaccination for over 70 years, the exact mechanism of immune response 
enhancement has not been fully elucidated [67].  There are several proposed mechanisms 
for the immune response enhancement using Alum and it is possible that each 
contributes, at least in part, to stimulating stronger immune responses to the antigen in 
vivo.  The following have been proposed for immune response enhancement with Alum:  
enhancement of uptake of associated antigen into antigen presenting cells (APCs), 
formation of depot at the site of injection and in macrophages present in muscle, local 
inflammatory response due to necrosis at injection site possibly resulting in activation of 
APCs and stimulating release of cytokines [66-69].    
Studies over the last several years with various adjuvants have allowed for broad 
classification of adjuvants depending on their mode of action [1,64].  The first class of 
adjuvants, immunostimulatory adjuvants, functions mainly at the cytokine level 
enhancing immune responses via activation and up regulation of co-stimulatory 
molecules on APCs.  Many of the adjuvants belonging to this class are derived from 
bacterial components.  On the contrary, the second class of adjuvants is mainly of 
synthetic/chemical nature consisting of particulate systems.   This class includes 
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 particulate delivery systems, such as microparticles, nanoparticles, and liposomes, and 
they are thought to exert their activities by acting as delivery vehicles for the antigens and 
promoting the uptake of the antigen by: 1) directly enhancing uptake into APC via 
passive and active targeting; and/or 2) forming a depot of the antigen at the site of 
injection, providing a slow release and uptake by APCs.  Studies with many particulate 
delivery systems such as nanoparticles and microparticles have demonstrated that they 
are taken up by APCs [239-242,427] and these systems are believed to enhance immune 
responses in vivo by promoting the uptake of the associated antigen [4,13].  Moreover, in 
one study a modest upregulation in co-stimulatory and MHC class II molecules was also 
reported [239], suggesting a possible role of these delivery systems in the maturation of 
APCs or enhancement in antigen presentation.   
  To this end, nanoparticles (NPs) prepared from oil-in-water microemulsion 
precursors have been reported to enhance immune responses to pDNA [14,15], cationized 
β-galactosidase [16], and HIV-1 Tat [253].  In addition, further enhancements in immune 
responses with these NPs were observed by incorporating mannan to target mannose 
receptors present on macrophages and dendritic cells (DCs) [14,15].  It was also 
demonstrated that the uptake of nanoparticles in macrophages could be enhanced with the 
mannan ligand [428].  One of the most potent APCs are DCs and the targeting and 
presentation of antigens by DCs is of great interest.  The present studies were aimed at 
further understanding the mechanism(s) by which NPs enhance immune responses.  In 
vitro studies were carried out to evaluate the uptake and release of various pro-
inflammatory cytokines from DCs.  In addition, an in vivo study using a MHC class I-
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 restricted OVA transgenic mouse model was carried out to evaluate the utility of these 
NPs in enhancing presentation of exogenous protein via this pathway. 
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 6.3   Materials and methods  
 
Materials 
 
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of 
20:1), Alum and sodium dodecyl sulfate (SDS) were from Spectrum (New Brunswick, 
NJ).  Cetyl trimethyl ammonium bromide (CTAB), PBS/Tween 20 buffer, bovine serum 
albumin (BSA), ovalbumin grade VI (OVA) and Sepharose CL4B were purchased from 
Sigma Chemical Co. (St. Louis, MO).  Brij 78 was purchased from Uniqema (New 
Castle, DE).  TNF-α, IL-1β, and IL-12 ELISA kits were purchased from Pierce 
(Rockford, IL).  Murine CpG oligodeoxynucleotide (ODN 1826) was purchased from 
Invivogen (San Diego, CA).  ScintiVerse liquid scintillation cocktail and 2-
mercaptoethanol was purchased from Fisher Scientific (Hampton, NH).  Prolong® 
Antifade kit, Carboxy-fluorescein diacetate, succinimidyl ester (CFSE), and 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiOC18) were purchased from Molecular 
Probes (Eugene, OR).  Biotinylated anti-mouse CD11c primary antibody, and the 
monoclonal antibodies, anti-Valpha2 and anti-Vbeta5 were purchased from BD 
Bioscience (San Jose, CA).  RPMI 1640, 10% heat-inactivated fetal calf serum, Hanks 
Balanced Salt Solution (HBSS), HEPES, L-glutamine, penicillin, and streptomycin were 
from GIBCO (Carlsbad, CA).  3H-cetyl alcohol was purchased from Moravek 
Biochemicals (Brea, CA).  Lysis buffer (5X) was purchased from Promega (Madison, 
WI).  Lipid A from Salmonella Minnesota R595 (Re) was purchased from List Biological 
Laboratories (Campbell, CA).  APC-conjugated Streptavidin was purchased from 
eBioscience (San Diego, CA).  Unless stated otherwise, all water used in experiments 
was filtered (0.2 μm) deionized water. 
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 Preparation of cationic NPs 
Nanoparticles from oil-in-water microemulsion precursors were prepared as 
described previously with slight modification [14,15].  Briefly, 2 mg of emulsifying wax 
and 3.5 mg of Brij 78 was melted and mixed at ~60-65oC.  Water (980 μL) was added to 
the melted wax and surfactant while stirring to form an opaque emulsion.  Finally, 20 μL 
of CTAB (50 mM) or SDS (50 mM) was added to form clear microemulsions at 60-65oC. 
The microemulsions were cooled to room temperature, while stirring, to obtain solid NPs 
(2 mg/mL).  The final concentration of components in the NP suspension was 
emulsifying wax (2 mg/mL), Brij 78 (3 mM), and CTAB or SDS (1 mM).   To prepare 
neutral NPs, the amount of Brij 78 was increased to 4.6 mg or 4 mM final concentration, 
with no additional co-surfactants.  The NP sizes were measured using a Coulter N4 Plus 
Sub-Micron Particle Sizer (Coulter Corporation, Miami, FL) at 90o.  The overall charge 
of the NPs was measured using Malvern Zeta Sizer 2000 (Malvern Instruments, 
Southborough, MA). 
 
Coating of the cationic NPs with OVA and CpG  
Varying amounts of OVA were added to NPs (1000 μg/mL) in 5% (v/v) mannitol.  
The suspension was vortexed gently and placed on a horizontal shaker at room 
temperature for a minimum of 30 min to allow for coating.  A similar procedure was 
followed to coat CpG on cationic NPs at a 1:3 w/w ratio.  The coated NPs were diluted 
appropriately in water for measuring the size and charge of the particles.  
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 In vitro generation of murine BMDDCs 
Bone marrow cells were obtained by flushing the femurs of BALB/c mice with 
1X HBSS.  Cells were cultured in 100 mm bacteriological petri dishes at 2 x 105cells/mL 
in 10 mL of complete RPMI 1640 medium (supplemented with 10% heat-inactivated 
fetal calf serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL 
streptomycin, 50 μM 2–mercaptoethanol) containing 20-25 ng/mL GM-CSF at 37oC, 7% 
CO2.  The cells were supplemented with an additional 10 mL of complete RPMI 1640 
with 20-25 ng/mL GM-CSF on day 3.  On day 6, 10 mL of supernatant was removed 
from each plate and spun down.  The cells were resuspended in fresh 10 mL of complete 
RPMI 1640 with 20-25 ng/mL GM-CSF and added back to the Petri dishes.  Non-
adherent to lightly adherent cells were harvested on day 7 and used for in vitro studies.  
 
In vitro uptake of NPs using murine BMDDCs 
Cationic (CTAB), anionic (SDS), and neutral (Brij 78) NPs radiolabeled with 3H-
cetyl alcohol (50 μCi/mL) were prepared for quantitating uptake of NPs by BMDDCs.  
The preparation, entrapment and stability of the radiolabeled NPs has been described 
previously [429].  Day 7 harvested BMDDCs were plated in 200 μL of complete RPMI 
1640 at 2 x 105 cells/well in 48-well tissue culture plates.  After incubating the cells 
overnight at 37oC, 7% CO2, the wells were washed once with 500 μL of cold 1X HBSS 
and 100 μL of complete RPMI 1640 was added to each well.  The radiolabeled NPs were 
diluted appropriately in complete RPMI 1640 and 100 μL (equivalent of 1 μg of NPs) 
was added to each well and plates were incubated at 37oC, 7% CO2 for 1, 2, 4, 6 and 12 
hr.  As a control, cells were incubated at 4oC for 1, 2 and 4 hr.  At each time point, the 
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 media containing radiolabeled NPs was removed and the cells were washed three times 
with 400 μL of 1X cold PBS.  The cells were lysed with 100 μL of 1X lysis buffer with 
one freeze thaw cycle at -20oC.  The lysed cells were collected and counted in 
ScintiVerse liquid scintillation cocktail using a Beckman LS 6500 scintillation counter 
(Fullerton, CA). 
 
Confocal microscopy of BMDDCs incubated with fluorescent NPs  
Fluorescent NPs were prepared by using 2% w/w DiOC18.  Briefly, 40 μl of 
DiOC18 (1 mg/ml stock in chloroform) was added to a vial containing 2 mg of 
emulsifying wax and 3.5 mg of Brij 78.  The vial was mixed at ~60-65oC allowing for all 
solvent to be evaporated.  After complete evaporation of the solvent, 1 ml of water was 
added to the vial at 60-65oC and NPs were formulated as described above.  Unentrapped 
DiOC18 was separated from the NPs by gel permeation chromatography using a 
Sepharose CL4B packed column (15 x 70 mm) with 0.01 M PBS, pH 7.4 as the mobile 
phase.  Purified NPs were used further for in vitro studies with BMDDCs.  
Immunofluorescence staining was used to visualize the uptake of NPs by DCs.  
BMDDCs were seeded into sterile Petri dish at concentrations 4 x 105 cells/mL and 
incubated with 2 or 10 μg/mL of fluorescent NPs at 37oC, 7% CO2 in the dark. After 
incubating for 24 hr, the cells were washed with 1X PBS to remove excess NPs.  DCs 
were stained by labeling the cells with biotinylated anti-mouse CD11c primary antibody 
followed by labeling with APC-conjugated Streptavidin. Cells were washed with 1X PBS 
after staining, fixed on a glass slide using 2% formaldehyde for 15 min at room 
temperature in the dark, and mounted using Prolong® Antifade kit.  Cells were visualized 
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 using Leica Laser scanning confocal microscope equipped with Argon laser (488 nm 
green), Krypton laser (568 nm red), and HeNe laser (633 far red) using Leica confocal 
software.  
 
In vitro stimulation of with monocyte derived dendritic cells (MDDCs) with NPs 
Immature human MDDCs (5x105 cells/well) were plated in triplicate in 48-well 
plates and incubated for 24 hrs at 37oC, 5% CO2 with media alone (X-Vivo 15 
supplemented with 10% FBS, 1% penicillin-streptomycin, 20 ng/mL GM-CSF, and       
10 ng/mL IL-4) or in the presence of Alum, anionic NPs, or Lipid A at concentrations of 
10, 50, and 100 μg/mL.  The supernatants collected at 24 hr and assessed for TNF-α, IL-
1β, and total IL-12 release by ELISA.   
 
In vitro stimulation of murine BMDDCs 
BMDDCs (2x105 cells/well) were plated in triplicate in a 96-well plate and 
incubated overnight at 37oC, 5% CO2.  The cells were further incubated with varying 
concentrations of cationic NPs, Lipid A, CpG, or CpG coated on cationic NPs (1:3 w/w) 
for 24 hr and supernatants were collected. The size and charge of CpG-coated NPs was 
130 ± 15.2 nm and -32 ± 2.2, mV, respectively.  The total IL-12 release in the 
supernatants was quantified using ELISA kits.    
 
Adoptive transfer experiments using OT-1 cells 
OT-1 T cell receptor transgenic mice expressing a T cell receptor specific for an 
ovalbumin peptide presented by the H-2Kb molecule were used in adoptive transfer 
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 experiments as previously described [430].  Briefly, spleen and lymph node cells from 
OT-1 mice were labeled with CFSE and transferred into C57BL/6 mice (Jackson 
Laboratories, Bar Harbor, ME) such that each mouse received 2.5 x 106 OVA-specific T 
cells.  After 24 hr, mice (n=3/group) were immunized subcutaneously on the back and 
flanks with various concentrations of OVA alone or OVA-coated NPs.  Three days 
following immunization, cells were isolated from draining lymph nodes and stained with 
monoclonal antibodies to the transgenic T cell receptor (anti-Valpha 2 and anti-Vbeta 5) 
and analyzed by three-color flow cytometry.    
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 6.4 Results and discussion 
 
In vitro uptake  
Particulate delivery systems are thought to enhance immune responses mainly by 
promoting uptake or delivery of the associated antigen into APCs, such as DCs.  To this 
end, Singh et al. speculated that the enhanced immune responses obtained with the 
immunostimulatory adjuvant CpG coated on cationic microparticles may be due to 
enhanced delivery and uptake of both coated CpG and antigen into APCs [398].  In vitro 
studies with PLGA microparticles [241] and nanoparticles [239,240,431] demonstrated 
that the particles are taken up by DCs.  Consequently, the uptake also resulted a modest 
increase in the expression of MHC class II and co-stimulatory molecules with the 
nanoparticles [239]; however, this was not observed with microparticles.  It was 
suggested that particle size may have an effect on inducing the expression of these 
molecules [239].    
In the present studies, the uptake of NPs prepared from microemulsion precursors 
were evaluated using BMDDCs.  To determine the extent of uptake, radiolabelled NPs 
with varying charges were incubated with BMDDCs and the associated radioactivity was 
measured over time.  Figure 6.1 demonstrates that significantly more NPs were 
associated with BMDDCs at 37oC than at 4oC, suggesting active internalization.  There is 
some association of the particles to the cells at 4oC probably due to adsorption of the NPs 
to the cell surface.  In addition, Figure 6.2 confirms that all NPs, regardless of charge, 
were taken up by BMDDCs, with approximately 50-70% of the NPs taken up over 12 hr.  
The uptake of cationic NPs was found to be significantly higher than anionic and neutral 
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 NPs between 4 and 12 hr.  Interestingly, there was a linear increase in the number of 
particles taken up over 6 hr, after which there appeared to be a reduction in the uptake as 
indicated by the plateau around the 12 hr time point. This highly efficient uptake of NPs 
is clearly evident in Figure 6.3, where BMDDCs incubated with fluorescent labeled NPs 
demonstrate that the NPs, indicated by green fluorescence, are taken up and located 
intracellulary in DCs, outlined by red fluorescence. 
 
In vitro evaluation of anionic NPs using human MDDCs 
In vitro data indicate that the NPs are taken up into DCs.  To further evaluate if 
NPs are immunostimulatory after taken up by DCs, anionic NPs were incubated with 
human DCs for 24 hr and the supernatants were analyzed for three pro-inflammatory 
cytokines, IL-12, TNF-α, and IL-1β.  Lipid A, an immunostimulatory adjuvant, was used 
a positive control in these studies and Alum, which is a humoral immune response 
mediator was also included for comparison.  As shown in Figure 6.4 at the 10 μg/mL 
concentration of adjuvant, the positive control Lipid A, but not Alum or anionic NPs, 
caused significant release of IL-12 (a Th1 promoting cytokine), TNF-α and IL-1β from 
human DCs.  Furthermore, Lipid A caused a dose-dependent release of the pro-
inflammatory cytokines at the higher concentrations used; however, the anionic NPs and 
Alum treated cells did not cause release of pro-inflammatory cytokines at the higher 
concentrations (data not shown).  These data suggest that NPs are not immunostimulatory 
and do not enhance immune responses via the release of pro-inflammatory cytokines.  
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 In vitro stimulation using murine BMDDCs 
CpG has been shown to induce maturation and activation BMDDCs resulting in a 
release of several pro-inflammatory cytokines including IL-12 [97].  It has been reported 
that CpG treated DCs had an enhanced ability to activate T cells, which was significantly 
diminished in DCs derived from IL-12 knockout mice.  This suggested that CpG-
mediated IL-12 release from DCs plays a significant role in enhancement of Th1/cellular 
immune responses [432].    Since the receptor for CpG, TLR9, is located intracellularly, it 
has to be first taken up into BMDDCs where CpG can then bind to the TLR9 initiating 
the signaling cascade to cause IL-12 secretion.  Thus, it was expected that there would be 
significantly higher IL-12 release by BMDDCs if the uptake of CpG was enhanced using 
cationic NPs.  As shown in Figure 6.5, cationic NPs did not stimulate significant release 
of IL-12 from BMDDCs confirming that NPs by themselves have no significant 
immunostimulatory activity.  However, cationic NPs coated with CpG resulted in IL-12 
in a dose-dependent manner that was similar to Lipid A (positive control).  There was a 
significant amount of IL-12 release compared to unstimulated cells at a CpG or Lipid A 
dose of greater than 50 ng/mL.  NPs coated with CpG resulted in higher IL-12 release 
compared to CpG alone and this was statistically significant at a dose of 100 ng/mL of 
CpG.  These data in combination with the uptake data suggest that NPs functioned to 
enhance delivery, causing enhanced uptake of CpG by BMDDCs and therefore, allowing 
for more of the oligodeoxynucleotide to be available intracellulary to bind to TLR9 and 
causing enhanced IL-12 release.  Interestingly, Kwon et al. reported over a 10-fold 
increase in IL-12 release from BMDDCs after incubating with CpG coated on acid 
degradable nanoparticles [431] and in comparison, the enhancements in IL-12 release in 
 136
 the present studies were only modest.  Several factors may influence these discrepancies.  
First, the BMDDCs used by Kwon et al. were derived from C57BL/6 mice and reports 
suggest that these mice express TLR9 to a greater extent compared to BALB/c mice 
[425].  More importantly, BMDDCs are derived from primary cultures of cells from 
femurs of mice and several factors including the age of mice, the method used for 
generation of DCs, and the composition of the cultures at time of use may have an effect 
on the results.  Taken together, these factors may allow for more efficient stimulation of 
BMDDCs at lower concentrations of CpG than were obtained with our experiments.  An 
additional concern during these in vitro experiments is the presence of FBS in the media, 
which may disrupt electrostatic interactions between the cationic particle and CpG, 
possibly causing at least some of the CpG to dissociate from the NPs.   This would be 
less of a concern in the in vivo situation when the formulation is injected into the 
subcutaneous space.  Other factors that may also be of critical consideration is in 
identifying greater differences in IL-12 release such as the time of incubation/stimulation 
and the source of CpG.   
 
OT-1 cell proliferation in adoptive transfer experiments 
One of the major goals in vaccine development is to stimulate CD8+ T cell 
responses by presentation of antigen on MHC class I molecules.  To determine the extent 
to which antigens coupled to NPs stimulate CD8+ T cells in vivo, we utilized an adoptive 
transfer system with transgenic T cells from the OT-1 mouse, which express a class I 
restricted receptor specific for OVA presented by the H-2Kb class I molecule.  OT-1 cells 
were labeled with CFSE and transferred into normal C57BL/6 mice.  After 24 hr, the 
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 mice were immunized with OVA alone (no adjuvant) or OVA-coated NPs.  Flow 
cytometry was performed on day 3 to assess the extent of cell division by measuring 
CFSE dye dilution in the draining lymph nodes, which is a direct measure of the degree 
of antigen recognition.   All of the OT-1 cells in the control, unimmunized mice, 
remained CFSE bright indicating no cell division.  In contrast, OT-1 T cells from mice 
immunized with OVA alone or OVA-coated NPs showed extensive CFSE dye dilution 
indicating strong cell division in the draining lymph nodes.  These responses were at a 
plateau between 10 and 20 μg of OVA coated on NPs, as there were no significant 
differences in the T cell proliferation with a decrease in the antigen dose by one-half.  
However at the lowest dose evaluated, mice immunized with OVA-coated NPs showed 
significantly more cell division than OVA alone, indicating that OVA coated on NPs is 
superior to an equivalent concentration of soluble OVA in terms of stimulation of CD8+ 
T cells (Figure 6.6 and 6.7).  These results demonstrate that NPs can facilitate the entry of 
coated proteins into the MHC class I processing pathway resulting in enhanced 
presentation to CD8+ T cells in vivo.  This enhanced presentation via the MHC class I 
pathway is thought to be due to enhanced delivery into DCs, which are able to cross-
present exogenous antigens and are the primary cells involved in stimulation of T cells 
[74].  Moreover, these results are in agreement with the in vitro results using CpG coated 
NPs demonstrating that NPs were effective at enhancing delivery of the coated molecule.  
Studies evaluating CpG-coated NPs, lower doses of OVA with and without NPs, and 
time points of immunization in the adoptive transfer experiments will be helpful in 
further elucidating mechanism(s) of immune response enhancement. 
 138
 Taken together, these studies demonstrate that NPs prepared from oil-in-water 
microemulsions are effective systems for enhancing delivery of the associated antigen or 
immunostimulatory adjuvant into DCs.  It is hypothesized that this enhanced delivery 
causes the significant enhancements observed with antigen coated on NPs in vivo.  
However, the uptake and fate of NPs in vivo need to be further evaluated to further 
characterize their mechanism(s).  In vitro studies suggest that NPs do not enhance 
immune responses by release of cytokines; however, in vivo cell death by necrosis or 
apoptosis after injection may contribute to the immune response generation and will need 
to be further investigated. 
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Figure 6.1.  Uptake of H-NPs by BMDDCs at 37 C versus 4 C3 o o .  BMDDCs 
(1x106/mL) were incubated for various times with 1 μg of 3H-NPs prepared using various 
surfactants, CTAB, SDS, and Brij 78, to obtain cationic, anionic, and neutral NPs, 
respectively.  NPs were incubated with BMDDCs at 4oC as a control to distinguish 
association with the cells versus uptake at 37oC.  *indicates p<0.05 at 37oC compared to 
4oC at 1-4 hr by Students t-test.   
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 Figure 6.2 
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Figure 6.2.  Uptake of H-NPs by BMDDCs at 37 C3 o .  BMDDCs (1x106/mL) were 
incubated for various times with 1 μg of 3H-NPs prepared using various surfactants, 
CTAB, SDS, and Brij 78, to obtain cationic, anionic, and neutral NPs, respectively.  Data 
reported are the mean ± S.D. (n=3). *p<0.05 for CTAB NPs compared to SDS and Brij 
78 NPs. 
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 Figure 6.3 
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Figure 6.3.  Laser-scanning confocal microscopy images of fluorescent NPs present 
intracellularly in DCs.  DCs were visualized by staining with biotinylated anti-mouse 
CD11c primary antibody and APC-conjugated Streptavidin secondary antibody (red).  
NPs were labeled with DiOC18 (green).  All images were obtained at 100X magnification.  
A) Whole DC confocal image of BMDDCs incubated with 2 μg/ml fluorescent NPs.  B) 
Optically sectioned DC confocal image of  BMDDCs incubated with 2 μg/ml fluorescent 
NPs.  C) Whole DC confocal image of BMDDCs incubated with 10 μg/ml fluorescent 
NPs.  D) Optically sectioned DC confocal image of BMDDCs incubated with 10 μg/ml 
fluorescent NPs. 
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 Figure 6.4 
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Figure 6.4.  Pro-inflammatory cytokine release from human MDDCs.  Day 7 
MDDCs (1x106/mL) were cultured with media or 10 μg/mL Alum, anionic NPs, or Lipid 
A for 24 hr at 37oC, 5% CO2.  Pro-inflammatory cytokines were assessed in 24 hr 
supernatants by ELISA.  TNF-α levels for Lipid A were >1050 pg/mL.  Data reported are 
the mean ± S.D. (n=3).  *p<0.05 compared to all other groups.   
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 Figure 6.5 
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Figure 6.5.  IL-12 release from BMDDCs after in vitro stimulation.  Day 7 BMDDCs 
(1x106/mL) were cultured in complete RPMI 1640 alone (BMDCCs) or with cationic 
NPs, CpG, CpG coated on NPs (NPs+CpG) or Lipid A (positive control).    Total IL-12 
release from cells was measured in 24 hr supernatants by ELISA.  NP concentrations 
used were 3.35 times that indicated for CpG or Lipid A.  Data represents the mean ± S.D. 
(n=3). Experiment was performed in duplicate with similar trends and data shown here is 
representative of one experiment.  *p<0.05 for CpG-coated NPs compared to CpG alone 
by Students t-test. 
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 Figure 6.6 
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Figure 6.6.  Flow cytometry histograms comparing OVA-coated NPs to soluble OVA 
for stimulating a CD8  T cell clonal expansion in vivo+ .  The flow cytometry histograms 
from a representative mouse of the CFSE fluorescence of cells expressing the Valpha 2, 
Vbeta 5 T-cell receptor.  The left-most peak represents endogenous Valpha 2, Vbeta 5 
positive T-cells in the B6 mice and thus are CFSE negative.  The cells in peak M1 
represent OT-1 cells that have not divided while cells in peak M2 represent OT-1 cells 
that have undergone various numbers of cell divisions. 
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 Figure 6.7 
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Figure 6.7.   OVA-coated NPs are superior to soluble OVA at stimulating a CD8  T 
cell clonal expansion in vivo
+
.  The percent cell division (mean +/- S.D.) of the OT-1 
cells was determined by calculating the number of cells under marker M2 as a percent of 
the total cells under marker M1 + M2.  *p<0.05 compared to OVA by Student’s t-test. 
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 Chapter 7 
 
Preparation and characterization of nickel nanoparticles for enhanced immune 
responses to his-tag HIV-1 Gag p24   
 
7.1 Summary 
Particulate delivery systems have been widely investigated for obtaining 
enhanced immune responses to protein-based vaccines.  Previous reports from our 
laboratory have demonstrated that anionic or cationic nanoparticles prepared from oil-in-
water microemulsion precursors can be used to enhance immune responses to antigens 
coated on the surface of the particle by charge interactions.  A stronger interaction of the 
antigen to the surface of nanoparticles may provide greater association of antigen with 
the particles in vivo and prove beneficial in further enhancing the immune responses.    
The purpose of these studies was to prepare nanoparticles with a small amount of surface-
chelated nickel to enable stronger interactions with histidine-tagged (his-tag) proteins.  
The surface-chelated Ni nanoparticles were shown to bind to his-tag green fluorescent 
protein and his-tag HIV-1 Gag p24.  Furthermore, his-tag Gag p24 bound to the nickel 
nanoparticles resulted in significant enhancements in humoral responses, including IgG2a 
responses, compared to the protein adjuvanted with Alum or coated on the surface of 
negatively charged nanoparticles. 
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 7.2 Introduction 
The need for improved adjuvants for enhancing immune responses to protein-
based vaccines is widely recognized [2,7,59,60,94,433-435].  Presently, Alum continues 
to be the only approved adjuvant for routine human vaccination in the U.S [3].  However, 
there has been considerable interest in the development of particulate delivery systems 
for enhancing immune responses with protein-based vaccines over the past few years 
[4,6,8,172,198,263,436].  In fact, both PLGA microparticles and liposomes are currently 
under clinical evaluation with potential HIV and hepatitis vaccines, respectively [77,94].    
Particulate delivery systems are attractive as they offer numerous advantages such as the 
ability to: control the release of the antigen [202,230,232], target the delivery of antigen 
to antigen presenting cells (APCs) [169,283,296], and incorporate immunostimulatory 
adjuvants for synergistic enhancements in immune responses [79,257,260].  Moreover, 
particulate delivery systems are of similar sizes as naturally occurring pathogens and 
considered to be rapidly taken up by APCs, leading to increased accumulation of the 
associated protein inside the cell [125].  
Particulate delivery systems for protein-based vaccine applications have most 
often utilized entrapment of the antigen within the particle for obtaining enhanced 
immune responses [8,213,214,216,217,437].  Although effective, concerns associated 
with this approach include protein instability and entrapment efficiency.  For example, 
the protein stability is of significant concern with the most often investigated PLGA 
microparticles [235]. The protein degradation can occur during the entrapment by 
conditions such as the presence of organic solvents, during freeze drying, and also by the 
acidic environment created by polymer degradation in vivo [229].  Moreover, low 
 148
 entrapment of the protein and instability of the delivery system are challenges faced with 
using liposomal systems.   Alternatively, the use of charged particles has been 
investigated for coating antigens to the particle surface by ionic interactions and thus, 
enhancing immune responses to the coated antigen in vivo [9,235,237,248,398].   
Negatively charged PLGA microparticles have been shown to enhance immune responses 
to HIV-1 Gag p55 [238].   To this end, reports from our laboratory have demonstrated the 
potential of charged nanoparticles (NPs) prepared from oil-in-water microemulsion 
precursors for enhancing immune responses with cationic proteins such as β-
galactosidase [16] and HIV-1 Tat protein [253,438], and with the anionic model antigen 
ovalbumin (OVA) as shown in Chapter 5.   
Several studies suggest that the higher uptake of antigens into APCs using 
particulate delivery systems may result in enhanced immune response to associated 
antigens in vivo [239-242].  Studies in our laboratory suggest that NPs are taken up 
effectively in vitro by DCs and that the enhanced delivery of associated antigen or 
molecules, at least in part, contributes to the enhanced immune responses observed in 
vivo [439].  It is important to note that these are simply antigens coated on charged 
particles and some dissociation of the coated protein from the particle may occur in vivo 
due to other charged molecules present, resulting in a decreased accumulation in APCs.  
It is hypothesized that increasing the affinity of the antigen for the particles could allow 
even more of the antigen accumulate in the APCs compared to antigen coated on the 
surface of the NPs and thus, enabling greater enhancements in immune responses in vivo.   
The attachment of proteins and antibodies to particulate delivery systems has been 
investigated extensively by covalent linkages that involve the use of sulfhydryl-, amine- 
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 and carboxyl-reactive moieties on the protein or the particle [440-443].  However, these 
approaches are often cumbersome and require the use of activating or reducing agents.  In 
addition, these methods have the potential for causing protein degradation during 
attachment, random or multiple point attachment of the protein, and quite often, low 
coupling efficiencies are obtained.  An alternative approach that takes advantage of 
affinity interactions has been extensively used for purification of recombinant proteins 
[444-447].  This approach exploits the interaction between chelated divalent metal ions 
such as nickel, copper, or cobalt and a short sequence of histidine residues (4 to 10 
repeating units) added to the N- or C-terminus of the protein, referred to as histidine-tags 
(his-tag).  These purification methods generally involve immobilizing the metal ion onto 
the column packing material using a chelating agent such as nitrilotriacetic acid (NTA) 
[444].  In the case of Cu2+ and Ni2+ which have six coordination sites, NTA forms a 
strong complex with four of the metal sites, leaving two additional sites for interaction 
with the his-tag present on the protein [445].  Moreover, the interaction of his-tags with 
NTA-Ni has been reported to be equivalent or stronger than that of antibody interactions 
(10-6 to 10-9), with a dissociation constants (Kd) in the range of 10-6 to 10-13 M at pH 7-8 
depending on the protein and location of the his-tag on the protein [448,449].  The 
binding is reversible by competing off with excess imidazole (> 100 mM) or by lowering 
the pH which results in release of the his-tag protein due to protonation of electron 
donating histidine groups (pKa = 6.0).  In addition to its extensive use in protein 
purification, the use of NTA-Ni has been also reported for immobilization of his-tag 
proteins onto surfaces for structural and functional studies [450] and for studying protein 
interactions by flow cytometry [449]. More recently, hydrophobized NTA-Ni ligand 
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 integrated in the liposomal lipid bilayer was reported for attaching his-tag peptides and 
proteins on the surface [451] and for targeting the uptake of entrapped antigen to DCs via 
surface immobilization of his-tag antibodies for DC-specific receptors [290]. 
The interaction of chelated Ni with his-tag proteins for enhancing immune 
responses to antigens with particulate delivery systems would be advantageous since it is 
simple, applicable to a wide range of proteins, and offers stronger interactions between 
the particle and antigen compared to conventional charged particles, consequently 
allowing for higher accumulation of the antigen inside the cell.   Once the antigen is 
taken up into the cells, it can also be released because the interactions weaken in the 
acidic environment of the lysosomes.  Therefore, the present studies were aimed at 
investigating the preparation of NPs with a small amount of surface-chelated nickel for 
binding to his-tag proteins.  In addition, the utility of these NPs for enhancing the 
immune responses to protein-based vaccines was evaluated in vivo using his-tag HIV-1 
Gag p24 protein (his-tag p24). 
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 7.3 Materials and methods 
 
Materials 
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of 
20:1) and Alum were purchased from Spectrum (New Brunswick, NJ).  Phosphate 
buffered saline, pH 7.4 (PBS), PBS, pH 7.4 with 0.05% Tween 20 (PBS/Tween 20), 
bovine serum albumin (BSA), and Sepharose CL4B were from Sigma Chemical Co. (St. 
Louis, MO).  Brij 78 was purchased from Uniqema (New Castle, DE).  Sheep anti-mouse 
IgG, peroxidase-linked species specific F(ab’)2 fragment was purchased from Amersham 
Pharmacia Biotech (Piscataway, NJ).  IFN-γ ELISA kit, streptavidin-horseradish 
peroxidase (Sv-HRP) and biotinylated rat anti-mouse IgG1 and IgG2a monoclonal 
antibodies were from BD Biosciences Pharmingen (San Diego, CA).  
Tetramethylbenzidine (TMB) substrate kit and HisGrab™ nickel-coated plates were 
purchased from Pierce (Rockford, IL).  Microcon® YM-100, CentriPlus® YM-100, 
certified nickel standard (Claritas® certified reference material), nitric acid (trace metal 
grade), and 2-mercaptoethanol were purchased from Fisher Scientific (Hampton, NH).  
RPMI 1640, 10% heat-inactivated fetal calf serum, Hanks Balanced Salt Solution 
(HBSS), HEPES, L-glutamine, penicillin, and streptomycin were from GIBCO  
(Carlsbad, CA). 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic 
acid)succinyl] nickel and ammonium salt, DOGS-NTA-Ni and DOGS-NTA, 
respectively, were purchased from Avanti Polar Lipids (Alabastar, AL).  PVDF 
membranes, 15% Tris-HCl SDS-PAGE gels, and Immun-star HRP substrate kit were 
from Bio-Rad (Hercules, CA).  Histidine-tag HIV-1 Gag p24 (his-tag p24) was obtained 
through the Centralised Facility for AIDS Reagents supported by EU Programme 
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 EVA/MRC and the UK Medical Research Council (donated by Dr. I. Jane).   For in vivo 
studies, female BALB/c mice (6-8 weeks old) were obtained from Harlan Sprague-
Dawley Laboratories (Indianapolis, IN). 
 
Preparation of NPs with surface-chelated Ni 
Nanoparticles were prepared from oil-in-water microemulsion precursors using 
emulsifying wax as the oil phase and Brij 78 as the surfactant.  In a 7 mL glass vial, 2 mg 
of emulsifying wax and 3.5 mg (3 mM) of Brij 78 was added.  To this vial, 10.6 μL (0.1 
mM) of DOGS-NTA-Ni (10 mg/mL stock in chloroform) was added and the chloroform 
was evaporated on a hot plate (~60-65oC) while stirring.  Water (1000 μL) was added to 
the vial at 60-65oC and the contents of the vial were mixed on the hot plate to form clear 
microemulsions.  NPs were obtained by cooling the vials to room temperature while 
stirring.  NPs of similar composition but without Ni were prepared in the same manner 
using 0.1 mM of DOGS-NTA lipid instead, referred to as NTA-NPs.  The NPs were 
characterized by measuring their size using a Coulter N4 Plus Sub-Micron particle sizer 
(Coulter Corporation, Miami, FL) at 90o and charge, using a Malvern Zeta Sizer 2000 
(Malvern Instruments, Southborough, MA). 
 
Binding of his-tag p24 and initial in vivo studies 
For the initial studies, his-tag p24 was bound to the surface-chelated Ni 
nanoparticles (Ni-NPs) at a 1:10 w/w ratio in PBS, pH 7.4 at 4oC overnight.  The 
effectiveness of these formulations was evaluated in vivo using BALB/c mice (n=5-6 per 
group).  The animals were dosed on day 0 and day 14 with his-tag p24 bound to Ni-NPs, 
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 adjuvanted with Alum, or as a control coated on NTA-NPs.  All mice were given 100 μL 
s.c. injections on the back containing 2.5 μg of his-tag p24 and 25 μg of the NPs or 
Alum.  The mice were bled by cardiac puncture on day 28 and the sera were separated 
and stored at –20oC for antigen-specific IgG analysis.  
 
Determination of his-tag p24-specifc total IgG levels 
His-tag p24-specific serum IgG levels were determined using an ELISA.  The 
plates (96-well Costar plates) were coated with 50 μL of his-tag p24 (5 μg/mL in PBS, 
pH 7.4) overnight at 4oC.  The plates were blocked for 1 hr at 37oC with 200 μL of 4% 
BSA prepared in PBS/Tween 20.  The plates were then incubated with 50 μL per well of 
mouse serum diluted at 1:100 and 1:1000 in 4% BSA/PBS/Tween 20 for 2 hr at 37oC.  
The plates were washed with PBS/Tween 20 and incubated with 50 μL/well anti-mouse 
IgG HRP F(ab’)2 fragment from sheep (1:3000 in 1% BSA/PBS/Tween 20) for 1 hr at 
37oC.  After washing the plates with PBS/Tween 20, the plates were developed by adding 
100 μL of TMB substrate and incubating for 30 min at RT.  The color development was 
stopped by the addition of 100 μL of 2 M H2SO4 and the OD at 450 nm was read using a 
Universal Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT).   
 
Optimization of Ni-NP formulation for binding to his-tag proteins using his-tag GFP  
To further optimize the binding of Ni-NPs to his-tag p24, studies evaluating the 
entrapment and binding ratios to a model protein, his-tag green fluorescent protein (GFP) 
were carried out.  Excess DOGS-NTA-Ni was separated from the Ni-NPs using a gravity 
packed Sepharose CL4B gel permeation chromatography (GPC) column (15 x 70 mm).  
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 Briefly, 200 μL of the Ni-NPs was passed down the GPC column using PBS, pH 7.4 as 
the mobile phase.  Fractions (1 mL) were collected and the fractions containing the NPs 
were used for binding to his-tag GFP.  To determine the optimal binding ratios, his-tag 
GFP was mixed with the GPC-purified Ni-NPs at a 1:16.9 and 1:33.7 w/w ratios in PBS, 
pH 7.4 at 4oC overnight.  Free protein was separated from bound protein by passing 
through the Sepharose CL4B column using PBS, pH 7.4 as the mobile phase.  Fractions 
collected (1 mL) were analyzed by fluorescence to determine the percent of his-tag GFP 
bound to Ni-NPs.  The stability of the binding at 1:33.7 w/w ratio at 37oC in PBS, pH 7.4 
was evaluated by removing aliquots at over 4 hr and passing through the GPC column.  
The fluorescence associated in fraction 1-12 was measured and particle sizes were 
measured using fraction 4.  The fluorescence was measured using a Hitachi F-2000 
fluorescence spectrophotometer (Fairfield, OH) with the excitation and emission 
wavelengths set at 395 nm and 508 nm, respectively.  
 
Optimization of his-tag p24 binding to Ni-NPs   
The Ni-NPs were purified by GPC as described and further reacted with the his-
tag p24 at 1:8.85, 1:17.7, 1:35.4, and 1:70.8 w/w ratios to determine the optimal binding 
conditions.  Unlike his-tag GFP, the binding of his-tag p24 to the Ni-NPs cannot be 
assessed directly.  Therefore, after GPC purification, fractions 7-13 were evaluated for 
the presence of free protein by ELISA. The NP containing fractions, fractions 3 to 5, 
were combined, concentrated using Microcon® YM-100 ultracentrifuge devices and 
analyzed by western blot.   
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 ELISA for analysis of free his-tag p24 
To detect the free his-tag p24 eluting from GPC column, a qualitative ELISA 
method was developed using HisGrab™ nickel-coated plates.  Samples (100 μL) were 
added to the plate and incubated for 1 hr at room temperature (RT) while shaking.  The 
wells were washed 3 times with PBS/Tween 20 and blocked with 200 μL of 1% fetal 
bovine serum (heat inactivated) in PBS/Tween 20 for 1 hr at RT.  The wells were washed 
3 times with PBS/Tween 20 and incubated with for 1 hr at RT with 100 μL of His-tag 
p24 anti-sera (from initial studies) at 1:1000 in the blocking solution.  The wells were 
washed again and incubated for 1 hr with 100 μL of anti-mouse IgG HRP F(ab’)2 
fragment from sheep diluted at 1:3000 in the blocking solution.  After washing the wells 
with PBS/Tween 20, they were developed by incubating with 100 μL of TMB substrate 
for 30 min at RT and the color development was stopped by the addition of 100 μL of 2 
M H2SO4.  The OD at 450 nm was measured using a plate reader. 
 
Western blot analysis for his-tag p24 bound to Ni-NPs 
The concentrated NP fractions after GPC purification along with various amounts 
of his-tag p24 as controls were loaded on 15% Tris-HCl SDS-PAGE gels using Bio-rad 
power supply (200 V constant for 45 min).  A semi-dry transfer of the proteins from the 
SDS-PAGE gel onto a PVDF membrane was performed using Trans-Blot semi dry 
transfer cell (Bio-rad) using the Bio-rad power supply (15 V, 120 mA, 400 W for 24 
min).  The membrane was blocked for 1 hr with 4% BSA prepared in PBS/Tween 20 and 
then incubated with a 1:1000 dilution of his-tag p24 anti-sera from the initial experiment 
for 2 hr.  Finally, the membrane was incubated with a 1:5000 anti-mouse IgG HRP 
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 F(ab’)2 fragment from sheep for 1 hr.  All antibodies were diluted in 4% BSA in 
PBS/Tween 20.  All steps were performed with shaking at RT and three to five washings 
for 5 min using PBS/Tween 20 were included in between each step.  The protein on the 
membrane was detected using the Immun-star HRP substrate kit and the membrane was 
exposed using a Kodak Image Station 2000 mm (New Haven, CT) and analyzed using 
Kodak 1D software. 
 
Atomic emission spectroscopy for quantitating the surface-chelated Ni on NPs 
Atomic emission spectroscopy (AES) using inductively coupled plasma as the 
excitation source was used to quantify Ni present on the Ni-NPs before and after GPC 
purification.  The method parameters set on the Varian Vista-PRO CCD simultaneous 
ICP-OES instrument (Palo Alto, CA) were as follows: plasma flow at 15.0 L/min; 
auxillary flow at 1.50 L/min; nebulizer flow at 0.90 mL/min; sample uptake 30 sec; rinse 
time 10 sec; and pump rate 15 rpm.  Yttrium was used as an internal standard for 
correction as needed.  The Ni was detected at 216.55 and 231.604 nm and the final results 
were calculated based on an average of both wavelengths.  The data was collected and 
analyzed by Vista-PRO ICP software v.4.1.0.  All samples and standards were prepared 
using 5% nitric acid.  A standard curve for Ni was prepared from 10 to 200 ppb Ni.  For 
quality control purposes, independent Ni standards at 20 and 100 ppb were prepared and 
analyzed prior to sample analysis.  The acceptance criteria for the quality control 
standards were based on greater 90% of theoretical Ni concentration.  To determine the 
recovery of Ni from the NP matrix, 0.4 and 2.0 mg of NTA-NPs were spiked with 10 and 
50 ppb of Ni and analyzed for Ni content.  For quantitation of Ni on the Ni-NPs, the NPs 
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 were purified by GPC to obtain a total of 2.0 mg of purified NPs and fractions 3-6 were 
collected.  The combined fractions were further desalted and concentrated using 
CentriPlus® YM-100 ultracentrifuge devices to a final volume of 1 mL and diluted in 
nitric acid for analysis.   
 
In vivo assessment of optimized his-tag p24 bound to Ni-NPs 
BALB/c mice (n = 6-8 per group) were immunized (s.c.) on day 0 and day 14 
with 100 μL of his-tag p24 bound to GPC purified Ni-NPs, coated on NTA-NPs, or 
adjuvanted with Alum.  As an additional control, his-tag p24 bound to unpurified Ni-NPs 
were also assessed.  The dose of his-tag p24 was 2.5 μg and of the NPs or Alum was 88.5 
μg.  On day 28, mice were bled by cardiac puncture; the sera were collected and stored at 
-20oC for IgG analysis.  The spleens for were collected and pooled for each group for 
splenocyte proliferation and IFN-γ release assays. 
 
His-tag p24-specific antibody isotype analysis 
His-tag p24 specific IgG1 and IgG2a levels were determined using an ELISA 
procedure similar to that described for total IgG levels.  Briefly, the plates were coated 
with 50 μL of his-tag p24 (1 μg/mL in PBS, pH 7.4) overnight at 4oC.  The plates were 
blocked with 4% BSA in PBS/Tween 20 for 1 hr at 37oC.  The sera (50 μL) diluted at 
1:1000 in the blocking solution were added to the wells and incubated for 1 hr at RT.  
The plates were incubated with 50 μL of IgG1 or IgG2a diluted at 1:5000 in blocking 
solution for 1 hr at RT and finally with Sv-HRP diluted at 1:4000 in blocking solution for 
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 30 min at RT.  The plates were washed 3-5 times with PBS/Tween 20 in between each 
step.  The plates were developed and read as described for the total IgG levels.   
 
Splenocyte proliferation and IFN-γ release assay 
The spleens were crushed in 1X Hanks Balanced Salt Solution (HBSS) using a 
stomacher homogenizer for 60 s at normal speed to obtain single cell suspensions and the 
suspensions were then transferred into centrifuge tubes. Red blood cells were lysed 
adding 1X ACK buffer (156 mM NH4Cl, 10 mM KHCO3 and 100 μM EDTA) and 
incubating for 1-2 min at RT.  The cells were spun down at 1500 rpm, 4oC for 10 min.  
Supernatants were decanted and the cells were washed 2 more times with 1X HBSS.  The 
cells were resuspended in RPMI 1640 (supplemented with 10% heat-inactivated fetal calf 
serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL streptomycin, 
50 μM 2–mercaptoethanol).  For splenocyte proliferation assay, cells (5x105 cells/well) 
were added to a 96-well plate and incubated with media, Con A (2 μg/mL), or his-tag p24 
(1 μg/mL) at 37oC, 7% CO2 for 4 days.  The cells were pulsed with 1 μCi of 3H-
thymidine on day 4 and incubated for an additional 24 hr at 37oC, 7% CO2.  The cells 
were harvested on filters and counted on day 5 to measure T cell proliferation.  To 
measure IFN-γ release from stimulated splenocytes, parallel 48-well plates were set up 
using 1x106 cells/well in 400 μL of media and stimulated as described for the 
proliferation assay.  The supernatants were collected at 72 hr and stored at -80oC for IFN-
γ analysis by ELISA. 
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 Statistical analysis 
Statistical analysis was performed using one-way analysis of variances (ANOVA) 
followed by pair-wise comparisons using Tukey’s multiple comparison test using 
GraphPad Prism software. 
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 7.4 Results and discussion 
 
Preparation of Ni-NPs and initial in vivo study with Ni-NPs 
 NPs prepared from oil-in-water microemulsion precursors have been reported 
from our laboratory [15,16,249].  These NPs offer great versatility in entrapment of 
ligands and molecules and can be easily engineered to be neutral, anionic, or cationic 
based on the appropriate choice of surfactant(s).  In these studies, neutral NPs were 
prepared using non-ionic emulsifying wax as the oil phase and the neutral surfactant Brij 
78.  To further incorporate a small amount of surface-chelated nickel, the use of the lipid 
DOGS-NTA-Ni (Figure 7.1) was explored.  The hydrophobic portion of this molecule is 
thought to be entrapped within the oil phase, exposing the NTA-Ni portion on the surface 
of the NPs for interaction with the histidine-tag on protein.  The Ni-NPs prepared were 
approximately 150 nm in size with a slightly negative charge (-30 to -20 mV).  Based on 
theoretical calculations, these Ni-NPs were initially bound to his-tag p24 at a 1:10 w/w 
ratio for initial in vivo evaluation to determine the applicability of this technology for 
further development.  The binding of his-tag p24 to the Ni-NPs was confirmed by SDS-
PAGE (data not shown).  The use of DOGS-NTA entrapped in NPs was also investigated 
to control for non-specific adsorption of the protein on the surface of the NPs.  The 
carboxylic groups of the NTA are thought to give the NPs a net negative charge and 
could allow his-tag p24, a cationic protein, to be coated on the surface of the particles.  
As shown in Figure 7.2, the Ni-NPs resulted in a significant enhancement in the antibody 
responses compared to both Alum and NTA-NPs. These initial studies were very 
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 encouraging in that they demonstrated that superior humoral responses could be obtained 
with these Ni-NPs compared to the conventional coated NPs and Alum. 
 
Ni-NP formulations optimized and characterized with his-tag GFP  
 Based on the promising results obtained with the initial in vivo studies, further 
work to optimize and characterize the Ni-NPs using his-tag GFP was performed.  The use 
of this protein offered numerous advantages in optimizing the formulations such as ease 
of detection by fluorescence, direct quantitation of the protein bound to the NPs and 
released from the NPs.  In addition, GFP is similar in molecular weight, 28 kDa for GFP 
versus 24 kDa for Gag p24, to the Gag p24 used in the in vivo studies.  Separation of his-
tag GFP bound to Ni-NPs from unbound his-tag GFP was achieved using a gravity 
column packed with Sepharose CL4B resins.  The eluent from the GPC purification can 
be fractionated (1 mL) and based on the particle size intensity and fluorescence intensity 
measurements, NPs and protein associated with NPs were found to elute in fractions 3 to 
6, where as free protein eluted in later fractions, 8 to 12 (Figure 7.3).  Moreover, during 
these binding studies, it was discovered that the Ni-NP formulation contained some 
unentrapped DOGS-NTA-Ni, which could also be separated from the NPs by GPC since 
it elutes mostly in Fractions 7-9 (Figure 7.4).  Thus, GPC purification with a Sepharose 
CL4B column allowed efficient separation of the unentrapped lipid from Ni-NPs and for 
separating unbound his-tag protein from the Ni-NP bound protein.  As shown in Figure 
7.4, the GPC purification of excess lipid from Ni-NPs resulted in a higher amount of his-
tag protein being bound to the surface of the NPs and subsequently, GPC purification of 
NPs was performed prior to reacting with his-tag proteins.   
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 The binding of his-tag GFP with Ni-NPs was evaluated at two ratios and it was 
found that at a 1:33.7 w/w ratio of his-tag GFP to Ni-NPs, greater than 80% of the protein 
was bound to the surface of the NPs (Figure 7.5).  Furthermore, to determine the 
specificity of the binding, GPC purified NTA-NPs were mixed with his-tag GFP at a 
1:33.7 w/w ratio and the binding was evaluated.  As shown in Figure 7.6, only 7% of the 
protein was associated with the NTA-NPs and the majority of the protein eluted in later 
fractions, where free protein is expected to elute, suggesting that the binding to the Ni-
NPs was stronger and more specific than simple adsorption on the surface of the 
particles.  The binding of his-tag GFP to Ni-NPs was found to be stable as determined by 
particle size and binding efficiency over 4 hr in PBS, pH 7.4 (Figure 7.7).  Furthermore, 
his-tag GFP bound to Ni-NPs at 1:33.7 w/w ratio was stable at 4oC, with comparable 
binding efficiency on day 7 as the initial day of preparation (data not shown).   
 
Entrapment efficiency of DOGS-NTA-Ni in NPs based on Ni 
The amount of DOGS-NTA-Ni entrapped in NPs was calculated indirectly by 
quantitating the amount of Ni associated with the NPs before and after GPC purification 
using AES.  The molar ratio of Ni chelated with DOGS-NTA is 1:1, therefore the 
entrapment efficiency of the lipid can be calculated based on the Ni.  As controls, the 
amount of Ni present in NTA-NPs was evaluated and the recovery of Ni from this matrix 
was also determined using NTA-NPs.  As expected, no Ni was detected in the control 
NTA-NP preparations.  In addition, the spike-recovery studies suggested that the Ni 
could be recovered from the NP matrix, with greater than 80% recovery at the highest 
amount of NPs evaluated (Table 7.1).  Based on the amount of Ni associated with NPs 
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 before and after GPC purification in four independent Ni-NP preparations, it was 
calculated that approximately 5% of the lipid initially used in the formulation was 
entrapped within the NPs (Table 7.2).  Furthermore, using these results, it was calculated 
that there was about a 3-fold excess of Ni present on the NPs at the 1:33.7 w/w ratio of 
his-tag GFP to NPs.  Interestingly, increasing the protein to NP ratio from 1:16.9 to 
1:33.7 w/w only resulted in a slight increase in binding efficiency (Figure 7.5) from about 
70% to 80%.  This combined with the fact that there is still a 3-fold excess of Ni on the 
NPs at the higher binding ratio suggests that there may have been some steric hindrance 
preventing accessibility to at least some of the Ni present on NPs for binding to the 
protein.   
  
Optimized Ni-NP formulations with his-tag p24 
 Based on the binding studies for his-tag GFP with Ni-NPs, the optimal binding 
ratios of his-tag p24 to Ni-NPs was evaluated for further use in in vivo studies.  
Evaluating the binding of his-tag p24 was more challenging because, unlike GFP, it could 
not be assessed directly on Ni-NPs.  To determine the optimal binding ratios, the relative 
amounts of unbound his-tag p24 were detected using ELISA (Figure 7.8) and the 
fractions containing Ni-NPs were analyzed for presence of bound his-tag p24 by western 
blot (Figure 7.9).  The western blot was further analyzed by densitometry and the results 
suggested that approximately 80% of the protein was associated with the Ni-NPs at ratios 
greater that 1:35.4 w/w.  Thus, for further in vivo evaluation the 1:35.4 w/w ratio was 
used to prepare the formulation with Ni-NPs and with control NTA-NPs. 
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 In vivo results using optimized Ni-NP formulations with his-tag p24 
 Initial in vivo studies demonstrated the potential of Ni-NPs for enhancing humoral 
immune responses to his-tag p24.  However, these formulations were not optimized and 
some of the protein could have been associated with excess, unentrapped lipid instead of 
NPs, leading to suboptimal in vivo responses.  The goal of this follow up in vivo study 
was to confirm that humoral immune responses could be obtained with the optimized 
formulations of Ni-NPs and to further evaluate the cellular immune responses.  Mice 
were immunized with his-tag p24 bound to Ni-NPs, coated on NTA-NPs or adjuvanted 
with Alum.  In addition, the use of unpurified Ni-NPs was also investigated to control for 
the immune responses that may have been enhanced by unentrapped lipid reacted with 
his-tag p24.  At the 1:1000 serum dilution, significantly higher his-tag p24- specific IgG 
levels were detected using the Ni-NPs compared to all groups (Figure 7.10). Moreover, 
NTA-NPs, Alum, and unpurified Ni-NP groups were statistically insignificant compared 
to the naïve group.    Interestingly, the unpurified Ni-NPs demonstrated similar potency 
in generating antibodies as the NTA-NPs and Alum, but significantly less compared to 
the purified Ni-NPs.  It is hypothesized that his-tag p24 would interact with unentrapped 
lipid, which exists freely in solution, in micelles, or loosely adsorbed on the NP surface, 
to a greater extent because the Ni would be more accessible for interactions compared to 
the  Ni-chelated to lipid which is entrapped in the NPs.  Thus, while there may be some 
enhancement in antigen uptake and subsequently antibody production with the unpurified 
Ni-NP formulation, the results demonstrate that they are less effective compared to the 
responses that can be generated with the antigen being bound to the Ni on the NPs.  
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 Moreover, these data support that protein bound to Ni-NPs was superior to Alum and 
NTA-NPs in enhancing humoral immune responses to his-tag p24. 
 The cellular immune responses in these studies were evaluated by splenocyte 
proliferation and IFN-γ release assays. Splenocytes from immunized mice that were 
stimulated in vitro with his-tag p24 demonstrated significantly higher proliferation with 
all groups compared to naïve group, with the exception of the unpurified Ni-NPs group 
(Figure 7.11).  In addition, the IFN-γ released from the stimulated splenocytes showed a 
similar trend in that all groups, except the unpurified Ni-NPs, produced significantly 
higher IFN-γ compared to the naïve group (Figure 7.12).   However, the IFN-γ release 
was only modest with both the Ni-NP and Alum groups (cytokine levels in the picogram 
per mL range).  It is interesting to note that although weak antibody responses could be 
generated with the unpurified Ni-NPs, this group did not induce strong cellular responses 
as demonstrated by both the splenocyte proliferation and IFN-γ release assays.  This 
could be due to very little antigen actually being bound to the Ni on the NPs because of 
binding with the more accessible unentrapped lipid, as discussed above.  Alternatively, 
the dose of DOGS-NTA-Ni given with these NPs is higher than that of the purified Ni-
NPs and could have an affect on the immune responses.  Therefore, further assessment 
various doses of Ni-NPs would be beneficial in elucidating the effect of Ni on the 
immune responses and the optimal doses for enhancing both cellular and humoral 
immune responses.  It is important to note that based on the AES characterization of Ni-
NPs, the dose of Ni administered to mice in each 100 μL injection in the purified Ni-NPs 
was 20 ng.  This amount of Ni is significantly lower than the levels of Ni that have shown 
adverse effects in mice [452-455].  To provide additional perspective, the average human 
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 diet is estimated to contain 0.15 mg Ni per day and drinking water alone contains 0.001 
to 0.01 mg Ni per Liter [456].  Thus, the dose of Ni used in these studies was considered 
to be within the tolerable range. 
An additional indicator of the type of immune response generated (i.e. Th1 or 
Th2) are the serum isotype levels, IgG1 versus IgG2a.  During an immune response, the 
release of Th1 or Th2 cytokines will affect the production of these antibodies.  BALB/c 
mice normally produce antibodies of IgG1 isotype; however, in the presence of Th1 type 
immune responses, the cells produce IFN-γ which causes a switch in the isotype 
produced to IgG2a.  The isotype analysis in these studies revealed that the Ni-NPs 
resulted in the highest levels of IgG2a compared to all groups, while the IgG1 levels were 
comparable to the other three immunized groups (Figure 7.13). 
In conclusion, the preparation of novel NPs containing a small amount of surface-
chelated nickel was shown to be effective for enhancing the interaction with his-tag 
proteins compared to simple charged particles.  This interaction of the antigen to the Ni-
NPs resulted in superior humoral immune responses in vivo compared to protein 
adjuvanted with Alum or coated on charged NPs.  Moreover, the Ni-NPs are also 
promising for generating Th1 type immune responses.  It is hypothesized that the Ni-NPs 
enhance immune responses by increasing the interaction of the antigen with the NPs and 
allowing for greater amount of the antigen to be taken up into APCs.  Although further 
studies are necessary to elucidate the exact mechanism(s) of immune response 
enhancement, preliminary in vitro data suggests that Ni-NPs do not enhance immune 
responses by causing the release of IL-12, a Th1 driving cytokine, from DCs (data not 
shown).  Taken together, these data demonstrate the potential applications of Ni-NP for 
 167
 vaccine delivery and warrant further investigation of these systems for enhancing cellular 
and humoral immune responses to protein-based vaccines.       
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 Table 7.1.  Ni spike and recovery from NTA-NPs.  Spike and recovery studies with Ni 
were performed at 10 and 50 ppb using 0.4 and 2.0 mg of NTA-NPs.  Results shown are 
average of n=3. 
 
  
NTA-NPs Ni spike 
Average  
 Ni 
Recovery 
(%) 
Standard 
Deviation 
0.4 mg 10 ppb 
 
 
102.1 19.0 
 
0.4 mg  
  
50 ppb 
  
104.8 
  
1.8  
  
 
2.0 mg 
   
10 ppb 
  
87.8 
  
9.6  
   
2.0 mg 
   
50 ppb 
  
89.6 
  
5.1 
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 Table 7.2.  Quantitation of Ni on NP surface before and after GPC purification by 
AES.  *Values reflect amount of Ni per 2 mg of NPs. 
Ni-NP 
Preparation 
μg 
Ni before 
GPC* 
μg Ni 
after 
GPC* 
Molecules 
Ni per 
particle 
Molecules of 
GFP per 
particle 
Molar ratio 
of GFP to 
Ni 
1 8.19 0.53 
2 7.87 0.38 
3 7.82 0.27 
4 7.85 0.49 
3557 1039 
 
1 to 3 
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 Figure 7.1 
 
 
 
 
 
 
 
 
 
 
Figure 7.1.  Structure of DOGS-NTA-Ni.  NTA occupies four of the Ni coordination 
sites, leaving two unoccupied sites (shown coordinating with water in figure) for 
interaction with the histidine residues.  (Structure was taken from Avanti Polar Lipids 
website: http://www.avantilipids.com/SyntheticNickel-ChelatingLipids.asp). 
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 Figure 7.2 
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Figure 7.2.  Gag p24-specific IgG levels in serum at 4 weeks post initial 
immunization.    Mice were immunized with 2.5 μg of his-tag p24 bound to Ni-NPs (25 
μg), coated on NTA-NPs (25 μg), or adjuvanted with Alum (25 μg) on day 0 and day 14.  
Data for each group represents the mean ± S.D. (n=5-6).  *p<0.01 compared to all 
groups. 
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 Figure 7.3 
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Figure 7.3.  Elution profile of Ni-NPs, his-tag GFP bound to Ni-NPs, and unbound 
his-tag GFP on Sepharose CL4B GPC column.  Ni-NPs eluted in fraction 3-6 as 
determined by particles size intensity.  The extent of his-tag GFP bound to Ni-NPs was 
determined by separating protein bound to Ni-NPs from free protein, which elutes in 
faction 8-12 as determined by fluorescence intensity measurements.  Fluorescence of the 
protein when bound to Ni-NPs overlaps with correlating particle size intensities in 
fraction 3-6. 
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 Figure 7.4 
 
 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0
25
50
75
100
125
Unpurified Ni-NPs
GPC purified Ni-NPs
Fraction (1 mL)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
His-tag GFP 
bound to Ni-NPs 
Unbound 
his-tag GFP 
 
 
Figure 7.4.  Separation profiles for his-tag GFP bound to GPC purified Ni-NPs and 
unpurified Ni-NPs.  Free protein elutes in fraction 8-12, whereas the peak for the protein 
bound to unentrapped lipid in unpurified Ni-NPs was shifted to the left to fractions 7-12.  
The binding efficiency of his-tag GFP to Ni-NPs was increased by first separating the 
unentrapped lipid from the NPs by GPC.  
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 Figure 7.5 
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Figure 7.5.  GPC purification profiles for his-tag GFP bound to Ni-NPs at 1:16.9 
and 1:33.7 w/w ratios of protein to Ni-NPs.  The binding of his-tag GFP to Ni-NPs was 
evaluated at the ratios indicated by separating free protein from protein bound to Ni-NPs 
using GPC.  At the 1:33.7 w/w ratio, greater than 80% of the protein was associated with 
the Ni-NPs. 
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 Figure 7.6 
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Figure 7.6.  GPC profile for his-tag GFP mixed with NTA-NPs.  His-tag GFP was 
incubated with NTA-NPs at 1:33.7 w/w ratio overnight at 4oC in PBS, pH 7.4.  The 
interaction of the protein with the NPs was evaluated to determine specificity of the 
binding with NTA-NPs compared to Ni-NPs.  Only 7% of the protein was associated 
with the NTA-NPs, based on fluorescence intensity measurements associated with 
fractions 3-6.  The majority of the protein was detected in later fractions, 8-12, where free 
his-tag GFP was expected to elute. 
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 Figure 7.7 
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Figure 7.7.  Stability of his-tag GFP bound to Ni-NPs at 37 C in PBS, pH 7.4o .   His-
tag GFP was bound to Ni-NPs (1:33.7 w/w) by overnight incubation at 4oC in PBS, pH 
7.4.  The formulation was then incubated at 37oC to evaluate stability of the interaction 
with the Ni-NPs.  Aliquots of the formulation were taken at various time points and 
passed through a Sepharose CL4B GPC column to evaluate the percent of his-tag GFP 
remaining associated with the Ni-NPs.  The particle sizes were measured using fraction 4 
from the GPC purification.  
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 Figure 7.8 
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Figure 7.8.  Free his-tag p24 eluting from GPC column.  His-tag p24 was bound to Ni-
NPs at various ratios and the relative amounts of free protein eluting from the Sepharose 
CL4B GPC column were traced in the fractions were free protein was expected to elute 
using ELISA.  Ni-NPs with no protein were run as control with the ELISA to account for 
any interference. 
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 Figure 7.9 
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Figure 7.9.  Western blot of his-tag p24 bound to Ni-NPs.  His-tag p24 was incubated 
to Ni-NPs at various ratios and the protein bound to Ni-NPs was separated from free 
protein by passing through a Sepharose CL4B GPC column.  Fractions 3-5 from the GPC 
purification were collected, combined, and analyzed by western blot to determine the 
relative amounts of his-tag p24 bound to the Ni-NPs.  The lanes correspond to the 
following samples: 1) 1:70.8 w/w; 2) 1:35.4 w/w; 3) 1:17.7 w/w; 4) 1:8.85 w/w; 5) Ni-
NPs as control; and lanes 6-9 are 50, 100, 200, and 250 ng of his-tag p24 standards 
loaded as controls, respectively.  Greater than 80% of the his-tag p24 was bound to the 
Ni-NPs at ratios greater than 1:35.4 w/w. 
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 Figure 7.10 
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Figure 7.10.  Total serum IgG levels for his-tag p24 immunization with optimized 
formulations.  Mice were immunized with 2.5 μg of his-tag p24 bound to Ni-NPs (88.5 
μg), coated on NTA-NPs (88.5 μg), adjuvanted with Alum (88.5 μg) or mixed with 
unpurified Ni-NPs (88.5 μg) on day 0 and day 14.  Serum IgG levels were measured on 
day 28.  Data for each group represents the mean ± S.D. (n=6-8).  ap<0.01 compared to 
Ni-NP group; bp< 0.001 compared to all groups; cp>0.05 compared to naïve group. 
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 Figure 7.11 
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Figure 7.11.  Splenocyte proliferative responses to his-tag p24 on day 5.  Mice were 
immunized with 2.5 μg of his-tag p24 on day 0 and day 14.  Spleens were harvested and 
pooled for each group on day 28.  Cells (5x105/well) were stimulated with 1 μg/mL his-
tag p24 and the incorporation of 3H-thymidine in cells was evaluated on day 5.  The data 
represents the mean ± S.D. (n=3).  *p<0.05 compared to unstimulated cells.  
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 Figure 7.12 
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Figure 7.12.  72 hr IFN-γ release from stimulated splenocytes.  Mice were immunized 
with 2.5 μg of his-tag p24 on day 0 and day 14.  The spleens were harvested and pooled 
for each group on day 28.  Cells (1x106) were stimulated with 1 μg/mL his-tag p24 and 
the supernatants were evaluated for IFN-γ release at 72 hr by ELISA.  The data represents 
the mean ± S.D. (n=3).  *p<0.05 compared to unstimulated cells.  
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 Figure 7.13 
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Figure 7.13.  His-tag p24-specific serum IgG1 and IgG2a levels.  Serum IgG isotype 
levels were measured on day 28 by ELISA using a 1:1000 serum dilution.  Data for each 
group represents the mean ± S.D. (n=6-8).  ap<0.001 compared to all groups; bp>0.05 
compared to naïve group. 
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 Chapter 8 
 
In vivo immune responses to Tat coated on different anionic nanoparticle 
formulations 
 
8.1 Summary 
Anionic nanoparticles can be prepared from oil-in-water microemulsion 
precursors using emulsifying wax as the oil phase and sodium dodecyl sulfate (SDS) as 
the surfactant.  The stability of these anionic nanoparticles in buffered solutions was 
improved by the inclusion of the co-surfactant Brij 78.  The studies in this chapter were 
carried out to evaluate the immune responses to nanoparticles prepared using different 
surfactant compositions.  Three anionic NP formulations were prepared using the 
following composition of surfactants: 15 mM SDS, 15 mM SDS/1 mM Brij 78 and 1 mM 
SDS/3 mM Brij 78.  These nanoparticle formulations were coated with the cationic HIV-
1 Tat protein and evaluated in vivo.  No significant differences in the humoral immune 
responses were generated among all the Tat-coated nanoparticle formulations evaluated.  
Moreover, an improved LTR-transactivation assay demonstrated that significant Tat-
neutralizing antibodies were generated with all formulations evaluated.  For the cellular 
responses, some differences were observed in an initial study using a 1 μg Tat dose; 
however, no significant differences among the groups were detected in a follow up study 
using a 5 μg Tat dose.  Taken together, these data suggest that the composition of 
surfactants used to prepare the anionic nanoparticles do not have a significant influence 
on the immune responses generated to HIV-1 Tat protein. 
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 8.2 Introduction 
Nanoparticles prepared from oil-in-water microemulsions precursors have been 
reported to enhance cellular and humoral immune responses to pDNA- and protein-based 
vaccines [14-16,46,253].  These nanoparticles (NPs) are prepared using emulsifying wax 
as the oil phase and appropriate surfactants to obtain particles with the desired surface 
properties.  For example, cationic surfactants such as cetyl trimethyl ammonium bromide 
(CTAB) can be used to obtain net positively charged particles and surfactants with a 
negative charge such as sodium dodecyl sulfate (SDS) can be used to obtain anionic 
particles.  These particles with different surface properties can be further used to coat 
anionic or cationic molecules and/or proteins on the NP surface for enhanced immune 
responses compared to the protein alone or adjuvanted with Alum. 
Previous studies in our laboratory have shown that anionic NPs prepared using 15 
mM SDS as the surfactant generate superior cellular and humoral immune responses to 
β-galactosidase [16] and HIV-1 Tat protein [253].  However, these NPs were also shown 
to contain an excess amount of the SDS surfactant, which could be removed by 
purification using gel permeation chromatography (GPC) [16].  In a more recent study, 
the use of sterically stabilized NPs prepared using 1 mM SDS/3 mM B78 was 
investigated with Tat as it allowed for preparation of net negatively charged NPs with a 
minimal amount of excess SDS present [438].  In our studies, this is advantageous 
because it avoids the need for GPC purification and estimating the dose of NPs used for 
in vivo studies.  Moreover, these NPs coated with Tat demonstrated superior humoral 
immune responses compared to Alum. 
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 To evaluate if anionic NPs prepared from different surfactant compositions could 
influence the type of immune responses generated to the coated antigen in vivo, anionic 
NPs having different surfactant compositions were investigated. Anionic NPs were 
prepared using emulsifying wax as the oil phase and the following surfactant 
combinations: 1) 15 mM SDS/1 mM Brij 78; 2)  1 mM SDS/3 mM Brij 78; and 3) 15 
mM SDS.  All anionic NP formulations were coated with HIV-1 Tat protein and the Tat-
specific cellular and humoral immune responses were evaluated to identify differences in 
the NP formulations. 
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 8.3 Materials and methods 
 
Materials 
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of 
20:1) and sodium dodecyl sulfate (SDS), were purchased from Spectrum (New 
Brunswick, NJ).  PBS/Tween 20 buffer, bovine serum albumin (BSA), Sephadex G75 
and mannitol were purchased from Sigma Chemical Co. (St. Louis, MO).  Brij 78 was 
purchased from Uniqema (New Castle, DE).  Sheep anti-mouse IgG, peroxidase-linked 
species specific F(ab’)2 fragment was purchased from Amersham Pharmacia Biotech 
(Piscataway, NJ).  Goat anti-mouse IgG2a and IgG1 horseradish peroxidase (HRP) 
conjugates were purchased from Southern Biotechnology Associates, Inc. (Birmingham, 
AL). IFN-γ ELISA kit was from BD Biosciences Pharmingen (San Diego, CA). 
Tetramethylbenzidine (TMB) substrate kit was purchased from Pierce (Rockford, IL). 
Centricon® YM-50 ultracentrifuge devices were from Fisher Scientific (Hampton, NH).  
HIV-1 Clade B consensus Tat peptides (15 aa) were obtained through the AIDS Research 
and Reference Reagent Program (Division of AIDS, NIAID, NIH, Bethesda, MA).  
Recombinant HIV-1 Tat (1-72 aa) was prepared as previously described [362]. 
 
Preparation of anionic NPs 
NPs from oil-in-water microemulsion precursors were prepared as previously 
described with slight modification [16,253].  The composition of the various formulations 
is described in Table 8.1.  For formulations incorporating Brij 78 (B78), 4 mg of 
emulsifying wax and appropriate amount of Brij 78 was melted and mixed at ~60-65oC.  
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 Deionized and filtered (0.2 μm) water was added to the melted wax and surfactant while 
stirring to form an opaque suspension.  Finally, an appropriate volume of sodium dodecyl 
sulfate (50 mM) was added to form clear microemulsions at 60-65oC.  The 
microemulsions were cooled to room temperature while stirring to obtain NPs (2 
mg/mL).  The NP sizes were measured using a Coulter N4 Plus Sub-Micron Particle 
Sizer (Coulter Corporation, Miami, FL) at 90o.  The overall charge of the NPs was 
measured using Malvern Zeta Sizer 2000 (Malvern Instruments, Southborough, IL). 
 
GPC to remove excess surfactant in anionic NP formulations 
Previously, it was demonstrated that there was an excess of surfactant present 
when formulating NPs with 15 mM SDS [16].  This excess surfactant was shown to be 
separated from the NPs by passing through a GPC column packed with Sephadex G75 
(15 x 75 mm).  Therefore, to remove excess surfactant from the NPs prepared in this 
study, 300 μL of the NP formulation was passed through a Sephadex G75 column and the 
fractions containing the NPs (fraction 3-5) were collected for further use in coating with 
Tat.  The GPC purification was also performed on the 1 mM SDS/3 mM B78 NPs to 
serve as an additional control in the in vivo experiments.  All purifications were 
performed three times to obtain a total of 1.8 mg of purified NPs and the fractions 
collected from the GPC purifications were further concentrated using Centricon® YM-50 
ultracentrifuge devices to obtain NPs at a final concentration of 2 mg/mL. 
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 Coating of the anionic NPs with Tat  
To prepare formulations for in vivo analysis, Tat, at a final concentration of 10 or 
50 μg/mL, was added to the appropriate NP formulations (1000 μg/mL) in 5% (v/v) 
mannitol.  The suspensions were vortexed gently and placed on a horizontal shaker at 
room temperature for a minimum of 30 min to allow for coating.  The coated NPs were 
diluted appropriately in de-ionized water for measuring the size and charge of the 
particles.  
 
Mouse immunization study 
Two animal studies were carried out to determine the immune response to Tat 
coated on various anionic NP formulations.  A summary of the experimental design is 
presented in Table 8.2.  For both studies, female BALB/c mice (8-10 weeks old) obtained 
from Harlan Sprague-Dawley Laboratories (Indianapolis, Indiana) were immunized 
subcutaneously with 100 μL of the formulations.  In the first study (study 1), mice were 
dosed three times at 2 week intervals with 1 μg of Tat coated on anionic NPs that had 
been purified by GPC or with 1 μg Tat coated on unpurified NPs (100 μg) prepared using 
1 mM SDS/3 mM B78.  The dose of anionic NPs for the GPC purified formulations was 
also estimated to be about 100 μg.  The IgG responses were monitored by collecting sera 
via tail-vein bleed prior to boosting with Tat-coated NPs.  On day 42, mice were bled by 
cardiac puncture and sera were separated.  All sera collected were stored at -20oC.  In 
addition, spleens were harvested from all mice and pooled for each group for splenocyte 
proliferation and IFN-γ release assays.  In the second study (study 2), a similar protocol 
was followed except a 5 μg dose of Tat was evaluated with the anionic NP formulations 
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 and the spleens in the study 2 were collected on day 42 and prepared individually for 
splenocyte proliferation and IFN-γ release assays.  
 
Determination of antibody titers 
Tat-specific serum IgG, IgG1 and IgG2a antibody titers were determined using an 
ELISA.  This procedure is described in detail in Chapter 4 of the dissertation. 
 
Tat anti-sera recognition of N-terminal and basic regions of Tat protein 
 
Tat anti-sera in the first study were tested by ELISA to determine reactivity to the 
N-terminal and basic regions of Tat.  The ELISA procedure is described in detail in 
Chapter 4. 
 
LTR-transactivation assay 
 The LTR-transactivation assay was performed essentially as described in Chapter 
4 with the following modifications.  First, HeLa cell lines transfected with pHIV-CAT 
were used for the assay.  Secondly, supernatant containing Tat released from HeLa cell 
lines (transfected with a Tat plasmid) was used as the source for extracellular Tat.  The 
Tat-contatining supernatants were diluted at 1:40 and incubated with the sera for the 
assay.  Sera were diluted at 1:10, 1:50, 1:250, and 1:1250 to evaluate for Tat-neutralizing 
antibodies. 
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 Splenocyte proliferation and IFN-γ release assays 
The spleens were crushed in 1X Hanks Balanced Salt Solution (HBSS) using a 
stomacher homogenizer for 60 s at normal speed to obtain single cell suspensions and the 
suspensions were then transferred into centrifuge tubes. Red blood cells were lysed 
adding 1X ACK buffer (156 mM NH4Cl, 10 mM KHCO3 and 100 μM EDTA) and 
incubating for 1-2 min at RT.   The cells were spun down at 1500 rpm, 4oC for 10 min.  
Supernatants were decanted and the cells were washed 2 more times with 1X HBSS.  The 
cells were resuspended in RPMI 1640 (supplemented with 10% heat-inactivated fetal calf 
serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL streptomycin, 
50 μM 2–mercaptoethanol).  In Study 1, for the splenocyte proliferation assay, cells 
(5x105 cells/well) were added to a 96-well plate and incubated with media, Con A (2 
μg/mL), Tat (0.1 and 1 μg/mL) or pooled 15-mer Tat peptides (10 μg/mL each peptide) 
at 37oC, 7% CO2 for 4 days.  The cells were pulsed with 1 μCi of 3H-thymidine on day 4 
and incubated for an additional 24 hr at 37oC, 7% CO2.  The 15-mer Tat peptides were 
pooled as follows:  Set 1 = aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 17-31, 21-35, 25-39: Set 
3 = 29-43, 33-47, 37-51; Set 4 = aa 41-55, 45-59, 49-63, 53-67; Set 5 = 57-71, 61-75, 65-
79, 69-83.   To measure IFN-γ release from stimulated splenocytes, parallel 48-well 
plates were set up using 1x106 cells/well in 400 μL of media and stimulated as described 
for the proliferation assay.  The supernatants were collected at 72 hr and stored at -80oC 
for IFN-γ analysis by ELISA.   
For study 2, the splenocyte proliferation and IFN-γ release assays were carried out 
as described as above.  The IFN-γ assay was set up in parallel to splenocyte proliferation 
assay using 96-well plates using 5 x 105 cells/well.   
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 Statistical analysis 
Statistical analysis was performed using one-way analysis of variances (ANOVA) 
followed by pairwise comparisons with Tukey’s multiple comparison test, when 
appropriate, using GraphPad Prism software. 
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 8.4 Results and discussion 
 
Preparation and characterization of Tat coated anionic NPs 
Previously our laboratory reported on the preparation of anionic NPs from 
microemulsions precursors using 15 mM SDS as the anionic surfactant.  These NPs were 
demonstrated to effective enhance immune responses to a model protein, β-galactosidase 
[16], and HIV-1 Tat [253].  Further work with this system revealed that upon removal of 
excess surfactant from this formulation, the NPs were unstable in buffered solutions.  To 
further stabilize these systems, the used of B78 as a co-surfactant was investigated and it 
was found that at least 1 mM of B78 was required to provide stable NPs in buffered 
solutions (data presented in Appendix B).  In addition, it was found that NPs prepared 
using various compositions of surfactant (Table 8.1) resulted in sizes of around 100-150 
nm with a net charge of approximately -60 mV (Table 8.3).  Upon GPC purification to 
remove excess surfactant all formulations retained a net negative charge, with the 1 mM 
SDS/3 mM B78 having a slightly lower zeta potential.  Coating the NPs with an 
increasing concentration of Tat resulted in a decrease in the overall charge of the 
particles; however, the Tat-coated NPs continued to have a net negative charge possibly 
due to the exposed negatively charged amino acids of the protein or due to an excess 
amount of anionic NPs present. 
 
Immune responses to Tat coated on anionic NPs:  Study 1 
 In vivo responses to the different anionic NPs were evaluated in BALB/c mice to 
identify if using different surfactant compositions would affect the cellular and/or 
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 humoral immune responses generated to Tat.  As shown in Figure 8.1, there were no 
significant differences in the Tat-specific antibody titers produced at all time points 
assessed.  Moreover, the evaluation of IgG1 and IgG2a antibody titers did not 
demonstrate any significant differences in the formulations (Figure 8.2).  These data 
combined suggest that the different formulations were equally effective at generating 
humoral immune responses and Th1 type immune responses, as indicated by the IgG2a 
production with the various formulations. 
 Previous results with Tat coated on anionic NPs (1 mM SDS/3 mM Brij 78) 
demonstrated that the anti-sera from Tat immunized animals produced antibodies with 
specificity in the N-terminal and basic regions of the protein [438].  To further assess the 
different anionic formulations in their ability to produce antibodies to Tat specific for 
these regions, the anti-sera collected in Study 1 was evaluated for binding to 15-mer Tat 
peptides covering the N-terminal and basic regions of Tat.  As shown in Table 8.4, all 
groups contained antibodies that recognized these regions of Tat and no obvious 
differences due to the different formulations of NPs were noted. 
 The Tat-neutralizing antibodies generated using different anionic NP formulations 
were assessed using an LTR-transactivation assay.  In the previous study presented in 
Chapter 4, modest Tat-neutralizing activity was demonstrated with all Tat anti-sera 
compared to literature reports.  This was speculated to be due to differences in assay 
conditions and thus, further work to optimize the LTR-transactivation assay was carried 
out.  In attempt to improve the assay, two modifications were made to the existing LTR-
transactivation assay:  1) HeLa cells transfected with pHIV-CAT were used instead of the 
SVGA cells, and 2) Tat-containing supernatants replaced the use of recombinant Tat as 
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 the source for extracellular protein in the assay.  Using this modified assay, the sera from 
all Tat-immunized groups demonstrated the ability to neutralize extracellular Tat as 
shown in Figure 8.3.  More importantly, the Tat-neutralizing activity was retained at 
higher serum dilutions, which was not possible in the assay described in Chapter 4.  
Therefore, the altered conditions improved the sensitivity of the assay and studies to 
further optimize the assay are ongoing. 
 To evaluate cellular immune responses, the spleens were pooled and stimulated 
with 0.1 and 1.0 μg/mL Tat or with pooled 15-mer Tat peptides.  No significant Tat-
specific splenocyte proliferative responses compared to the naïve group were detected at 
a concentration of 0.1 μg/mL Tat (Figure 8.4).  However, at Tat concentration of 1.0 
μg/mL, significantly higher Tat-specific proliferation was seen with all NP groups 
compared to the naïve group.  In addition, the Tat-specific splenocyte proliferative 
response with the 15 mM SDS group was significantly higher than both of the 1 mM 
SDS/3 mM B78 groups (p<0.05).  Tat has been observed to induce non-specific 
proliferation of naïve cells as seen in Figure 8.4.  This has also been reported by other 
groups [412].  Thus, the use of pooled 15-mer Tat peptides was also evaluated in effort to 
identify the appropriate sequence(s) for future assays.  As shown in Figure 8.5, the 
strongest response compared to the naïve group was observed with peptide set 5, which 
included the C-terminus peptides for Tat; however, no significant differences were 
observed among the test groups.   
The IFN-γ release from stimulated splenocytes was evaluated in 72 hr 
supernatants by ELISA.  Once again, Tat-induced non-specific IFN-γ release in naïve 
cells, proving it difficult to assess cellular responses with the test groups (Figure 8.6).  
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 The strongest IFN-γ release was observed with the 1 mM SDS/3 mM B78 control (Ctrl) 
and 15 mM SDS NP groups using the 1.0 μg/mL Tat concentration.  Moreover, IFN-γ 
release from splenocytes stimulated with the pooled 15-mer Tat peptides demonstrated 
strongest responses with the 15 mM SDS NP group with set 4 and 5 as shown in Figure 
8.7; however, it should be noted that the IFN-γ release was quite modest compared to that 
obtained with Tat protein.  In addition, non-specific IFN-γ release from naïve cells 
stimulated with peptide set 5 was also observed.  Taken together, these data suggested 
that while no differences existed in the humoral immune responses to the various 
formulations, potential differences in the cellular responses (IFN-γ release) to Tat using 
the different formulations may exist and were further evaluated in a second study.   
 
Immune responses to Tat coated on anionic NPs:  Study 2 
 Based on the immune responses results from Study 1, a second study to evaluate 
the immune responses to Tat was carried out with these three formulations: 15 mM 
SDS/1 mM B78; 1 mM SDS/3 mM B78 (unpurified control); and 15 mM SDS.  In this 
study, purification of 1 mM SDS/3 mM B78 was not included because of the lack of 
significant differences between this group and the control group in the first study.  In the 
second immunization study, a higher dose of Tat, 5 μg, was used for evaluating Tat-
specific cellular responses to enable easier identification of differences among the NP 
groups.  As observed in Study 1, no significant differences were observed in the Tat-
specific IgG titers on day 42 (Figure 8.8).  Furthermore, the splenocyte proliferation 
assay demonstrated Tat-specific proliferation with all groups including the naïve group 
making it difficult to point out any differences among the groups (Figure 8.9).  
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 Surprisingly, no proliferation to any of the pooled Tat peptide sets was observed with the 
groups and in the IFN-γ release assay only one animal from the 1 mM SDS/3 mM B78 
group demonstrated a strong response after stimulation with all of the pooled Tat peptide 
sets (data not shown).  The IFN-γ release data also did not show any significant 
differences among the groups, and non-specific IFN-γ release after stimulation with the 
Tat protein in the naïve group was observed (Figure 8.10). 
 In summary, previous reports from our laboratory have demonstrated that anionic 
NPs were effective at enhancing the immune responses to protein-based vaccines.  In the 
present studies, further work was carried out to evaluate if any differences in the cellular 
and/or humoral immune responses could be identified using anionic NPs of varying 
surfactant composition.  Based on the data from two in vivo studies using 1 and 5 μg of 
Tat coated on these various anionic NP formulations, no significant differences in the 
humoral responses were observed.  Likewise, all NP formulations used were effective at 
generating neutralizing antibodies to Tat as demonstrated by the improved LTR-
transactivation assay.  Overall, the cellular responses to the anionic NPs also did not 
show strong differences.  However, there were numerous challenges faced with assessing 
cellular immune responses to the Tat protein.  For example, Tat demonstrates mitogenic 
activity in the cellular assays.  The use of Tat peptides was also investigated but it was 
difficult to identify the optimal regions to include in future studies and further studies 
optimizing the cellular assays to evaluate Tat-specific responses are necessary. 
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 Table 8.1.  Composition of anionic NP formulations. 
Volume of 
50 mM SDS 
(μL) 
Formulation Brij 78 (mg) DI Water (mL) 
 
15 mM SDS 
 
 
0 
 
600 
 
1.4 
 
15 mM SDS/1 mM Brij 78 
 
 
2.3 
 
600 
 
1.4 
 
1 mM SDS/3 mM Brij 78 
 
 
6.9 
  
40 1.96 
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Table 8.2.  Experimental conditions for mouse immunization studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Formulation Tat Dose 
Immunization 
Schedule 
Sera 
Collected 
Naïve - - 
15 mM SDS 1 μg 
15 mM SDS/1 mM B78 1 μg 
1 mM SDS/3 mM B78  1 μg Study 1 
1 mM SDS/3 mM B78 
(unpurified Control) 1 μg 
Day 0, 14, 28 Day 13, 35, 42 
Naïve - - 
15 mM SDS 5 μg 
15 mM SDS/1 mM B78 5 μg Study 2 
1 mM SDS/3 mM B78 
(unpurified Control) 
5 μg Day 0, 14, 28 
Day 42 
Table 8.3.  Physical characteristic of anionic NP formulations.   
 
 
The mean sizes and charges ± S.D. (n=3) are shown.   
*represents mean ± S.D. (n=2). 
 
 
 
 
 
 
 
 
 
 
 
 
Before GPC After GPC Tat Coated (10 μg/mL) 
Tat Coated 
(50 μg/mL) 
Formulation Mean size 
(nm) 
Mean 
Charge 
(mV) 
Mean size 
(nm) 
Mean 
Charge 
(mV) 
Mean size 
(nm) 
Mean 
Charge 
(mV) 
Mean 
size (nm)
Mean 
Charge 
(mV) 
15 mM SDS 113.3  ± 13.3 
-64.6  
± 1.8 
150.6  
± 5.4 
-63.2  
± 2.0 
119.7 
± 9.8 
-58.9  
± 6.2 
114.8  
± 19.4 
-51.1  
± 2.3 
15 mM SDS/1 mM B78 121.4 ± 10.1 
-61.3  
± 1.9 
145.9 
± 11.4 
-63.9  
± 3.6 
130.7 
± 10.5 
-62.0  
± 4.3 
122.2 
± 0.3 
-51.7 
 ± 2.6 
1 mM SDS/3 mM B78 147.9 ± 10.9 
-61.2  
± 3.6 
172.4 
± 9.9* 
-43.3  
± 5.5* 
146.7 
± 13.3 
-44.4  
± 5.8 - - 
1 mM SDS/3 mM B78 
(unpurified Control) 
147.9 
± 10.9 
-61.2  
± 3.6 - - 
151.27 
± 20.8 
-53.8  -46.5  153.4  
± 14.9 ± 3.3 ± 1.4 
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 Table 8.4.  Tat anti-sera reactivity to N-terminal and basic regions of Tat.  All sera 
from Study 1 were diluted 1:100.  The reactivity of anti-sera from each animal is 
presented.  *Cutoff = (AVG Naïve response) + (3*SD). (-) indicates no response – 
ELISA OD values equal to cutoff/background. 
 
Tat Peptide aa 1-15 aa 5-19 aa 9-23  aa 45-59 aa 49-63 
15 mM SDS/1 mM B78 
1.880 2.887 - - - 1 
1.998 2.831 0.509 0.358 0.423 2 
2.743 2.862 - - - 3 
- - - 0.286 0.314 4 
1.073 1.355 0.184 - - 5 
0.884 2.515 0.187 - - 6 
2.691 2.656 7 0.168 - 0.227 
1 mM SDS/3 mM B78  
0.847 0.749 0.183 - 0.235 1 
1.118 2.042 2.837 - - 2 
2.183 1.010 0.181 - - 3 
2.526 2.515 - 0.472 0.388 4 
0.397 1.515 0.231 0.356 0.305 5 
1.363 1.695 6 - - 0.32 
15 mM SDS 
1.407 2.267 0.234 0.593 0.341 1 
2.443 2.630 0.447 - - 2 
2.984 2.708 0.192 - 0.551 3 
2.423 2.875 0.167 - 0.274 4 
2.457 2.465 - - - 5 
2.715 2.565 1.734 - - 6 
0.680 1.392 7 0.194 - 0.254 
1 mM SDS/3 mM B78 Ctrl 
2.520 2.999 1.356 - - 1 
1.726 2.89 0.685 - 0.351 2 
1.609 2.523 0.215 - - 3 
- 0.790 0.200 - 0.228 4 
0.368 1.440 - - - 5 
1.110 1.468 - - - 6 
2.984 3.047 - - - 7 
2.934 2.531 0.172 0.275 0.228 8 
0.31 0.18 0.16 0.27 Cutoff* 0.20 
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 Figure 8.1 
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Figure 8.1.  Tat-specific serum IgG titers.  BALB/c mice were immunized (s.c.) on day 
0, 14, and 28 with 1 μg of Tat coated on the anionic NPs (100 μg).  Sera were collected 
and analyzed by ELISA at various time points.  Data represent the mean ± S.D. (n=6-8).   
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 Figure 8.2 
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Figure 8.2.  Tat-specific IgG1 and IgG2a titers.  BALB/c mice were immunized (s.c.) 
on day 0, 14, and 28 with 1 μg of Tat coated on the anionic NPs (100 μg).  Tat-specific 
serum IgG1 and IgG2a titers were evaluated on day 42 by ELISA.  The mean 
IgG2a/IgG1 ratio is indicated on top of the graphed titers for each group.  Data represent 
the mean ± S.D. (n=6-8).   
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 Figure 8.3 
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Figure 8.3.  Neutralizing activity of Tat anti-sera using an improved LTR-
transactivation assay.   BALB/c mice were immunized on day 0, 14, and 28 with 1 μg 
of Tat-coated NPs and sera were collected on day 42.  Serum from each mouse was 
diluted as indicated in the figure legend and evaluated for Tat neutralizing antibodies 
using an optimized LTR-transactivation assay.  The relative amounts of CAT expression 
determined using an ELISA.  Data represents mean ± SD (n = 6-8). *p<0.05 compared to 
naïve group; ap<0.05 compared to 1mM SDS/3mM B78 and 15mM SDS group; bp<0.05 
compared to 1mM SDS/3mM B78 and 15mM SDS group; cp<0.05 compared to 15 mM 
SDS group. 
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 Figure 8.4 
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Figure 8.4.  Splenocyte proliferation on day 5.  BALB/c mice (n=6-8 per group) were 
immunized (s.c.) on day 0, 14, and 28 with 1 μg of Tat coated on the anionic NPs (100 
μg) and spleens were harvested and pooled for each group on day 42.  Single cell 
suspensions of the spleen were stimulated with Con A or Tat for 4 days and the 
incorporation of 3H-thymidine was evaluated on day 5.  The data represent the mean ± 
S.D. (n=3).  *p<0.01 compared to naïve group; #p<0.05 compared to the Ctrl and 1 mM 
SDS/3 mM B78 group. 
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 Figure 8.5 
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Figure 8.5.  Splenocyte proliferative responses to 15-mer Tat peptides.  BALB/c mice 
(n=6-8 per group) were immunized (s.c.) on day 0, 14, and 28 with 1 μg of Tat coated on 
the anionic NPs (100 μg) and spleens were harvested and pooled for each group on day 
42.  Single cell suspensions of the spleen were stimulated with pooled 15-mer Tat 
peptides for 4 days.  The incorporation of 3H-thymidine was evaluated on day 5.  Set 1 = 
aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 17-31, 21-35, 25-39; Set 3 = 29-43, 33-47, 37-51; 
Set 4 = aa 41-55, 45-59, 49-63, 53-67; Set 5 = 57-71, 61-75, 65-79, 69-83.    The data 
represent the mean ± S.D. (n=3).  *p<0.05 compared to naïve group. 
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 Figure 8.6 
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Figure 8.6.  INF- γ release from Tat stimulated splenocytes.  BALB/c mice (n=6-8 per 
group) were immunized (s.c.) on day 0, 14, and 28 with 1 μg of Tat coated on the anionic 
NPs (100 μg) and spleens were harvested and pooled for each group on day 42.  Single 
cell suspensions of the spleen were stimulated with Tat for 72 hr and the IFN-γ release in 
the supernatants was quantitated by ELISA.  The data represent the mean ± S.D. (n=3).  
*p<0.001 compared to naïve group; #p<0.05 compared to naïve group. 
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 Figure 8.7 
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Figure 8.7.  INF-γ release from splenocytes stimulated with 15-mer Tat peptides.  
BALB/c mice (n=6-8 per group) were immunized (s.c.) on day 0, 14, and 28 with 1 μg of 
Tat coated on the anionic NPs (100 μg) and spleens were harvested and pooled for each 
group on day 42.  Single cell suspensions of the spleen were stimulated in triplicate with 
pooled 15-mer Tat peptides and the supernatants were pooled at 72 hr from triplicate 
wells and the assayed for IFN-γ by ELISA.  Set 1 = aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 
17-31, 21-35, 25-39; Set 3 = 29-43, 33-47, 37-51; Set 4 = aa 41-55, 45-59, 49-63, 53-67; 
Set 5 = 57-71, 61-75, 65-79, 69-83.    The data represent the mean ± S.D. (n=2).  ap<0.01 
compared to all groups; bp<0.001 compared to all groups; cp<0.001 compared to all 
groups. 
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 Figure 8.8 
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Figure 8.8.  Tat-specific serum IgG titers.  BALB/c mice were immunized (s.c.) on day 
0, 14, and 28 with 5 μg of Tat coated on the anionic NPs (100 μg).  Sera were collected 
and analyzed by ELISA at various time points.  Data represent the mean ± S.D. (n=6-8).   
 
 
 
 
 
 
 
 
 
 
 
 210
 Figure 8.9 
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Figure 8.9.  Splenocyte proliferation on day 5.  BALB/c mice were immunized (s.c.) 
on day 0, 14, and 28 with 5 μg of Tat coated on the anionic NPs (100 μg) and spleens 
were harvested on day 42.  Single cell suspensions of the spleen were stimulated in 
triplicate for 4 days.  The incorporation of 3H-thymidine was evaluated on day 5.  Set 1 = 
aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 17-31, 21-35, 25-39; Set 3 = 29-43, 33-47, 37-51; 
Set 4 = aa 41-55, 45-59, 49-63, 53-67; Set 5 = 57-71, 61-75, 65-79, 69-83.    The data 
represent the mean ± propagated error. (n=6-8).   
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 Figure 8.10 
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Figure 8.10.  IFN-γ release from Tat stimulated splenocytes.  BALB/c mice (n=6-8) 
were immunized (s.c.) on day 0, 14, and 28 with 5 μg of Tat coated on the anionic NPs 
(100 μg) and spleens were harvested on day 42.  Single cell suspensions of the spleen 
were stimulated with Tat (1.0 μg/mL) for 72 hr and the IFN-γ release in the supernatants 
was quantitated by ELISA.  The graph show IFN-γ release from stimulated splenocytes 
for each mouse in the group and the horizontal line represents the mean for each group.   
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 Chapter 9 
 
Summary and conclusions 
 
 The purpose of the studies presented herein was to investigate the potential of 
nanoparticles for enhancing immune responses to the HIV-1 proteins, Tat and Gag p24.  
The hypotheses driving this research were that: 1) mice dosed with anionic nanoparticles 
coated with HIV-1 proteins would result in enhanced humoral and cellular immune 
responses compared to those dosed with protein adjuvanted with Alum, 2) increasing the 
affinity of the protein antigen for the nanoparticles would result in a more stable 
attachment and lead to a corresponding enhancement in the immune responses in vivo 
compared to antigens coated on anionic nanoparticles by charge interaction, and 3)  mice 
dosed with nanoparticles co-formulated with protein antigen and an immunostimulatory 
molecule would produce enhanced immune responses compared those dosed with protein 
antigen with either nanoparticles or immunostimulatory molecule alone. 
 In these studies, anionic NPs were prepared from oil-in-water microemulsions 
using emulsifying wax as the oil phase and Brij 78 and SDS as the surfactants.  The 
overall composition of surfactants used to prepare the anionic NPs did not significantly 
affect the immune responses generated to Tat.  Anionic NPs coated with HIV-1 Tat were 
demonstrated to generate superior immune responses compared to Tat adjuvanted with 
Alum.  A dose-response study with Tat demonstrated that NPs were able to generate 
comparable levels of Tat-specific IgG titers using a 1 and 5 μg Tat dose, whereas Alum 
resulted in significantly lower IgG titers at the lower dose of Tat.  To determine the 
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 antibody epitopes generated, the Tat anti-sera was evaluated for recognition to 15-mer 
Tat peptides by ELISA.  It was found that the Tat anti-sera from immunized animals 
reacted greatest with the N-terminal and basic regions of the protein, which is consistent 
with literature reports [387,412-414].  The NP groups demonstrated higher levels of 
antibodies recognizing the basic region compared to Alum.  Moreover, the anti-sera from 
Tat-immunized mice were capable of blocking extracellular Tat in a LTR-transactivation 
assay.   
 To investigate the potential of these NPs for synergistic enhancements in immune 
responses with immunostimulatory molecules, cationic NPs were prepared and 
formulated with three different immunostimulatory molecules.  These molecules are TLR 
ligands and were expected to enhance immune response via stimulation of the innate 
immune system.  The cationic NPs were coated with the immunostimulatory molecules, 
LTA, CpG, and Poly I:C, and evaluated for immune responses generated to OVA.  From 
these studies, CpG demonstrated the greatest immunostimulatory activity and further in 
vivo evaluation demonstrated that CpG coated NPs resulted in significant enhancements 
in the OVA-specific antibody titers compared to either adjuvant alone.   
 To gain an understanding of the mechanism(s) by which nanoparticles may be 
enhancing immune responses to the associated antigens, two studies were carried out.  In 
the in vitro studies, the uptake of NPs into DCs and consequently, the release of pro-
inflammatory cytokines were evaluated.  These studies demonstrated that NPs were taken 
by into DCs and accumulated intracellularly in the cytoplasm.  Analysis of pro-
inflammatory cytokines after 24 hr incubation of NPs with DCs demonstrated that the 
NPs did not cause release of any significant levels of TNF-α, IL-1β or IL-12.  
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 Furthermore, significant enhancements in IL-12 release were observed after incubating 
the CpG coated NPs with DCs compared to CpG alone.  These in vitro studies suggested 
that NPs were enhancing the uptake of the associated molecule into DCs and this 
mechanism, at least in part, contributes to the enhancements in immune responses 
observed in vivo.   
In the second study, the extent to which antigens coupled to NPs stimulated CD8+ 
T cells in vivo were evaluated by performing an adoptive transfer of  transgenic T cells 
from the OT-1 mouse into C57BL/6 mice.  The OT-1 transgenic mouse model expresses 
a class I restricted receptor specific for OVA presented by the H-2Kb class I molecule.  
These studies demonstrated that NPs significantly enhanced the uptake of the associated 
protein into the MHC class I processing pathway and thus, resulted in enhanced 
presentation to CD8+ T cells in vivo compared to soluble OVA.  This enhanced 
presentation via the MHC class I pathway was thought to be due to enhanced delivery of 
coated OVA into DCs compared to soluble OVA.   
These in vitro and in vivo data together suggest that NPs enhance immune 
responses primarily through enabling greater accumulation of the associated antigen into 
DCs compared to soluble antigen.  The NPs investigated so far have taken advantage of 
coating the antigen on the surface through simple ionic interactions.  It was hypothesized 
that by increasing the affinity of the antigen for the NPs, a greater accumulation of the 
antigen into DCs can be achieved and this would result in further enhancements in the 
immune responses compared to the surface coated antigen on anionic NPs.  For this, NPs 
containing a small amount of surface-chelated Ni were prepared and shown to bind to 
his-tag proteins with more strongly compared to NPs prepared without the Ni.  
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 Furthermore, in vivo evaluation of his-tag Gag p24 bound to Ni-NPs generated superior 
IgG responses, including IgG2a, compared to protein adjuvanted with Alum or coated on 
the surface of NPs. 
In conclusion, these studies highlight the potential applications of NPs prepared 
from oil-in-water microemulsion precursors for enhancing immune responses to both 
HIV-1 Tat and Gag p24.  Of significant importance is the demonstration that the 72 aa 
Tat protein was effective at generating antibodies that recognized the same regions of the 
protein when compared to the full-length Tat protein (1-86 or 1-101) [387,412-414].  
Many researchers believe that a Tat-based vaccine may play a vital role in controlling the 
disease progression [346,368,400].  To this end, the use of the full-length Tat protein as a 
potential HIV vaccine has been investigated [384].  However, some reports suggest that 
the full-length Tat is immunosuppressive.  As an alternative, one group has reported on 
the use of Tat-toxoid as a potential Tat vaccine [457].  A previous study in our laboratory 
demonstrated that Tat (1-72) is not immunosuppressive [253] and the studies presented 
here further confirm the ability to generate antibodies to both the N-terminal and basic 
regions, which is consistent with literature reports using the full-length Tat protein.  In 
addition, the antibodies to Tat (1-72) are able to neutralize extracellular Tat as 
demonstrated by the LTR- transactivation assays.  Therefore, the use of Tat (1-72) coated 
on NPs in a potential HIV vaccine may be a good alternative to the current approaches 
with the full-length Tat protein or Tat-toxoid. 
A significant contribution in the advancement of delivery systems for protein-
based vaccines was further demonstrated through the development of a simple and rapid 
approach for attaching protein antigens to the surface of NPs via surface-chelated nickel.  
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 Several studies, including those presented herein, suggest that particulate delivery 
systems may result in enhanced immune responses in vivo due to the higher uptake of 
antigen associated with the particles [239,427].  However, the conventional approach of 
coating the protein antigen on a charged particle, while effective at enhancing immune 
responses, may be inefficient or sub-optimal due to possible dissociation of some of the 
antigen from the particle after in vivo administration.  Typical approaches utilized for 
attachment of antibodies or proteins to particles often require activating agents or 
multiple steps and pose challenges in obtaining high conjugation yields.  As an 
alternative, the studies presented in this dissertation demonstrated that NPs containing a 
small amount of surface-chelated nickel could be prepared.  The Ni-NPs provide a 
relatively simple approach for attaching protein antigens containing his-tag on the surface 
of the NPs.  More importantly, this technology may be widely applicable to protein-based 
vaccines because the interaction uses a simple histidine tag that could be incorporated in 
the expression vector during the protein production process.        
Although the studies presented here illustrate the potential applications of NPs for 
HIV-1 protein-based vaccines, more experiments to further characterize and optimize 
these systems will be necessary.  The studies presented in this dissertation were based on 
using the in vivo immune responses as the end point; however, minimal work was carried 
out to correlate the effect of formulation parameters on the in vivo immune responses.  It 
must be recognized that several steps are involved between the protein formulation with 
the NPs and the in vivo responses that may prove to be critical in the generating the 
immune responses but are missing in the work presented here.  For example, the protein 
stability and release, as well as the uptake of the associated antigen by DCs using both 
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 the charged NPs and Ni-NPs are critical parameters to evaluate.  These types of in vitro 
studies may provide clues for further improvements that could be made in the 
formulations, which may lead to greater enhancements in the cellular and humoral 
immune responses.   Moreover, additional in vitro studies investigating the expression of 
co-stimulatory molecules on DCs and the processing and presentation of antigens on DCs 
may provide insight into the possible mechanisms by which NPs are enhancing the 
immune responses in vivo.    
While in vitro studies may provide a basic understanding of mechanistic 
processes, ultimately in vivo studies will be necessary to providing a greater 
understanding of the possible functions of NPs.  Along these lines, the fate of the protein 
associated with the NPs after in vivo administration would provide a greater 
understanding of their role in stimulating immune responses.  Additional studies 
evaluating the responses occurring at the site of injection, i.e. inflammation, may reveal 
other contributing mechanisms through which NPs enhance the immune responses to 
antigens.    Furthermore, if the uptake of the NPs is found to be critical in enhancing the 
immune responses, exploring the use of a DC-targeting ligand may also provide 
additional benefits in improving the immune responses to the antigen.  Combined these 
additional studies may reveal further improvements or alternative formulation approaches 
that could be investigated for building better nanoparticle-based delivery systems for 
HIV-1 protein-based vaccines.   
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 Appendices 
 
 
This section contains the following information and additional experiments: 
 
• Appendix A:  Structures and physical properties for various materials used in the 
dissertation 
• Appendix B:  Preparation and characterization of sterically stabilized anionic 
nanoparticles for delivery of HIV-1 Tat and Gag proteins 
• Appendix C:  Synthesis of mannopentaose targeting ligand and in vitro 
evaluation  
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 Appendix A 
 
Figure A1 
 
  
 
 
 
 
 
Polysorbate 60 (Polyoxyethylene 20 sorbitan monostearate);  
W+X+Y+Z = 20; Mw 1312; HLB 14.9
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O 
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CH3 (CH2)14CH2OH 
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Figure A1.  Structure and properties of emulsifying wax.  Emulsifying wax is 
comprised of cetyl alcohol and polysorbate 60 in a 20:1 molar ratio. 
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 Figure A2 
 
 
 
CH3 (CH2)17 (OCH2CH2)20OH 
Polyoxyethylene 20 Stearyl Ether (Brij® 78); Mw 1150;  
m.p. 38oC; HLB 15.3 
 
 
CH3(CH2)11 SO4Na 
Sodium Dodecyl Sulfate (SDS); Mw 288;  HLB 40 
 
 
CH3(CH2)15N(CH3)3Br 
Cetyl Trimethyl Ammonium Bromide (CTAB); Mw 364.5; HLB 10 
 
 
 
 
Figure A2.  Structure and physical properties of surfactants used for preparing 
nanoparticles.  Neutral, anionic, and cationic nanoparticles were prepared using Brij 78, 
SDS, and CTAB, respectively. 
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 Figure A3 
 
 
 
 
3,3'-dioctadecyloxacarbocyanine perchlorate (DiOC18); Mw 881.72 
Ex: 484 nm and Em: 501nm 
 
 
 
 
Figure A3.  Chemical structure and physical properties of DiOC18.  This green 
fluorescent marker was used for labeling nanoparticles for confocal microscopy studies 
looking at nanoparticle uptake into BMDDCs. (Structure obtained from 
http://probes.invitrogen.com/servlets/structure?item=275) 
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 Appendix B 
 
Preparation and characterization of sterically stabilized anionic nanoparticles for 
delivery of HIV-1 Tat and Gag Proteins 
 
B.1   Preparation of sterically stabilized anionic NPs  
 Anionic NPs have been previously prepared in Dr. Mumper’s laboratory from 
microemulsion precursors [16].  Briefly, the microemulsions were prepared at 50-55°C 
by forming a homogeneous slurry of emulsifying wax (comprised of 20:1 cetyl 
alcohol/polysorbate 60) in water followed by the addition of sodium dodecyl sulfate 
(SDS) at a final concentration of 15 mM to result in the formation of stable, clear 
systems.    The mircoemulsion systems were cooled to room temperature while stirring to 
form NPs of approximately 100 nm in size.  Excess surfactant was removed by gel 
permeation chromatography (GPC) using a Sephadex G75 column (15 mm x 70 mm) and 
the particle size was measured by photon correlation spectroscopy (PCS) using a Coulter 
N4 Plus Particle Sizer at 90° for 60 s.      
Initial stability studies of these anionic NPs prepared from 15 mM SDS revealed 
that the particles aggregated at 25°C in 150 mM sodium chloride (NaCl) (Figure B1).  To 
sterically stabilize these NPs, the use of Brij 78 as a co-surfactant was investigated.  The 
anionic NPs were prepared as stated above using concentrations of 0.5 to 1 mM Brij 78.  
NPs were further purified by GPC to remove the excess surfactant and then evaluated in 
150 mM NaCl at 25°C to determine the concentration of Brij 78 required for stabilization 
of the particles.   As shown in Figure B1, a minimum of 0.5 mM Brij 78 was required to 
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 stabilize the NPs under the conditions tested.  Anionic NPs prepared using 0.5 and 1.0 
mM of Brij 78 were further evaluated at 37°C in simulated biological media.  Anionic 
NPs prepared with 1.0 mM Brij 78 were found to be stable in 150 mM NaCl, 10 mM 
phosphate buffered saline (PBS) pH 7.4, 10% (v/v) fetal bovine serum (FBS) in 150 mM 
NaCl and 10% (w/v) lactose at 37°C (Figure B2).   In addition, characterization of these 
anionic NPs prepared using 15 mM SDS and 1 mM Brij 78 by Transmission Electron 
Microscopy (TEM) revealed that the particles were approximately 50 to 100 nm in size 
with spherical morphology (Figure B3).  This formulation was chosen for further work 
for coating with the HIV-1 protein antigens. 
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 Figure B1 
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Figure B1.  Stability of GPC purified anionic NPs in 150 mM NaCl at 25 Co .  All NPs 
were prepared using 15 mM SDS and varying concentrations of Brij 78 (B78) as 
indicated on the graph.  The formulations were passed through a GPC column to remove 
excess surfactant and the size after purification (GPC) was measured.  The stability of the 
particles was determined over 2 hr in 150 mM NaCl by measuring the size and 0 hr on 
graph indicates the sized immediately after adding the NaCl.  Data represents mean ± 
S.D. (n=3). 
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 Figure B2 
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Figure B2.  Stability of anionic NPs in simulated biological media at 37 Co .  
Negatively charged NPs were prepared using emulsifying wax as the oil phase and 15 
mM SDS and 1 mM Brij 78 as the surfactants.  NPs were purified by GPC to remove any 
excess surfactant and stability of the particles was evaluated based on particle size 
measurements.  Data represents mean ± SD (n=3).      
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 Figure B3 
 
 
 
 
 
 
 
 
 
 
 
Figure B3.  TEM of anionic NPs.  Anionic NPs prepared using 15 mM SDS and 1 mM 
Brij 78 surfactants were purified by GPC.  
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 B.2 Preparation and characterization of HIV-1 Tat-coated NPs 
Anionic NPs were purified by GPC to remove excess surfactant, and filtered 
through a 0.2 μm filter.  A volume of 200 μL of the purified NPs (~40 μg) was gently 
mixed at varying concentrations of Tat for 1 hr at room temperature.  The adsorption of 
Tat on the surface of NPs was verified by measuring the overall charge (Figure B4) using 
a Zeta Sizer 2000 from Malvern Instruments, Inc. and TEM analysis of the Tat-coated 
NPs suggested that the particles retained a spherical shape and ~100 nm size (Figure B5).   
As expected, an increase in the concentration of Tat adsorbed on the surface of the NPs 
resulted in an increase in the overall charge of the NPs (Figure B4) up to a final 
concentration of 25 μg/mL, above which a plateau observed.  This may be due to the 
negative residues in the Tat protein being exposed at the surface of the particle. 
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 Figure B4 
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Figure B4.  Anionic NPs coated with HIV-1 Tat.  The size and charge of the particles 
was characterized before (Ctrl) and after coating with increasing concentrations of Tat.  
Data represents mean ± SD (n=2). 
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 Figure B5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B5.  TEM of HIV-1 Tat-coated NPs.  Anionic NPs were prepared using 15 mM 
SDS and 1 mM Brij 78 and excess surfactant was separated by GPC.  The GPC purified 
NPs were coated with Tat (25 μg/mL). 
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 B.3 Preparation and characterization of HIV-1 Gag-coated NPs   
HIV-1 Gag p55 (obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: HIV SF2 Gag p55 from Chiron Corporation 
and the DAIDS) is insoluble in water and most other buffer systems.  Therefore, the 
protein is supplied in 50 mM sodium phosphate (pH 7.9) with 0.4 M NaCl and 6 M urea.  
To coat anionic NPs with Gag p55, first, excess surfactant was removed by GPC using    
6 M urea as the mobile phase.  The purified NPs were collected and filtered through a  
0.2 μm filter, and 200 μL (40 μg) of NPs were gently mixed with 1, 5, and 10 μg of Gag 
p55 for 1 hr at room temperature.  The coated and uncoated NPs (Ctrl) were centrifuged 
at 8000 x g at 20oC using Microcon® YM-100 (Millipore, MWCO 100 kDa) 
ultracentrifuge devices to desalt and remove urea by washing three times with water.  The 
NPs were re-suspended in water (0.2 μm filtered), and characterized by size and charge 
(Figure B6).   The adsorption of Gag p55 on the NPs was also confirmed by TEM (Figure 
B7), where small, 50 nm size particles formed by Gag p55 were shown to be adsorbed on 
anionic NPs.   
NPs coated with Gag p55 were analyzed using SDS-PAGE and densitometry to 
quantify the amount of protein adsorbed on the surface.  Samples and standards were 
loaded on pre-cast Novex® 4-20% Tris-Glycine gradient gels and were run under 
reducing conditions at 125V for 90 min.  The gels were developed by silver staining, 
photographed using GeneSnap, and analyzed by densitometry using GeneTools software.  
For densitometry, five standards (100, 200, 300, 500, and 700 ng of Gag p55) were run 
on each gel along with the samples.    The amount of protein in all samples was 
calculated from the standard curve and the coating efficiency for Gag p55 was 
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 determined using these results.  The percent of protein adsorbed after ultrafiltration was 
calculated based on the initial (before ultrafiltration) concentration of Gag p55 for NPs 
having a final protein concentration of 25 μg/mL and 50 μg/mL. For NPs coated with 
Gag p55 at a final concentration of 5 μg/mL, the samples were below detection limit; 
thus, the sample was only analyzed after ultrafiltration and the percent of protein 
adsorbed was calculated based on the theoretical concentration.  As shown in Figure B8, 
approximately 100% of the protein was adsorbed on the surface of the NPs when the Gag 
p55 was at a final concentration of 5 μg/mL and 25 μg/mL.  In contrast, when the Gag 
p55 was at a final concentration of 50 μg/mL, only 75% of the protein was adsorbed on 
the surface of NPs.  Gag p55 coated NPs were found to be stable (as determined by 
retention in particle size) for up to 60 min in 150 mM NaCl, 10 mM PBS, 10% (v/v) 
FBS, and 10% (w/v) lactose at 37oC (data not shown). 
As mentioned above, the use of Gag p55 provides some difficulties in handling 
the protein since it is insoluble and must be dissolved in 6M urea.  As a result, the urea 
must be removed.  This poses potential difficulties in carrying out in vivo studies for 
immunization with protein adjuvanted with Alum.  For further studies, the use of Gag 
p24, which is positively-charged and water-soluble, was investigated.  More importantly, 
it has been previously shown that Gag p24 is highly conserved and leads to cross-reactive 
CTL responses [353,354,356].  After GPC purification of the NPs, 1, 5, and 10 μg of Gag 
p24 (Trinity Biotech; Carlsbad, CA) were gently mixed with approximately 40 μg of NPs 
for 1 hr at room temperature.  The size and charge of Gag p24-coated NPs is presented in 
Figure B9.  The overall charge of the NPs becomes more positive with increasing 
concentrations of Gag p24, confirming adsorption to the surface of NPs.  As seen with 
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 Tat, a plateau in the charge of the NPs results above a Gag p24 concentration of              
25 μg/mL thought to be possibly due to negatively charged residues of the protein being 
exposed on the surface of the NPs. 
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 Figure B6 
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Figure B6.  Anionic NPs coated with HIV-1 Gag p55.  The size and charge of the 
particles was characterized before (Ctrl) and after coating with increasing concentrations 
of Gag p55.  Data represents mean ± SD (n=2). 
.   
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 Figure B7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B7.  TEM of HIV-1 Gag p55-coated NPs.  Anionic NPs were prepared using 15 
mM SDS and 1 mM Brij 78 and excess surfactant was separated by GPC.  The GPC 
purified NPs were coated with Gag p55 (25 μg/mL).  Gag p55 forms small particles of 
approximately 50 nm in size as shown on the overlayed TEM.  Thus, the smaller particles 
adsorbed on the larger size particles were confirmed to be Gag p55.   
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 Figure B8 
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Figure B8.  Coating efficiency of HIV-1 Gag p55 on anionic NPs.  The amount of Gag 
p55 associated with the NPs was determined by SDS-PAGE/densitometry.  Data 
represent mean  ± S.D. (n=2-6).  
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 Figure B9 
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Figure B9.  Anionic NPs coated with HIV-1 Gag p24.  The size and charge of the 
particles was characterize before (Ctrl) and after coating with increasing concentration of 
Gag p24.  Data represents mean ± SD (n=2). 
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 B.4 Immune responses to HIV-1 Tat- and Gag p24-coated NPs 
BALB/c mice (n=5-6/group) were immunized intramuscularly (i.m., 50 μL per 
gastrocnemius muscle) on day 0 and day 20 with 2.5 μg Tat or Gag p24 adjuvanted with 
Alum (Spectrum) or 2.5 μg Tat or Gag p24 coated on NPs.  In this study, Alum was used 
as a positive control for a Th2 type immune response.  The sera from all mice were 
collected on day 36 for further assessment of humoral immune responses generated in the 
various groups.  The Tat- and Gag p24-specific serum IgG levels, determined by ELISA, 
are shown in Figure B10 and B11, respectively.   
The IgG antibody responses from the Tat-immunized mice were stronger than the 
Gag p24-immunized mice, which may be indicative of the higher immunogenicity of Tat 
compared to Gag p24.  However, in both the Tat- and Gag p24-immunized mice, the 
antibody levels for mice immunized using NPs versus Alum, a control for Th2 type 
immune response, were comparable and statistically insignificant.  This demonstrates the 
potential of anionic NPs for producing similar enhancements in immune responses to the 
approved Alum adjuvant after i.m. administrations.  However, previous results using 
anionic NPs coated with the model antigen β-galactosidase suggests that NPs produced 
superior immune responses to Alum after subcutaneous (s.c.) immunization.  The 
differences in the responses with NPs obtained in the two studies may be antigen specific 
or may indicate that the s.c. route may be better compared to i.m. for generating immune 
responses with the NPs.              
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 Figure B10 
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Figure B10.  Tat-specific total serum IgG levels on day 36.  Mice were immunized 
with 2.5 μg of Tat coated on anionic NPs or adjuvanted with Alum on day 0 and day 20 
by 50 μL injection into each gastrocnemius muscle.  Data represent mean ± S.D. (n=5-6). 
*p<0.05 compared to naïve group by ANOVA.   
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 Figure B11 
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Figure B11.  Gag p24-specific total serum IgG levels on day 36.  Mice were 
immunized with 2.5 μg of Gag p24 coated on anionic NPs or adjuvanted with Alum on 
day 0 and day 20 by 50 μL injection into each gastrocnemius muscle.  Data represent 
mean ± S.D. (n=5-6).  *p<0.05 compared to naïve group by ANOVA.   
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 B.5   Conclusions 
These studies demonstrated that simple anionic NPs prepared using 15 mM SDS 
could be stabilized by inclusion of Brij 78.  Furthermore, the resulting anionic NPs could 
be coated with HIV-1 Tat, Gag p55, and Gag p24.  The in vivo immune responses to Tat- 
and Gag p24-coated NPs demonstrated that these systems were similar in enhancing 
immune responses compared to protein adjuvanted with Alum after i.m. immunization. 
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 Appendix C 
 
Synthesis of mannopentaose targeting ligand and in vitro evaluation 
 
The mannose receptor (MR) has been utilized for targeting antigens to DCs and 
thus, obtaining enhanced immune responses [275].  Many groups have investigated the 
use of hydrophobized mannan for enhancing immune responses to antigens [15,282,283].  
Mizuochi et al. have investigated various oligosaccharide ligands and demonstrated that 
hydrophobized mannopentaose (Figure C1) attached to the surface of liposomes 
generated enhanced cellular responses compared uncoated liposomes [283,285].  Thus, 
the use of hydrophobized mannopentaose was further investigated as a potential targeting 
ligand for increasing NPs uptake in vitro into DCs.   
The conjugation of mannopentaose to the lipid, 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (DPPE) has been previously described and was followed with 
minor modifications [458].  Briefly, 7.7 mg of DPPE (Avanti Polar Lipids; Alabaster, 
AL) was reacted with 1.2 mg mannopentaose (Sigma; St. Louis, MO) in 1.5 mL of 
chloroform/methanol (1:1 v/v) at 60°C for 2 hr in an 8 mL glass vial with a Teflon coated 
cap.  Sodium cyanoborohydride was added after 2 hr and the reaction was allowed to 
proceed at 60oC.  The progress of the reaction was monitored by thin layer 
chromatography using chloroform/methanol/water 105:100:28 (v/v/v) using orcinol 
reagent (Fisher; Hampton, NH) to visualize the mannopentaose and the lipid conjugate.  
The reaction was stopped when the mannopentaose was undetectable by TLC (~5 days).  
The product was purified by column chromatography using silica gel 60 (EM Science; 
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 Gibbstown, NJ) with the following solvent systems (all indicate volume to volume 
ratios):  1) 1:1 chloroform/methanol; 2) 11:9:2 chloroform/methanol/water; and 3) 
10:10:3 chloroform/methanol/water.  The eluent from the column was fractionated, 
checked for presence of the lipid-mannopentaose conjugate by TLC, and the fractions 
positive for conjugate were combined and the solvent was evaporated.  The product was 
confirmed to be DPPE-mannopentaose by mass spectrometry with the molecular ion peak 
present at 1504 m/z (Figure C2). 
To determine if the DPPE-mannopentaose could serve as a targeting ligand to 
enhance the uptake of NPs into BMDDCs, radiolabeled anionic NPs using Brij 78 and 
SDS (3 mM and 1 mM, respectively) as the surfactant were prepared with 1 to 10% w/w 
of DPPE-mannopentaose.  BMDDCs were confirmed to express the mannose receptor by 
flow cytometry (Figure C3).  The uptake by BMDDCs of the DPPE-mannopentaose NPs 
was compared to the anionic NPs (B78/SDS) at 37oC.  As a control, the various 
formulations were also incubated with BMDDCs at 4oC to differentiate the binding 
versus active uptake expected at 37oC and significantly accumulation of all NP 
formulations was observed at 37oC compared to 4oC (data not shown).  As shown in 
Figure C4, there were no significant differences in the uptake of the particles with 
inclusion of DPPE-mannopentaose over the 4 hr evaluated.  It is important to note that 
the NPs without the targeting ligand were efficiently taken up by the BMDDCs, with 
about 40% accumulation into the cells over the 4 hr.  This highly efficient uptake of NPs 
may present difficulty in evaluating differences in uptake due to the targeting ligand in 
vitro.  However, this strategy may be viable in vivo and may cause enhanced immune 
responses since there are other cells present and the presence of the ligand may facilitate 
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 targeting and higher uptake into DCs versus other cell types. Alternatively, it is possible 
that the ligand on the NPs is not accessible for interaction with the mannose receptor on 
the BMDDCs.  This may be evaluated by inclusion of a hydrophilic spacer such as 
polyethylene glycol between the lipid and mannopentaose moieties to allow for more 
flexibility and accessibility for interaction with the receptor.   
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 Figure C1 
 
 
 
 
 
 
 
 
 
 
Figure C1.  Structure of DPPE lipid conjugated to mannopentaose. The molecular 
weight of this ligand was calculated to be 1504.70.  (Structure from Shimizu et al. [286]) 
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 Figure C2 
 
 
 
Figure C2.  Mass spectrum for purified DPPE-mannopentaose ligand.  The mass 
spectrum was obtained in a negative ion mode by MALDI-TOFMS. 
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 Figure C3 
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Figure C3.  Mannose receptor expression on BMDDCs.  A)  Cells from primary 
culture of murine bone-marrow were identified as DCs by staining the cells with CD11c 
and MHC I antibodies.  The double positive cells, circled, were gated to see expression of 
mannose receptor on the BMDDCs.  B)  Cells were labeled with a murine mannose 
receptor antibody (CD206).  Double positive cells from (A) that are also positive for 
mannose receptor are shown.   
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 Figure C4 
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Figure C4.  Uptake of radiolabeled NP formulations in BMDDCs.  An amount of 1 
μg of anionic NP (B78/SDS) or anionic NPs containing 1, 5 and 10% w/w DPPE-
mannopentaose were incubated with BMDDCs at 37oC.  The radioactivity associated 
with the cells was measured at the time points shown to evaluate uptake of the various 
NP formulations. 
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